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Abstract and Keywords 
 
The effects of solar ultraviolet radiation that reaches the Earth surface can be beneficial 
but also harmful depending on the circumstances. The recent search for new chemical 
entities against photo-induced skin disorders has received particular focus on 
phytocompounds investigation. The use of natural compounds, working through 
different pathways in the cell, in both skin care products and therapeutic purposes may 
be an effective approach for reducing UV-B generated reactive oxygen species (ROS) 
mediated photoaging and photocarcinogenesis. In this work, the role of two active 
molecules is presented and discussed: tretinoin (the acid form of vitamin A) and 
lycopene (a carotenoid without vitamin A activity) in the context of photoaging and 
photocarcinogenesis, respectively. Tretinoin is involved in the control of cell 
differentiation and proliferation in several tissues, particularly in the skin epithelium. It 
has been demonstrated that photoaging can be ameliorated by topical retinoids, such 
as tretinoin, and long term effects of their topical application on the skin can be the 
reduction and redistribution of epidermal melanin, improved ultrastructural 
characteristics of the epidermis, increased anchoring fibrils, increased deposition of 
papillary dermal collagen, and increased vascularity in the papillary dermis. On the 
other hand, the anticancer activity of lycopene has already been demonstrated in both 
in vitro and in vivo different tumour models. The mechanisms underlying the inhibitory 
effects of lycopene on carcinogenesis could involve ROS scavenging, upregulation of 
detoxification systems, interference with cell proliferation, induction of gap-junctional 
communication, inhibition of cell cycle progression and modulation of signal 
transduction pathways. 
Dermal delivery after topical application of actives has gained increased interest and 
development due to the lower risk of systemic side effects. In particular, for 
antioxidants skin delivery, the search for a new delivery system that, simultaneously, 
preserves the antioxidant stability and enhances its deposition on the skin, opened a 
new chapter in drug delivery design. Since epidermal lipids are predominantly found 
within the penetration skin barrier (stratum corneum, SC), topically applied lipid 
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nanocarriers, allowing lipid interaction between the outermost layer of SC and the 
carrier, appear promising. In fact, nanocarriers, and among these advanced drug 
delivery systems, liposomes and cyclodextrins, have successfully enhanced the clinical 
efficiency of several drugs. Liposomes are typically hollow spheres surrounded by a lipid 
bilayer. More recently, specially designed carriers have claimed the ability to cross the 
skin intact and deliver the loaded drugs into the systemic circulation, being at the same 
time responsible for the percutaneous absorption of the drug within the skin. These 
carriers were firstly introduced as transfersomes®*, and this denomination as well as 
deformable vesicles, were used to differentiate them from the more conventional 
liposomes. The highly flexible membranes are the result of combining into a single 
structure phospholipids and an edge-active component (surfactant) in order to give to 
transfersomes the necessary deformability to move spontaneously into the skin, 
delivering the associated drugs dermal or systemically. Cyclodextrins are cyclic water-
soluble, non-reducing and macrocycle carbohydrate polymers. Some derivatives, such 
as β- and methylated-β-cyclodextrins are usually used for topical formulations. 
The aim of this thesis was to use cyclodextrins and transfersomes, or their 
combination, as delivery systems for tretinoin and lycopene, and further investigate the 
resulting systems behavior in in vitro and in vivo conditions. 
Tretinoin was incorporated in transfersomes (tretinoin-in-dimethyl-β-cyclodextrin-in-
ultradeformable vesicles and tretinoin-in-ultradeformable vesicles) in order to fully 
characterize these new formulations, and further study its dermal delivery.  
The need of an appropriate source of lycopene led to the development of a simple and 
fast process for the extraction of lycopene from tomato. The incorporation of this 
lycopene-rich-extract in vesicular nanocarriers suitable for topical application was also 
performed and reported on this thesis. Lycopene was described as the antioxidant most 
quickly depleted in the skin upon exposure to solar radiation, and consequently, might 
play a role for protecting skin against UV radiation. To test this hypothesis, the main 
effects of UV-B irradiation on human keratinocytes (HaCaT cells line) after lycopene 
exposure were studied. 




Regarding the methods used, the tretinoin-cyclodextrin complex was prepared by the 
kneading process and transfersomes resulted from the combination of soybean 
phosphatidylcholine and Tween®
The topical delivery of the tested formulations involved different studies, such as the 
release and permeation profiles (tape stripping); skin penetration (fluorescence 
analysis) and induced electrical changes in skin barrier properties. The in vitro toxicity 
was also achieved.  
 80 to make 10 % - 20 % lipid suspension. The resulting 
suspension was brought to the final mean vesicles size of approximately 100-150 nm, by 
sequential filtration. In the case of lycopene, an extraction process from dried tomatoes 
was previously carried for 30 min at room temperature, protected from light. The 
extracts were analyzed by high-performance liquid chromatography and mass 
spectroscopy and incorporated in deformable vesicles. The physicochemical 
characterization of the vesicular formulations was based on the evaluation of the 
following parameters: mean particle size and polydispersity index measured by photon 
correlation spectroscopy and atomic force microscopy; zeta potential determined by 
laser-doppler anemometry; phospholipid concentration determined by an enzymatic-
colorimetric test; and drug assay by an adequate high performance liquid 
chromatography method.  
The irritation potential of the developed tretinoin formulation was evaluated in vivo 
using a modified Draize test and compared to a commercially available tretinoin 
semisolid form. The in vivo therapeutic effect of lycopene topical formulations was 
tested in mice, using the anthralin-induced ear swelling model, being anthralin topical 
application responsible for the generation of reactive oxygen species in the skin. 
Thiazolyl blue tetrazolium bromide (MTT) assay was performed in order to select the 
UV-B irradiation protocol specific conditions. After lycopene exposure and irradiation 
experiments, HaCaT cells were analyzed in order to achieve information on the 
following parameters: genotoxicity/clastogenicity by determining the cell cycle by flow 
cytometry (FCM) and analyzing apoptosis biomarkers and gene expression by real time 
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– polymerase chain reaction quantification; apoptosis by performing the Annexin V 
assay by FCM; and oxidative stress damage by ROS quantification by FCM. 
Results of tretinoin-loaded transfersomes revealed that the incorporation efficiency 
was high for all formulations tested. However, the tretinoin vesicular formulation with 
20 % lipid concentration presented better drug stabilization, attending to the higher 
chemical stability achieved.  
Tretinoin-loaded deformable vesicles applied on the skin were able to decrease the skin 
resistance, suggesting their ability to induce barrier disruption, as theoretically 
expected. It was also observed by fluorescence microscopy that these vesicles were 
mainly concentrated in the SC and epidermis layers. Permeation studies showed that no 
tretinoin is measurable in the receptor phase. In fact, drug retention in the SC and in 
epidermis/dermis are indicative of topical delivery, whereas the drug quantification in 
the receptor phase is indicative of transdermal delivery. These results showed that 
tretinoin-in-transfersomes has a dermal instead of a transdermal delivery, which serves 
the therapeutic purpose since tretinoin receptors, such as RAR-γ, are mainly located in 
epidermis. Finally, tretinoin-in-transfersomes formulation was not toxic in in vitro and in 
vivo conditions at least at 5 × 10 -3
 
 mg/mL and 0.5 mg/mL of tretinoin, respectively. 
Regarding lycopene extraction, the little number of steps involved in the extraction 
process may have improved the yields of lycopene in the extract and exerted a 
beneficial role in the stability of this carotenoid. The vesicular formulations presented a 
good incorporation efficiency of lycopene in deformable vesicles (transfersomes and 
ethosomes). Cytotoxic data demonstrated that extracted lycopene and pure 
(commercial) lycopene present similar performances of low cytotoxicity, and were 
similarly affected by environmental conditions. The vesicular formulations containing 
extracted lycopene were able to inhibit the edema formation in vivo on anthralin-
induced ear swelling model relative to untreated controls, and without a statistically 




In vitro photocarcinogenesis studies with UV-B irradiated keratinocytes revealed that 
lycopene decreased the irradiated cells viability according to MTT and Annexin V results. 
It was also observed the cell cycle arrest (at G0/ G1 phase and a higher apoptotic Sub-
G1 peak), and a higher ROS level.  
 
In summary, according to the obtained results, an effective dermal delivery of actives 
could be achieved by the use of a carrier-mediated transport. Some aspects regarding 
the elucidation of drug biological activity behind this delivery system were also 




Keywords: Tretinoin; Lycopene; Nanocarriers: Cyclodextrins and Deformable vesicles; 
 Dermal Delivery; Photoaging and Photocarcinogenesis.  
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Resumo e Palavras-Chave 
 
Os efeitos da radiação solar ultravioleta (UV) que atinge a superfície da Terra podem ser 
benéficos, mas também prejudiciais, dependendo das circunstâncias. Nos últimos anos, 
a pesquisa de novas moléculas com actividade na prevenção e/ou tratamento de lesões 
cutâneas, associadas a uma excessiva exposição à radiação solar, tem focado com 
especial interesse os fitocompostos. A utilização de compostos naturais que atuem 
através de diferentes vias celulares, em produtos terapêuticos e de cuidados da pele, 
poderá ser uma abordagem eficaz ao nível da redução de espécies reativas de oxigénio 
geradas pela radiação UV-B e envolvidas nos processos de fotoenvelhecimento e 
fotocarcinogénese. Neste trabalho, é apresentado e discutido o papel de duas 
moléculas ativas, a tretinoína (forma ácida da vitamina A) e o licopeno (carotenóide sem 
atividade provitamina A) no contexto do fotoenvelhecimento e da fotocarcinogénese, 
respetivamente. A tretinoína está envolvida no controlo da diferenciação celular e 
proliferação em vários tecidos, especialmente no tecido epitelial da pele. Tem sido 
demonstrado que o fotoenvelhecimento pode ser tratado com retinóides tópicos, como 
é o caso da tretinoína, e que os seus efeitos a longo prazo, ao nível da pele, passam pela 
redução e redistribuição da melanina epidérmica, melhoria ultra-estrutural da 
epiderme, aumento das fibrilhas de ancoragem, aumento da deposição de colagénio da 
derme papilar e aumento da vascularização na derme papilar. Por outro lado, a 
atividade anticancerígena do licopeno foi já demonstrada em estudos in vitro e, in vivo, 
em diferentes modelos tumorais. Os mecanismos subjacentes aos efeitos inibitórios do 
licopeno ao nível da carcinogénese poderão envolver a captura de espécies reativas de 
oxigénio, a supra-regulação de sistemas de desintoxicação, a interferência com a 
proliferação celular, a indução da comunicação ao nível das junções intercelulares, a 
inibição da progressão do ciclo celular e a modulação de vias de transdução de sinal. 
A veiculação dérmica de moléculas ativas constitui um tema que tem captado cada vez 
mais interesse e crescente investigação, uma vez que o risco de efeitos colaterais 
sistémicos é mais reduzido. Particularmente, no que se refere à veiculação de 
antioxidantes para a pele, a procura de um novo sistema de veiculação que mantenha a 
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estabilidade da molécula antioxidante e, simultaneamente, aumente a sua deposição na 
pele, abriu um novo capítulo na área de veiculação de fármacos. Uma vez que os lípidos 
epidérmicos predominam ao nível da barreira de penetração da pele (estrato córneo, 
EC), os nanotransportadores lipídicos administrados topicamente, que permitam a 
interação dos lípidos entre a camada mais externa do EC e o transportador, parecem ser 
uma abordagem promissora. De facto, a utilização de nanotransportadores, tais como 
lipossomas e ciclodextrinas, tem sido bem-sucedida ao nível da eficácia clínica de vários 
fármacos. Os lipossomas são tipicamente vesículas rodeadas por uma bicamada lipídica. 
Mais recentemente, foram concebidos e desenvolvidos lipossomas deformáveis capazes 
de atravessar a pele intata, promovendo a absorção percutânea de moléculas ativas e a 
sua veiculação para a circulação sanguínea. Para os diferenciar dos lipossomas 
convencionais, foram nomeados de vesículas deformáveis, tendo sido inicialmente 
introduzidos com a designação de transfersomas*. As membranas altamente flexíveis 
destas vesículas são o resultado da combinação numa única estrutura de fosfolípidos e 
um tensioativo, que contribui para a sua deformabilidade e capacidade de se moverem 
espontaneamente através da pele, libertando as moléculas a eles associadas dérmica e 
sistemicamente. As ciclodextrinas são polímeros cíclicos de hidratos de carbono não-
redutores e solúveis em água. Alguns derivados, tais como β-ciclodextrinas e 
ciclodextrinas β-metiladas, têm sido geralmente utilizados em formulações tópicas. 
Esta dissertação teve como objetivo a utilização de ciclodextrinas e transfersomas, ou 
a sua combinação, como sistemas de veiculação de tretinoína e licopeno e, 
posteriormente, o estudo in vitro e in vivo das formulações desenvolvidas. 
A tretinoína foi incorporada em transfersomas (tretinoína-dimetil-β-ciclodextrina-
transfersomas e tretinoína-transfersomas), posteriormente caracterizadas e usadas nos 
estudos de aplicação tópica. 
A necessidade de obter licopeno de forma economicamente viável, relativamente à 
oferta do mercado, conduziu ao desenvolvimento de um processo simples e rápido de 
extração de licopeno a partir do tomate. Posteriormente, esse extrato rico em licopeno 
foi incorporado em nanotransportadores vesiculares adequados à aplicação tópica. 




O licopeno tem sido descrito com um dos antioxidantes mais rapidamente eliminados 
na pele após a exposição à radiação solar, podendo por isso desempenhar um papel de 
proteção contra a radiação UV. Para testar esta hipótese, foram feitos estudos sobre os 
principais efeitos da radiação UV-B em queratinócitos humanos (linha celular HaCaT) 
previamente expostos ao licopeno. 
Relativamente aos métodos utilizados, a complexação da tretinoína com 
ciclodextrinas foi obtida por malaxagem e os transfersomas foram preparados através 
da adição de fosfatidilcolina de soja ao Tween® 80, de modo a obter suspensões com 
concentrações lipídicas de 10 % a 20 %. A suspensão resultante foi filtrada até obter 
vesículas com um diâmetro médio de 100-150 nm. O licopeno foi obtido previamente 
por um processo de extração a partir de tomate seco, durante 30 minutos, à 
temperatura ambiente e sob proteção da luz. Os extratos de licopeno foram analisados 
por cromatografia líquida de alta eficiência e por espectroscopia de massa e 
incorporados em transfersomas e etossomas. A caracterização físico-química das 
formulações vesiculares foi baseada na avaliação dos seguintes parâmetros: diâmetro 
médio das vesículas e índice de polidispersão, medidos por espectroscopia de 
correlação fotónica e microscopia de força atómica; potencial zeta, determinado por 
anemometria laser-doppler; concentração de fosfolípidos, determinada por um ensaio 
enzimático-colorimétrico e doseamento do fármaco por cromatografia líquida de alta 
eficiência. 
A aplicação tópica das formulações desenvolvidas envolveu diversos estudos, 
nomeadamente, os perfis de cedência e permeação, penetração na pele e alterações 
induzidas ao nível da barreira cutânea. A toxicidade das formulações finais foi testada in 
vitro. 
O potencial de irritação da formulação vesicular de tretinoína foi avaliado in vivo, 
utilizando o teste de Draize modificado, e comparado com uma forma tópica 
comercializada de tretinoína. Em relação às formulações vesiculares de licopeno, foi 
avaliado o efeito terapêutico in vivo, utilizando o modelo de inflamação aguda cutânea, 
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induzido pela formação de espécies reativas de oxigénio após a aplicação de antralina 
na orelha de ratinho. 
As condições de irradiação dos queratinócitos por UV-B, previamente expostos ao 
licopeno, foram determinadas através da realização do ensaio MTT. Após a exposição 
ao licopeno e irradiação UV-B, as células foram analisadas a fim de se obter informação 
sobre: genotoxicidade / clastogenicidade, através da análise do ciclo celular e de 
biomarcadores de apoptose e expressão genética, por citometria de fluxo e 
quantificação da reação da transcriptase reversa em tempo real, respetivamente; 
apoptose, através do ensaio da anexina V; danos causados pelo stresse oxidativo, 
através da quantificação de substâncias reativas de oxigénio por citometria de fluxo. 
Os resultados referentes à formulação tretinoína-transfersomas revelaram que a 
eficácia de incorporação foi elevada para todas as condições testadas. No entanto, a 
formulação tretinoína-transfersomas com 20 % de concentração lipídica apresentou 
maior estabilidade química. 
De acordo com os resultados dos estudos de libertação tópica da formulação tretinoína-
transfersomas, as vesículas deformáveis diminuíram a resistência elétrica da pele, 
sugerindo a sua capacidade para induzir a rutura da barreira cutânea, tal como 
teoricamente seria esperado. Além disso, através da microscopia de fluorescência, foi 
possível observar uma maior concentração destas vesículas ao nível do EC e epiderme. 
No entanto, a tretinoína não foi detetada na fase recetora nos estudos de permeação. A 
maior concentração de fármaco a nível do EC, epiderme e derme é indicativa de 
veiculação dérmica, ao passo que a presença de fármaco na fase recetora é indicativa 
de veiculação transdérmica. Deste modo, os resultados demonstraram que se obteve 
uma veiculação dérmica com a formulação tretinoína-transfersomas, a qual serve o 
propósito terapêutico, uma vez que os recetores da tretinoína, tais como RAR-γ, estão 
localizados sobretudo na epiderme. Finalmente, esta formulação não revelou toxicidade 





Em relação à extração do licopeno, o número reduzido de passos envolvidos neste 
processo pode ter melhorado o rendimento e exercido um papel benéfico na 
estabilidade deste carotenóide. Os resultados experimentais mostraram ainda uma 
incorporação eficiente do licopeno nas vesículas deformáveis. Além disso, tanto o 
licopeno extraído como o comercializado apresentaram valores reduzidos e 
semelhantes de citotoxicidade. As formulações vesiculares de licopeno extraído, 
posteriormente testadas in vivo, usando o modelo de inflamação aguda em orelha de 
ratinho induzida por antralina, promoveram a redução do edema tal como o controlo 
tratado com um fármaco modelo. 
 Nos estudos in vitro de fotocarcinogénese com queratinócitos irradiados com UV-B, foi 
possível observar que o licopeno reduziu a viabilidade destas células de acordo com os 
resultados obtidos nos ensaios de MTT e anexina V. Foi também observada a paragem 
do ciclo celular (na fase G0/G1 e um pico mais alto Sub-G1 apoptótico) e, ainda, um 
aumento do nível de espécies reativas de oxigénio. 
Em suma, e de acordo com os resultados obtidos, a veiculação dérmica de fármacos 
pode ser conseguida com sucesso através da utilização de um nanotransportador. 
Foram ainda identificados, com sucesso, alguns aspetos relacionados com a atividade 
biológica das moléculas estudadas associadas a este tipo de transporte.  
 
Palavras-Chave: Tretinoína; Licopeno; Nanotransportadores: Ciclodextrinas e 
Vesículas deformáveis; Veiculação Dérmica; Fotoenvelhecimento e Fotocarcinogénese. 
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Chapter 1.1- Tretinoin and Lycopene as Protectors Against UV-Radiation: 






























Chapter 3.1- Lycopene from Tomatoes: Vesicular Nanocarrier Formulations for 





Chapter 3.2- The Effect of UV-B Irradiation on Human Keratinocytes after 













Aims and Organization of the Thesis 
 
The aim of this thesis was to contribute to the understanding of the mechanisms 
involved in the dermal delivery of active molecules mediated by lipid-based carriers. 
Thus, the proposed work “CARRIER-MEDIATED DERMAL DELIVERY FOR PREVENTION OR 
TREATMENT OF SKIN DISORDERS” includes the use of a similar strategy of delivering 
two entities, Tretinoin and Lycopene, with similar physicochemical characteristics with 
different therapeutic interests. 
In addition to the evaluation of drug dermal delivery, chemical drug stabilization in the 
formulation was another objective addressed. 
The thesis is organized as a collection of chapters, each one with a scientific paper 
format. The first chapter is introductory to the work, with two review articles containing 
the state-of-the-art. The following chapters have the structure of research articles. 
Format differences were kept, intrinsically, according to each journal requirements and 
some aspects of the introduction, materials and methods are repeated in the different 
chapters, being these repetitions needed for each research article to be an independent 
document. 
Chapter 1.1 (Tretinoin and Lycopene as Protectors against UV-Radiation: Photoaging 
and Photocarcinogenesis) provides an overview of the role of tretinoin and lycopene for 
the treatment and/or prevention of skin disorders, such as photoaging and 
photocarcinogenesis, respectively. In fact, human skin is constantly exposed to the UV 
irradiation that may induce a number of pathobiological cellular changes. Tretinoin is 
currently marketed for topical treatment of acne vulgaris and has also been used for 
photoaging prevention and/or treatment by increasing the proliferation of 
keratinocytes on damaged skin. Lycopene was reported as the antioxidant most quickly 
depleted in skin upon exposure to solar radiation and may play a role on protecting skin 
against UV radiation. Lycopene has been implicated in reduced incidence of certain 
cancers and it was described to act as an antioxidant, act via gap-junction 
communications, modulate cell proliferation and present apoptotic properties.  
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Chapter 1.2 (Topical Delivery of Antioxidants) provides an overview of reactive oxygen 
species (ROS), antioxidants and its topical delivery by means of conventional and 
advanced delivery systems, including cyclodextrins, non-ionic surfactant vesicles, solid 
lipid nanoparticles and, in particular, liposomes and deformable vesicles. ROS and free 
radicals have been implicated in a number of diseases and disorders and the skin, for its 
localization, it is exposed to a large number of environmental insults. Free radical 
scavengers and antioxidants have thus been proposed as protective or therapeutic 
agents against ROS-mediated injuries. Topical delivery of antioxidants has gained 
increasing interest and development, especially by offering better targeting to the 
upper skin layers. However, topical delivery of antioxidants for dermal action is a 
challenging field of research since the molecules are, in general, susceptible to 
degradation. The search for a new delivery system that, simultaneously, preserves the 
antioxidant stability and enhances its deposition on the skin, opened a new chapter in 
drug delivery design. Nanocarriers have been successfully used in enhancing the clinical 
efficacy of several drugs. More recent approaches in modulating through-the-skin 
delivery led to the development of specialized nanoparticulated systems such as 
ultradeformable liposomes, cyclodextrins and the combination of both. 
Chapter 2 is related to Dermal Delivery of Tretinoin Carrier Formulations: Tretinoin-
loaded ultradeformable vesicles or transfersomes, in which the drug is complexed or in 
the free form. 
Chapter 2.1 (Novel Tretinoin Formulations: a Drug-in-Cyclodextrin-in-Liposome 
Approach) reports Tretinoin incorporation in special lipid vesicles. The ultradeformable 
systems used in this work comprised a mixture of soybean phosphatidylcholine and a 
surfactant, in a ratio that ensured adequate vesicle adaptability, drug loading and 
stability. Special attention was paid to maximize drug chemical stability. 
Chapter 2.2 (In Vitro and In Vivo Studies of a Novel Topical Tretinoin Formulation) 
presents the releasing profile and skin permeation and penetration of Tretinoin-loaded 




changes in its barrier properties in the presence of the formulation. Finally, the 
evaluation of cellular viability and the potential of skin irritation were also considered. 
Chapter 3 is related to the Dermal Delivery of Lycopene Carrier Formulations in which 
the extracted lycopene was incorporated into the carrier (transfersomes and 
ethosomes). 
Chapter 3.1 (Lycopene from Tomatoes: Vesicular Nanocarrier Formulations for its 
Dermal Delivery) presents the development of a rapid, simple and low cost extraction 
method of lycopene from tomatoes. Extracted lycopene was incorporated in 
deformable vesicles. The cellular uptake of deformable vesicles and the in vivo 
performance of lycopene formulations were also evaluated. 
Chapter 3.2 (The Effect of UV-B Irradiation on Human Keratinocytes after Lycopene 
Exposure) deals with in vitro photocarcinogenesis studies in the presence of lycopene, 
using HaCaT cells to analyze genotoxicity/clastogenicity, apoptosis and oxidative stress. 
This thesis ends with Conclusions and Future Perspectives. 
In Annex (only in electronic version) to this thesis, there are three research articles 
published during PhD work period and resulting from Master Thesis work plan. Most of 
the studies published in these articles are the background of tretinoin experiments 
performed in the PhD thesis work. 
This thesis was performed according to “Despacho n.º 4624/2012, Diário da República, 
2.ª série — N.º 65 — 30 de Março de 2012 and Deliberação n.º 1062/2008, Diário da 
República, 2.ª série — N.º 70 — 9 de Abril de 2008”. I also declare that all experiments 
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Tretinoin and Lycopene as Protectors against UV-Radiation: Photoaging 
and Photocarcinogenesis 
Abstract 
Background: The search for new anti-skin cancer drugs is particularly focused on natural 
compounds. Tretinoin (acid form of vitamin A) is involved in the control of cell differentiation and 
proliferation in several tissues, particularly in the skin epithelium. Lycopene (carotenoid with non 
vitamin A activity) has been proposed to play a critical role on anticarcinogenic action at different 
levels in both in vitro and in vivo tumour models. 
Scope of the review: This review focuses on the effect of UV-radiation on skin, and the 
photoprotection conferred by two different active molecules: tretinoin an d lycopene against  
photoaging and photocarcinogenesis, respectively. Regarding this context, skin cancer (non- 
melanoma and melanoma cancer) is addressed as well as other current therapeutic strategies.  
Major Conclusions: UV irradiation may induce a number of pathobiological cellular changes, 
including photoaging and photocarcinogenesis. Tretinoin can be used for photoaging treatment by 
different mechanisms, including the inhibition of the activated protein-1 and blocking dermal matrix 
degradation followed by sun exposure. The photoprotective properties of lycopene remain unclear. 
Some studies point out a positive and others a negative effect both in in vitro and in vivo models. 
Currently, researchers recognize that crucial gaps endure in our understanding of the role of 
carotenoids as effective modulators of apoptosis, cell cycle dynamics and/or of their in vivo behavior 
as cellular antioxidants.  On other hand, it remains to confirm if these compounds, supplied through 
a suitable diet combining different natural antioxidants, contribute to basal protection and improve 
skin defense against UV light-mediated damage to skin.  
General Significance: The development of novel preventive and therapeutic strategies for skin 
disorders depends on our understanding of the molecular mechanism of UV damage on skin cells.  
The use of several effective phytocompounds, working through different (preventive and/ or 
corrective) pathways in the cell, may be an effective approach for reducing UV-B generated damage 
mediated photoaging and photocarcinogenesis. 
 
Keywords: Photoaging; Photocarcinogenesis; Lycopene; Tretinoin 
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The effects of solar ultraviolet radiation (UVR) on most living organisms and, 
particularly, on human health are well known. Some of the beneficial and most 
detrimental effects of UVR on human health have been recently reviewed by Norval et 
al. (1). In order to cope with the consequences of UVR exposure, both plants and 
animals possess various protective small molecules and enzymatic defences such as the 
families of superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase 
(GPx). If the concentration of free radicals increases significantly and reaches a critical 
level, the generated oxidative stress can destroy cells and cell compartments and, 
consequently, origin premature skin aging and also skin cancer (2).  
The search for new anti-cancer drugs is particularly focused on natural compounds, such 
as botanical antioxidants, available in the regular human diet. These compounds 
efficiently regulate a wide range of cellular pathways involved in carcinogenesis, and 
rarely exhibiting severe side-effects (3). Botanical antioxidants can be divided in 
different chemical groups, such as: polyphenols, phenols, flavonoids, isoflavonoids, 
phytoalexins, anthocyanidins and carotenoids. They can work in preventive ways 
(sunscreen and antioxidant effects) and/or in corrective ways  (redox regulation of signal 
transduction pathway) (4, 5). The use of effective phytocompounds in skin care 
products may be an approach for reducing UV-B generated reactive oxygen species 
(ROS) mediated photoaging and photocarcinogenesis (4). 
Carotenoids are protective pigments at the complex I and II in plants photosynthetic 
systems, and are in abundant quantities in several crops (6, 7). Carotenoids defence 
properties in human cells may involve their potent antioxidant activity  and their ability 
to induce cellular protective responses (8). In fact, the influence of carotenoids and/or 
their metabolites on the expression of certain genes and on the inhibition of regulatory 
enzymes has already been discussed regarding its cancer preventive properties (9).  
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In this review, a special focus will be given to the two carotenoid related compounds 
tretinoin and lycopene in the context of their protective effects of photoaging and 
photocarcinogenesis, respectively.   
Tretinoin is a natural-occurring acid of retinol, an active metabolite of vitamin A, and is 
an agent involved in the control of cell differentiation and proliferations in several 
tissues, particularly in the skin epithelium. It binds to and activates retinoic acid 
receptors (RAR), inducing changes in gene expression that leads to cell differentiation, 
decreased cell proliferation, and inhibition of tumourigenesis. It has been demonstrated 
that photoaging resulting from UV-B radiation can be treated by retinoid formulations. 
Pretreatment of human skin with tretinoin blocks dermal matrix degradation (followed 
by sun exposure) inhibiting the induction of the activated protein-1 (AP-1) transcription 
factor and AP-1 regulated matrix-degrading metalloproteinases (MMP). Tretinoin is 
largely used in cosmetics, and is commercially available worldwide under several brand 
names.  
Lycopene is a non-provitamin A carotenoid that is responsible for the red to pink colors 
seen in tomatoes, pink grapefruit, and other foods (10). Lycopene has been recognized 
as the most effective singlet oxygen quencher among carotenoids (11) and it is currently 
receiving considerable scientific attention (3). Epidemiological, tissue culture, and 
animal studies provide convincing evidence supporting the role of lycopene in the 
prevention of chronic diseases. Human intervention studies are now being conducted to 
validate epidemiological observations and to understand the mechanisms of action of 
lycopene in disease prevention (12).  
The anticancer activity of lycopene has already been demonstrated in both in vitro and 
in vivo tumour models (13). The inhibitory effects of lycopene on carcinogenesis may be 
due to different mechanisms, such as: ROS scavenging, upregulation of detoxification 
systems, interference with cell proliferation, induction of gap-junctional communication 
(GPC), inhibition of cell cycle progression and modulation of signal transduction 
pathways (13). Some of these mechanisms will be discussed in this review within the 
photocarcinogenesis context. 
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1. UV-Radiation and its Effects on Skin 
 
Although both the environment and genetics may play a role in the development of skin 
cancer, UVR is considered to be one of the most efficient skin carcinogens and 
mutagens as well as immunosuppressive agent. The UV spectrum is composed by: UV-C 
(200-280 nm), UV-B (280-320 nm) and UV-A (320-400 nm) (Table 1). The UV-C has the 
higher energy radiation, but it is (almost) blocked by the ozone layer and the UV-B and 
UV-A represent about 5 % and 90 % of UVR, respectively. Although there are beneficial 
effects of UVR on skin, such as the generation of vitamin D and therapy of some skin 
diseases (atopic eczema, psoriasis), there are also acute and chronic harmful effects 
especially if the UVR exposure is too prolonged. The main effects of acute exposure 
include “sunburn” or erythema, acanthosis (i.e. increase of epidermal thickness), 
desquamation, immunosuppression (increase of interleukins IL-10 and IL-12) and 
immediate pigmentation darkening. The effects of chronic exposure  are the solar 
elastosis (i.e. the accumulation of elastin in the superficial dermis ), degradation of 
collagen and skin cancer (4, 11). 
UV-A and UV-B radiation can cause photoaging and photocarcinogenesis through lipid 
peroxidation, protein cross linking and DNA damage. (14). 
 
       Table 1 - Global Solar Spectral Irradiance measured at sea level  (15). 
Wavelength 
(nm) 
Domain Energy (W/m2) % 
280-320 UV-B  4-2 
 6.8 
320-400 UV-A  72-50 
400-780 Visible  580-660  55.4 
780-1400 IR A 
 410-430  37.8 
1400-3000 IR B 
 
The minimal erythema dose (MED) is the threshold dose required to cause a 
perceptible reddening of the skin 24 h after exposure. The estimated MED narrow band-
UV-B radiation in north Indian patients varied from 500 to 1100 mJ/cm2  (16). However, 
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MED values differ among individuals and depend on the endogenous protection 
provided by melanin and on the skin type which is usually categorized according to the 
Fitzpatrick scale (type-I to IV). Skin type I corresponds to people with white or freckled 
skin, green or light –blue eyes, red hair and high sensitivity to sun light; skin type IV 
shows black skin, dark brown eyes and black hair, rarely experiencing sunburn. The 
repair of UVR skin damages occurs within 24 h only if the irradiation dose is ≤ 60 % of 
the MED (17, 18). The sunburn starts to develop few hours after irradiation, worsening 
about 18-24 h post-irradiation. When UVR exposure causes irreversible cell damage, cell 
death follows via apoptotic mechanisms, leading to the appearance of sunburn cells in 
the epidermis layer (18, 19).  
The skin has natural defenses against the damaging effects of UVR, such as: (1) The SC 
that absorbs, reflects and scatters UV rays; (2) skin pigmentation: melanin absorbs and 
scatters UVR, and is a free radical/ROS scavenger; (3) naturally occurring antioxidants 
such as lipophilic carotenoids, alpha-tocopherol (or vitamin E), glutathione and ascorbic 
acid (or vitamin C); (4) antioxidant enzymes such as CAT, SOD and GPx; (5) DNA repair 
mechanisms and (6) epidermal hyperplasia and hyperkeratosis that increase the 
physical barrier to UVR (20, 21).  
The importance of the skin’s natural defenses against the damaging effects of UVR can 
be observed in several clinical syndromes, such as Xeroderma Pigmentosum and 
Oculocutaneous Albinism (20). 
 
 
1.1 Photoaging and Photocarcinogenesis 
Aging is a complex process in which several mechanisms operate simultaneously. These 
mechanisms may include accumulation of genome mutations and toxic metabolites, 
hormonal deprivation, increased ROS, and cross-linking of macromolecules by glycation 
(22). ‘Photoaging’ or ‘extrinsic aging’ is the process by which sunlight or artificial UVR 
gradually induces clinical and skin histological changes (20). On one hand, UV-A 
radiation is considered to be the main cause for premature skin aging (23) because it 
corresponds to the major percentage of total UVR, and has a higher depth of 
Tretinoin and Lycopene as Protectors against UV radiation:  






penetration into the dermis (24). On the other hand, UV-B-induced DNA damage leads 
to MMP-1 induction, the main enzyme responsible for collagen 1 digestion (25). UVR-
induced cutaneous alterations may be characterized by dryness, rough texture, 
irregular pigmentation (hyper or hypomelanosis), yellowish color, telangiectasia, 
plaque-like thickening, deep creases and wrinkles. These skin changes may vary 
considerably among skin types (20, 26).  
Skin Histological changes (Table 2) due to chronic UVR exposure may involve both 
epidermis and dermis layers, and ultimately, to malignant skin cells transformation (20).  
 
Table 2- UVR-induced Histological Changes in Epidermis and Dermis Layers  (adapted from (20, 24, 26)) 
Epidermis Dermis 
 epidermal hyperplasia or atrophy 
 disappearance of dermal papillae  
 thickening of the basement membrane 
 ↑ and irregular distribution of melanocytes and melanosomes  
 atypical proliferation of keratinocytes (solar keratosis) 
 ↓ naturally occuring antioxidants (↑ROS) 
 thickening of Stratum Corneum (SC)  
 elastosis 
 presence of deformed collagen fibers 
 ↓collagen 
 dilated blood vessels 
 ↑ Matrix Metalloproteinases (MMPs) 
 
Solar Elastosis is clinically manifested as yellow discoloration and pebbly surface of the 
skin, being a prominent characteristic of photoaging. The dermis displays accumulation 
of elastotic material in the mid and upper layers. In addition, glycosaminoglycans and 
proteoglycans increase, while the amount of collagen decreases in photodamaged skin. 
UVR-induced collagen degradation is usually incomplete, contributing to the 
accumulation of partially degraded collagen fragments in the dermis that may interfere 
with skin integrity. Besides, the large collagen degradation products inhibit new collagen 
synthesis. In addition, there is also a cellular accumulation of lipofuscin related to 
chronological aging that further inhibits proteasome function (24).  
UVR may also disrupt the telomere loop, expose the TTAGGG overhang, and promote 
aging. In fact, intrinsic aging is accompanied by repeated cell divisions that shorten 
telomeres (24).  
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Photodamaged skin generally presents an increased number of hyperplastic fibroblasts 
as well as inflammatory cells. This chronic inflammation in photoaged skin corresponds 
to heliodermatitis. Perivascular veil cells may display dilations (telangiectases) in severe 
photodamaged skin. UVR has also been involved with the immunosuppression system 
which may have implications in cutaneous tumour surveillance (24, 27). Rijken (20) 
believes that neutrophils may play an important role in the pathophysiology of 
photoaging. 
The oxidative stress generated by UVR in keratinocytes and fibroblasts can modify 
proteins forming carbonyl derivatives which accumulate in the papillary dermis. In 
addition to their oxidative effects on lipids and proteins, ROS also attack nucleic acids, 
mainly nuclear and mitochondrial DNA. The 8- hydroxyl-2´-deoxyguanosine (8-OHdG) is 
a representative DNA base –modified product generated by ROS and is considered as 
one of the most important biomarkers of carcinogenesis.  It induces G-C  T-A 
transversions during DNA replication. The transversions residual presence in DNA of 
normal and neoplastic tissues results from the imbalance between oxidative attack and 
DNA repair (28). Upon DNA repair, 8-OHdG is excreted in the urine. According to the 
European society of pigment research (29), a strong generation of 8-OHdG was related 
with the proliferation of melanocytes.  
Overall, the increase of ROS levels may regulate a cascade of signal transduction, 
including the involvement of Mitogen-activated protein kinase (MAPK) pathways, and 
leading to the up-regulation of the activator protein 1 (AP-1) and of the Nuclear Factor 
(NF-kB), and to the down-regulation of the Transforming Growth Factor (TGF-β). While 
NF-kB regulation increases interleukin-1 family (IL-1) and Tumour Necrosis Factor (TNF-
α) levels, the AP-1 up-regulation activates MMPs. On the other hand, the decrease of 
TGF-β expression decreases the synthesis of collagen. Ultimately, the combination of 
these changes lead to the increase of collagen breakdown and elastin production in 
extracellular matrix and, therefore, to matrix degradation (Fig.1) (30).  
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Fig.1- Effects of ROS increase on transcriptional regulation of some important proteins in the skin matrix, 
involving NF-kB, AP-1 and TGF-β pathways. Adapted from Chen et al. (30) 
 
Photocarcinogenesis is a complex multistage phenomenon involving three distinct 
stages exemplified by initiation, promotion and progression. Each of these stages 
involves biochemical and molecular alterations in the cell (Fig.2). 
                                
Fig.2- Brief overview of the main cell  mechanisms involved in photocarcinogenesis. Adapted from 
Matsumura & Ananthaswamy (31). 
Cell  Cycle Arrest DNA repair 
  Apoptosis 
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Keratinocytes apoptosis contributes to the regulation of epidermal development and 
carcinogenesis restrain. The extrinsic pathway (via cytoplasm) is stimulated by UV-B or 
binding of Fas ligand, tumor necrosis factor, or other cytokines to death receptors that 
results in the activation of a caspase cascade. The intrinsic pathway (via mitochondria) 
is also stimulated by UV-B and involves mitochondrial depolarization and higher 
membrane permeability, leading to the release of multiple proapoptotic factors 
including cytochrome c,  Smac and the apoptosis inducing factor (AIF) (31). Bid protein 
links both extrinsic and intrinsic pathways, and the activated Bid fragment will cause the 
mitochondrial content release. Activation of upstream caspases (caspase-8 or -9) leads 
to the activation of downstream caspases (caspase-3 or -7) resulting in the cleavage of 
intracellular substrates, cellular condensation and nuclear fragmentation. Apoptosis 
inhibitors include caspase inhibitors and the big complex Bcl-2 family proteins, most of 
which prevent mitochondrial membrane permeability (32). 
Caspase-14 is a keratinocyte-specific caspase only found in skin. It was only expressed in 
HaCaT cells and normal human keratinocytes under culture conditions mimicking 
terminal differentiation. In addition, caspase-14 could not be induced by death 
receptors signaling or UV-B irradiation.  Although the targets of activated caspase-14 








Tretinoin and Lycopene as Protectors against UV radiation:  






In general, the process of skin cancer development involves many different cellular 
mechanisms and events, as synthetically indicated (4, 33-35): 
• abnormal stimulation of DNA synthesis and 
unability to repair DNA damages. A major 
reason of these abnormal events is the 
frequent mutation of the suppressor tumour 
p53 gene, which protects cells from DNA 
damage through repair mechanisms or 
apoptosis of damaged cells ;  
• formation of pyrimidine photodimers in 
nucleic acids and activation of the ataxia 
telangiectasia mutated family proteins  of 
keratinocytes;  
• deregulation of apoptosis leading to 
abnormal proliferation of keratinocytes, 
inflammation, epidermal hyperplasia and 
immunosuppression (increase of IL-10, IL-12); 
 •    activation of proto-oncogenes (e.g. Ras); 
 cell cycle deregulation;  
• increase of ROS levels and depletion of 
antioxidant enzymes activity;  
• impairment of signal transduction pathways 
and induction of ornithine decarboxylase (ODC) 
activity (an important enzyme linked to the 
development of skin tumors) and of 
cyclooxygenase-2 (COX-2, an enzyme involved 
in inflammation process); 
• photoisomerization of trans to cis-urocanic 
acid, which acts as an endogenous sunscreen 
against UV-B. 
 
Exposure to UVR also causes alterations in the morphology and function of antigene-
presenting Langerhans cells (36), release of immunosuppressive cytokines (37), and 
enhanced prostaglandin synthesis (38). In fact, Langerhans cells and dendritic cells of 
lymphatic system are the major cellular chromophores absorbing UV-B radiation (25). 
Excessive UVR leads to calcium increase in keratinocytes, resulting in the activation of 
the inflammasome (a multiprotein of the innate immune complex) and in the synthesis 
and release of IL-1, which can activate the synthesis of other proinflammatory cytokines 
(8, 39). IL-10 appears to be a key mediator of UVR-induced immunosupression (8, 40), 
while IL-12 was found to accelerate the removal of UVR-induced DNA lesions in 
keratinocytes by inducing nucleotide-excision repair. These findings strongly suggest 
that it plays a protective role in photocarcinogenesis (8, 41). In addition, UVR induces 
the synthesis of granzyme B and perforin in keratinocytes (proteins only present in 
cytotoxic lymphocytes and natural killer cells ), leading keratinocytes cytotoxic to 
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transformed cells. This cellular transformation strongly suggests that UV-irradiated 
keratinocytes participate in skin cancer surveillance (24). 
 
Abnormal DNA methylation is a hallmark of most cancers. It is a marker of epigenetic 
events, i.e. susceptible to change with environmental factors, and a fundamental 
process that modulates gene expression and regulates the chromosomal stability.  
Hyper or hypomethylation in G-C rich regions can contribute to carcinogenesis by 
silencing tumour suppressor genes (e.g. p53), upregulating oncongenes at dipyrimidine 
sites and by decreasing genomic stability. The maximum absorption of DNA purine and 
pyrimidine bases lies between 230 and 300 nm. Therefore, DNA is a major UV-B-
absorbing cellular chromophore in the skin  The major types of DNA photoproducts 
induced by carcinogenic UV-B are: cyclobutane pyrimidine dimmers (CPD) and 
pyrimidine (6-4) photoproducts (33). The primary response to DNA photodamage is the 
photolesions repair in surviving cells. Different repair pathways become active, such as: 
direct repair, base excision repair, mismatch repair, double strand break repair, and 
nucleotide excision repair. The latter is considered to be the major line of defense 
against carcinogenesis. Phosphorylated p53-induced transcription of p21 causes G/S cell 
cycle arrest, allowing the cellular repair pathway to remove DNA lesions before DNA 
synthesis and mitosis (25). However, if the damage persists into the S-phase, other 
repair mechanisms might lead to mutagenesis  resulting mainly in characteristic C→T 
substitutions. When such mutations occur in the p53 gene, keratinocytes lose their 
ability to undergo the apoptosis process following UVR exposure. The degenerative 
changes in keratinocytes include mitochondrial swelling and rupture, condensation of 
the cytoplasm and the appearance of pyknotic nuclei. Macrophages bind and 
phagocytise apoptotic keratinocytes and their number increase significantly in the skin 
after UV-B exposure (5, 8, 33, 42, 43). Chemopreventive agents may be used to correct 
aberrant methylation patterns and restore the control of tumour cells growth and/or 
against UVR side effects (43). 
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Several strategies are applicable for photoprotection and subsequent impairment of 
molecular and cellular functions. Behavioral changes (avoidance of sun exposure and 
protective covering) and sunscreens with a high sun protection factor are highly 
recommended during times of intense exposure. In order to increase the barrier for 
UVR, the compound should absorb UVR over a broad range of wavelength with high 
efficacy, and sufficient photostability is also required.  Topically applied organic 
(previously called chemical) and inorganic (previously called physical) sunscreens 
protect by absorbing or reflecting radiation at the skin surface, respectively. Organic 
sunscreens are usually “not visible” and cosmetically appealing. However,  the first-
generation of organic sunscreens were quite unstable and reactive. Allergic sensitization 
could occur due to UVR absorption which could lead to the interaction of the suncreen 
with cutaneous molecules. Inorganic sunscreens contain 10–100 nm particles (eg. zinc 
oxide or titanium), and are chemically inert, and thus, not potentially allergenic (24). 
Nanoencapsulation of organic UV filters is a more recent approach to improve skin 
retention, photostability and the UV blocking ability of the free molecules  (25). 
 
Compounds that interfere with stress-dependent signaling are demanded for the 
induction of repair systems dealing with UVR-induced damage (11). Furthermore, DNA 
damage repair enzymes (enzyme T4 endonuclease V; photolyase; oxoguanine 
glycosylase 1; thymidine nucleotides); antioxidants and dietary lipids; iron quelators (eg. 
Kojik acid); osmolytes; retinoids (tretinoin); fluorouracil, imiquimod, lipospondin; 
chemical peels (eg. α-hydroxy acids), dermabrasion, photodynamic, laser and 
radiofrequency therapies (44), injectables (eg. botulinum toxin and hyaluronic acid), and 
surgical procedures have also been proposed as strategies for the prevention and/or 
treatment of photoaging (20, 24).  Another approach is related to the induction of 
melanin production without sun exposure. Although the regulation of the tanning 
response is complex and only partially elucidated, current facts suggest that UVR-
induced DNA damage or its repair is, at least, one of the initial signals that stimulates 
melanogenesis (24). Gilchrest et al. (45) showed that administration of the repair 
enzyme T4 endonuclease V to irradiated melanoma cells increased both their rate of 
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repair and UVR-induced pigmentation. These data also suggest that tanning can be 
stimulated through enhanced DNA repair. Other approaches for increasing skin 
pigmentation are based on telomere homologue oligonucleotides, Forskolin and α-
melanocyte-stimulating hormones analogues (24).  
Finally, natural substances extracted from herbs (polyphenols, phenolic acids, 
flavonoids, carotenoids) can acts as other potential photoprotective resources due to 
their UVR absorbing and antioxidant properties (46). However, their photoprotective 
effect is not itself comparable to the use of a sunscreen (7). 
 
 
2. Skin Cancer 
Skin cancer remains one of the most common human cancers and, despite educational 
efforts, it shows a high incidence which has a tremendous impact on public health and 
healthcare expenditures (47). Although both the environment and genetic components 
play a role in the development of skin cancer, UVR is considered to be one of the most 
efficient skin carcinogenic and mutagenic agents, besides being an effective 
immunosuppressive agent (48).  
The risk of skin cancer is expected to increase as the population ages and larger 
amounts of UVR reach the surface of the Earth because of depletion of the stratospheric 
ozone (43, 49). Although keratinocytes are resistant to UVR- induced damage, repeated 
exposure results in accumulated DNA mutations that can lead to skin malignancies. 
Therefore, it is desired to develop newer and effective chemopreventive agents and 
strategies, which can inhibit or slow down the UVR-induced risk of melanoma and non-
melanoma skin cancers (Fig.3) especially among high-risk human populations (43). 
Preventive strategies including personal behavioral modifications and public educational 
initiatives are considered to be both life-changing and life-saving (50). 
Fig.3 shows the fate of the different solar UVR components. The specific DNA lesions 
produced by UV-A and UV-B in this range of wavelengths include the production of  
various types of DNA photoproducts (33).  
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Fig.3- Exposure to UV radiation and development of melanoma and non-melanoma skin cancers. UV-A 
radiation reaches the dermis and to some extent also the subcutis, whereas UV-B does not pass beyond 
the epidermal layer.  
 
The importance of epigenetic events is that it represents a mechanism by which gene 
function is selectively activated or inactivated. Because epigenetic events are 
susceptible to change, they represent excellent targets to explain how environmental 
factors, including dietary constituents, supplements, chemopreventive agents may 
modify cancer risk and tumour behaviour (43, 51).  
The formation of skin cancers is a biological process much more complex than narrow 
scientific aspects that are individually and, sometimes, independently investigated. 
Recent studies have focused the investigation on the regulation of apoptosis in the skin 
and its application for understanding skin carcinogenesis  (32). Acute UV irradiation 
causes apoptosis involving p53 and Fas-FasL pathways (FasL, a member of TNF 
superfamily involved in the elimination of apoptotic cells and prevention of cell 
transformation). Chronic UV irradiation results in deregulation of apoptosis, leading to 
the abnormal proliferation of photodamaged keratinocytes, acquisition of p53 
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mutations, loss of Fas-FasL interaction besides decreased death receptors, Stat3 
activation and variation of Survivin, Bcl-2 and Bcl-XL expression. All of these events 
contribute to the onset of skin cancer (25, 32). Dysfunctional apoptosis occurring in skin 
cancer has been studied and gene silencing by RNA interference may become a new 
approach to reverse apoptosis resistance (52) as it has been successful in tissue cultures 
and tumor tissues, as well as, in a mouse model (53).  
The current tools for measuring cumulative sun damage are biopsy histology and skin 
microtopography. Nevertheless, skin biopsies are too invasive and skin replicas provide 
only superficial skin architecture data. Reflectance confocal microscopy is a noninvasive 
imaging tool that allows in vivo skin imaging (54). The Raman spectroscopy is well suited 
for the screening of cancer patients prior to chemotherapy, to detect high-risk patients, 
who can be successfully treated with topical antioxidants, thus preventing the 
occurrence of palmar–plantar erythrodysesthesia (PPE), a dermal side effect of 
chemotherapy (2). 
 
2.1 Non-Melanoma Cancers 
The non-melanoma skin cancers (NMSC), basal cell carcinoma (BCC) and squamous cell 
carcinoma (SCC) are the most frequent cutaneous malignancies and represent around 
80 % and 16 % of all skin cancers, respectively, whereas malignant melanomas 
represent only about 4 % of all skin cancers (55). Both BCC and SCC are derived from the 
basal layer of the epidermis. SCC especially affects people over 40 years of age who 
sunburn easily without tanning, and people who are immunosuppressed (55). BCC 
doesn’t metastasize but can be locally invasive and destructive. On the contrary, SCC is 
an invasive non-melanoma cancer and can metastasize. Dermoscopy improves the 
diagnosis of NMSC at different stages of progression (55). 
The combination of genetic factors usually with long term sun exposure contribute to 
the formation of these cancers, being UVR responsible for the induction of DNA damage 
in keratinocytes (56). However, UVR damaged DNA may be repaired or DNA damaged 
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cells undergo elimination process via an apoptotic mechanism (57). It is currently 
considered that deregulated cell proliferation and apoptotic pathways lead to the 
development of cancer. Therefore, it appears that exploiting the apoptotic potential of 
cancer cells might lead to new therapies that could be less toxic to normal cells due to 
their physiologically controlled survival pathway.  
The most significant pathogenic event in BCC is considered the mutations in the 
Hedgehog pathway related genes, especially PTCH, a human homologue of the patched 
gene in Drosophila melanogaster (25). In general, BCC have reduced expression of Bax 
and increased expression of Bcl-2, while Bcl-XL is overexpressed in SCC.  However, a 
relatively higher apoptotic rate in BCC may account for the slow growth of clinical 
lesions. In SCC, expression of Survivin, Bcl-2 and Bcl-XL is associated with metastasis or 
poor prognosis. Progression of SCC is also associated with constitutive activation of 
keratinocytes survival signaling pathways (32). 
Prevention of SCC is directly achievable through sunscreen protection (58) being dietary 
factors and nonsteroidal anti-inflammatory drugs potential second-line preventions 
(59). By targeting different pathways identified as important in the pathogenesis of 
NMSC, an approach combining multiple agents (with different targets in the cell) or the 
addition of chemopreventative agents to topical sunscreens may offer the potential for 
novel and synergistic therapies in preventing and/ or treating NMSC (60). Recently 
published data showed the failure of topical tretinoin in chemoprevention of NMSC 
(61). Photodynamic therapy (PDT) with topic 5-  aminolaevulinic acid was used in NMSC 
therapy as a non-invasive therapy with possibility of treatment for multiple lesions in 
only one session (62). However, the recurrence rate increase after drug-PDT diode laser 
single session can be observed in a long-term follow-up, and the repetitive sessions is 
strongly recommended (62). Other potential therapies could include the introduction of 
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2.2 Melanoma Cancers 
Cutaneous malignant melanoma arises through the interplay of both environmental and 
genetic factors and is highly invasive. This type of skin cancer is capable of metastasizing 
to distant sites. Melanoma is thought to develop starting with a benign nevus (63). The 
propensity to develop nevi is genetically determined. For the skin with low propensity, 
repeated and cumulative exposure to the sun is required for melanoma development. 
However, in people with high nevus propensity, even short exposure to the sun could 
lead to melanoma development (64). The role attributed to the intermittent sun 
exposure in the genesis of most melanoma and BCC in the case of sunbeds has been 
also discussed (65). Patients with advanced melanoma with dissemination to distant 
sites and visceral organs have a very poor prognosis. PDT for patients with skin 
metastases from melanoma only works in 20 −30 % of these patients (66). Melanoma 
research on the mechanisms by which UVR initiates this cancer are needed to improve 
prevention strategies and have been investigated in mouse models (67). Eggermont & 
Robert (68) reviewed the later 40 years of lack of progress on melanoma treatment.  
However, in the last decade, great advances have been made, both in terms of targeted 
drugs that kill melanoma cells and in terms of host immune system modulating drugs, 
which use however still remains under discussion (69, 70).  
A new development in 2011 in melanoma adjuvant therapy resulted with interferon 
IFN-alpha2b on the basis of the ECOG 1697 trial which found no difference in 
recurrence-free or overall survival (71). In March 2011, pegylated IFN-alpha2b 
(PegIntron®) was approved by the Food & Drug Administration (FDA) for the treatment 
of stage III melanoma based on the result of the EORTC 18991 trial, which found that 
PegIntron®  induced a significant increase in recurrence-free survival in patients with 
stage III melanoma, with lymph-node-positive melanoma (72, 73). Two other adjuvant 
therapy trials, the EORTC 18071 and DERMA trial are completed.  The importance of 
ulceration and IFN sensitivity in adjuvant trials have led to the EORTC 18081 trial, in 
course, in patients with ulcerated primary melanomas to prospectively investigate IFN 
sensitivity (68). A current trial, ECOG 1609, is comparing treatment with Yervoy™ 
(Ipilimumab) against standard high-dose IFN-2b. Ipilimumab, anti-Cytotoxic T 
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Lymphocyte Antigen 4 (CTLA-4) monoclonal antibodies treatment induces low response 
rates but durable responses (74). Vemurafenib (Zelboraf® from Roche) was the first FDA 
approved treatment for the B-Raf proto-oncogene (BRAF) mutation-positive metastatic 
melanoma and it has been associated with high response rates in up to 70 % of patients 
(55). The combination of the BRAF inhibitors with MAPK/ERK kinase protein inhibitors 
have fewer side effects and induced higher response rates. However, resistance to the 
drugs was developed and relatively short periods of response were achieved (55). 
In conclusion, new drugs and probable combinations are under investigation and 
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3. Photodamage Skin Care Agents 
3.1 Tretinoin 
3.1.1 Physicochemical Properties 
Tretinoin, also known as all-trans-retinoic acid (ATRA), is a naturally occurring derivative 
of vitamin A (retinol). The 13-cis isomer is called isotretinoin. Tretinoin belongs to the 
first generation of non-aromatic retinoids. The physico-chemical properties of tretinoin 
are represented in Table 3. There are two sources of dietary vitamin A. Active forms, 
retinaldehyde and retinol, are obtained from animal products. Precursors or 
provitamins, which are converted to active forms by the body, are obtained from fruits 
and vegetables containing yellow, orange and dark green pigments, known as 
carotenoids (75). 
 
Table 3- Physicochemical properties of Tretinoin (75-78). 
Molecule Tretinoin 
Molecular Structure  
 
IUPAC Name  (2E,4Z,6E,8E)-3,7-Dimethyl -9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid 
MF C20H28O2 
MW (g/mol) 300,44 
Physical state yellow to light-orange crystalline powder 
Solubility  Insoluble in water (20 °C); Soluble in chloroform; slightly soluble in ethanol  
Log P  4-5 
Melting Point (C) 180 – 181 
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3.1.2 Bioavailability and Metabolism 
The human cells convert precursors to retinol, and then the de-esterified alcohol can be 
converted to metabolically active retinal (the aldehyde of retinol) and retinoic acid (the 
oxidized form of retinol) formed by carboxylation of retinal. The steps of metabolism, 
especially the inactivation of the retinoids, are not yet fully understood (77). 
When applied on skin, all forms of trans-retinoic acid isomerize partly on the epidermis 
in 9-cis and 13-cis-retinoic acid, among other metabolites. Approximately 80 % of 
retinoic acid remains on the skin surface, and it penetrates depending on the type of 
vehicle formulation (79).  
 
3.1.3 Safety 
The collateral effects of topical administration of tretinoin include redness, 
desquamation, dryness, and burning tingle (80). The transdermal penetration and 
systemic bioavailability of topical retinoids are not yet completely clarified. Despite its 
short half-life, some authors defend that overexposure to tretinoin may cause 
teratogenesis and embryotoxicity (81, 82). However, there is not a consensual opinion 
about the use of topical retinoids during the pregnancy (83). 
 
3.1.4 Biological Activity and Pharmacological Action 
The retinoic acid receptors are α, β and γ -RAR and retinoid X receptor (RXR), and the 
cytosolic skin binding proteins are the CRABP (cellular retinoic acid binding proteins). 
This connection promotes various action mechanisms, such as normalization of 
proliferation and differentiation of the epidermis, decrease of prostaglandins, 
leukotrienes and cytokeratins release and inhibition of neutrophil chemotaxis (84). An 
alternative pathway may be via aquaporin type 3 present in keratinocytes, facilitating 
the movement of water and glycerol through the skin (79, 85).  
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Retinoids, including tretinoin, are important regulators of cell proliferation and 
differentiation, and are mainly used to treat acne and photodamaged skin and to 
manage keratinization disorders such as ichthyosis and keratosis follicularis.  
Retinoids have also been used as chemopreventive and anticancer agents because of 
their pleiotropic regulator function in cell differentiation, growth, proliferation, DNA 
repair and apoptosis. Although oral retinoids have not been effective for 
chemoprevention of skin cancer in the general population (86), the use of topical 
retinoids as chemopreventive agents has yielded variable results, some positive (87) 
others not (51, 60, 61, 88). However, according to Shimizu et al. (89) ATRA can suppress 
the process of carcinogenesis both in vitro and in vivo, especially in the treatment of 
various cancers, including SCC. Tretinoin represents the class of anticancer drugs called 
differentiating agents and is used in the treatment of acute promyelocytic leukemia  
(90). Roméro et al. (91) have demonstrated in vitro that retinoic acids are potent 
inhibitors of UV-B induced melanogenesis  via tyrosinase related proteins (TRP-1 and 
TRP-2) expressions. 
 
3.1.4.1    Acne 
Retinoids are considered the first line treatment for acne, being also used in 
maintenance therapy. These drugs cause the desobstruction of the pores, preventing 
the formation of white spots, which lead to an anti–inflammatory and comedolytic 
action. Also, it is usual the topical combination of antibiotics with retinoids to treat 
comedogenesis, bacterial growth and inflammation. This combination also increases the 
effectiveness and tolerance to the treatment. On the other way, benzoyl peroxide can 
be used in combination with topical retinoids to reduce the dose of antibiotic. It is 
important to use daily solar protection during the treatment due to the skin 
sensitization to the solar exposure (92, 93).  
The currently commercial available formulations include 0.025-0.1 % of tretinoin topical 
creams or gels. However, new sustaining release systems are emerging, in which the 
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active substance is vehiculated in microsponges or polymers in order to remain at the 
SC, the outermost layer of the skin, thus promoting comedolisis and modulation of the 
keratinocytes proliferation (94). Recently we have developed a new formulation of 
tretinoin-loaded ultradeformable vesicles, which revealed to be a promising delivery 
system for tretinoin dermal delivery without promoting skin irritation that is usually 
observed in currently available commercial formulations (95). 
 
3.1.4.2    Photoaging 
Tretinoin is also used on fine wrinkling, mottled hyperpigmentation, roughness 
associated with photodamaged skin (90). The described (long term) effects of topical 
retinoids on the skin are: (1) reduction and redistribution of epidermal melanin, (2) 
improved ultrastructural characteristics of the epidermis, (3) increased anchoring fibrils, 
(4) increased deposition of papillary dermal collagen, and (5) increased vascularity in the 
papillary dermis (21, 70).  
UV irradiation results in a functional deficiency of vitamin A as a consequence of the 
lower expression of the two predominant retinoid receptors in human skin, RAR- and 
RXR-. The same happens in UV-B irradiated cultured keratinocytes and melanocytes. 
Contrarily to keratinocytes, irradiated melanocytes return to normal values 2 to 3 days 
after irradiation (27, 96, 97). Pretreatment of human skin with tretinoin blocks dermal 
matrix degradation following sun exposure inhibiting the induction of the AP-1 
transcription factor and AP-1 regulated matrix-degrading MMPs. Tretinoin does not 
interfere with UVR-induced upregulation of tissue inhibitors of metalloproteinases 
(TIMP) thus favoring collagen preservation (24, 98).  In fact, Singh et al. (26) 
demonstrated by photomicrography the restoration of procollagen-1 in the papillary 
dermis after treatment with 0.1 % tretinoin during 40 weeks. 
Clinically modest but highly statistically signficant improvements in global appearance of 
photoaged skin treated with tretinoin were shown in several double-blind vehicle-
controlled trials involving more than 700 subjects. These data led to the first U.S. FDA 
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product (Renova®) approval for the indication of improving photoaged skin (24, 99). The 
beneficial effects are dose-dependent and increase with duration of therapy for at least 
10–12 months (24, 99).  
Kossard et al. (100) reported that 0.05 % tretinoin cream appeared to be effective in 
reversing epidermal atrophy and diminishing fine wrinkling, mottled hyperpigmentation 
and skin roughness in a randomized double-blind vehicle controlled trial. However, the 
solar elastosis was not treated at least during this period (6 months).  
Fisher et al. (98) demonstrated that a single topical application of 0.1 % retinoic acid for 
4 days promoted the proliferation of keratinocytes (increasing the number of cells and 
therefore the thickness of the epidermis), compression of the barrier and opening 
spaces between keratinocytes.  
 
3.2 Lycopene 
3.2.1 Physicochemical Properties 
Lycopene is a naturally occurring carotenoid found in a number of fruits and vegetables 
such as the tomato, watermelon, pink grapefruit, guava, apricots, papaya and rosehip 
(101). Lycopene is an acyclic hydrocarbon and its chemical structure has many 
conjugated carbon double bonds in the all-trans form, which account for lycopene´s 
stability and also for its attractive colour. These double bonds can be easily attacked by 
electrophilic reagents, resulting in an extreme reactivity. This reactivity of lycopene is 
the basis for its anti-oxidant activity (102).  
Synthetic lycopene is extremely expensive (103), and the resulting compound is 
equivalent to natural lycopene, including the isomer content (104-106). While in the 
plant matrix or in solid form, lycopene is relatively stable, but after extraction from the 
matrix and dissolution in a non-polar organic solvent, lycopene is quite unstable (107). 
Therefore, the stability of lycopene must be a consideration during experiments, 
especially in in vitro studies. A summary of the main physicochemical properties of 
lycopene is represented in Table 4. 
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Table 4- Physicochemical properties of Lycopene (105, 106, 108, 109). 








MF  C40H56 
MW (g/mol)  536.87264 
Physical state  Orange Powder  
Solubility 
Insoluble in water, ethanol and methanol 
Soluble in chloroform, hexane, benzene, carbon disulfide, acetone, petroleum ether and oil  




Abs. 444, 470 and 502 nm 
Stability 
Sensitive to light, oxygen, high temperature, acids, catalyst, metal ions.  
Store at -70C. Combustible. Incompatible with strong oxidizing agents. 
 
3.2.2 Bioavailability and Metabolism 
Although lycopene represents as much as 50 % of carotenoids found in human serum, it 
cannot be synthesized in human organism (9). Lycopene has high bioavailability and, in 
most cases, its bioavailability from dietary sources is increased by coingestion of dietary 
lipids and thermal processing (for example, in tomato paste) due to cis-isomerization 
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of the molecule because of the heat chemical reaction during processing. In addition, 
the physical disruption of the cell structure in processed tomato products compared to 
fresh tomatoes partially explains the difference in the bioavailability of lycopene. 
Although about 90 % of the lycopene in dietary sources is found in the linear, all-trans 
conformation, human tissues contain mainly cis-isomers. Several research groups have 
suggested that cis-isomers of lycopene are better absorbed than the all-trans form 
because of the shorter length of the cis-isomer, the greater solubility of cis-isomers in 
mixed micelles, and/or as a result of the lower tendency of cis-isomers to aggregate (9, 
47, 104, 106, 110, 111). 
The lycopene distribution in skin tissue is about 0.2-0.6 nmol/g wet weight, with higher 
concentration in the upper skin layers because of the transportation of carotenoids  to 
the skin surface via eccrine sweat glands and/or sebaceous glands and migration of 
epidermal keratinocytes in which carotenoids have been suggested to be loaded. 
Through Raman spectroscopy studies, significant differences regarding the distribution 
and level of carotenoids were observed within different skin areas (2, 7, 18).  
 
Lycopene is cleaved in vitro to acycloretinal, acycloretinoic acid and apolycopenals 
(112) in a nonenzymatic manner. Kim et al. (113) suggested the susceptibility of 
carbonyl group of carotenoids, with a long chain of conjugated double bonds, to cleave 
by autooxidation, radical-mediated oxidation and by singlet oxygen. These reactions 
may also occur in in vivo conditions if the tissues are exposed to oxidative stress (114). 
Recently it was demonstrated that oxidation/cleavage products formed by chemical 
transformation impact the proliferation of certain cancer cells . In this process, the 
dialdehydes seem to be the most active metabolites (3). These studies strongly suggest 
that oxidation products as well as intact carotenoids have biological effects on human 
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Regarding the lycopene safety, no adverse effects from lycopene ingestion and topical 
administration have been described up to moment. Both pure crystalline lycopene and 
formulated lycopene (in stable conditions) are not genotoxic as demonstrated by a 
comprehensive battery of tests (106). 
 
3.2.4 Biological Activity  
 
In humans, carotenoids function primarily as dietary sources of provitamin A. When 
converted to vitamin A, these molecules play an important role mainly in vision and 
skin. However, lycopene lacks the b-ionone ring structure required to form vitamin A 
and has no provitamin A activity. The first reported in vivo activities of lycopene were 
the protection against bacterial infection, when lycopene was injected intraperitoneally 
to mice (115). Furthermore, protection against radiation and development of certain 
types of ascites tumours was also described (116, 117). 
Several studies (114, 118) have demonstrated potential benefits of lycopene related to 
its biological functions, as it is described above for antioxidant, gap-junction 
communication, retinoid activity, cell proliferation and apoptosis properties and the 
consequent implications for prevention of photocarcinogenesis. Some of these 
biological functions may be mediated by lycopene metabolites with more or less activity 
or with an entirely independent function (114). 
Epidemiological studies indicate that lycopene may be helpful in cardiovascular disease 
(119), diabetes (120) and cancer prevention (oral, esophageal, pancreatic, rectal, colon, 
cervical, breast cancer) (121) and, particularly, in prostate cancer prevention, which is 
reported in many clinical trials (47, 122). Being fat soluble, lycopene appears to be 
particularly effective in tissues with high lipid content, such as prostate. The skin, also a 
lipid-rich organ is likely to benefit from lycopene biological activity. However, the 
studies regarding the role of lycopene against some of these diseases are not 
completely conclusive and are still ongoing.  
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Although some published Phase I and II studies have established the safety of lycopene 
supplementation, these studies do not clearly address the potential efficacy of lycopene 
as a chemopreventive agent. It has been proposed that the most important studies that 
are expected to be reported during the next several years will be Phase II clinical trials 
that are placebo-controlled, randomized and double blind. Well designed and 
adequately powered clinical studies of lycopene efficacy are still needed (116). 
 
3.2.4.1  Antioxidant Properties 
The pharmacological properties of lycopene are mainly due to its antioxidant activity. In 
fact, antioxidant properties of many carotenoids have been long believed to play critical 
roles in their anticarcinogenic actions.  Using tomatoes or tomato products, numerous 
studies have demonstrated decreased DNA damage (28), decreased susceptibility to 
oxidative stress in lymphocytes (123), and decreased low density lipoprotein (LDL) 
oxidation or lipid peroxidation (124). Oxidative stress is one of the major factors of 
chronic diseases and cancer. In vitro, ex vivo, and in vivo studies have been carried out 
to demonstrate the effects of lycopene against oxidative stress (105). However, data 
regarding the antioxidant effects of lycopene alone in biological systems are limited 
(114). The investigation into the interaction of free radicals with antioxidants has been 
strongly stimulated, as it has become possible to measure the carotenoids in human 
skin in vivo, online and non-invasively by resonance Raman spectroscopy (125). In the 
past, these investigations were only possible by means of chemical analysis of biopsies, 
i.e. invasive measurements (2, 126). 
As mentioned above, lycopene is a powerful antioxidant both in vitro and in vivo 
against the oxidation of proteins, lipids and DNA. Many factors, including molecular 
and physical structure, location within the cells, ability to interact with other 
antioxidants, concentration and the partial pressure of oxygen were described to be key 
factors regarding the reactivity of lycopene in biological systems (127).  
Lycopene exerts its maximal antioxidant activity cellular membranes level  and naturally 
interacts with lipid components. This property is related to its highly lipophilic nature 
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(128). Tumour initiation could be reversed through lycopene membranes protection 
from lipid peroxidation. It was demonstrated that lycopene is more efficient than β –
carotene in preventing NO2 induced oxidation of lipid membranes and subsequent cell 
death (3, 129). 
 Lycopene has been identified as one of the most potent scavengers of singlet species 
of oxygen free radicals – the highest among the carotenoids (twice as potent as -
carotene and, approximately, 100 times more powerful than vitamin E). This effect is 
probably due to the greater number of conjugated double bonds in the lycopene 
structure (8, 114). At low oxygen tension, it can also scavenge peroxyl radicals, inhibiting 
the process of lipid peroxidation (18). 
It is predicted that three possible mechanisms are involved in the action for lycopene 
towards ROS: radical addition, electron transfer to the radical and hydrogen abstraction 
(Fig.4). Lycopene is the best antioxidant based on electron transfer reactions (130). 
















 + RHL 
Fig.4- Possible reactions of lycopene with radical species (R
•
) (102, 105). 
Regarding the interaction of lycopene with other antioxidants, it is already known that 
lycopene in combination with other antioxidants such as vitamins E and C, polyphenols 
and other carotenoids have wide potential for human health (Table 5) (127, 131). Bast 
et al. (132) suggested that lycopene might enhance the cellular antioxidant defense 
system by regenerating the non-enzymatic antioxidants vitamins E and C from their 
radicals. β-carotene not only quenches oxy radicals but could also enhance the radical-
protective properties of both vitamins E and C, as well (Fig.5).  In addition, the superior 
protection of these mixtures may be related to the specific location of different 
antioxidants in cell membranes and, also to different absorption wavelengths regarding 
the skin photodamage context. Recent formulations of antioxidant mixtures in the 
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Fig.5 . Squeme of the mechanism proposed by Black & Lambert (134) by which β-carotene participates in 
quenching oxy radicals and interacts to enhance the antioxidant properties of vitamin E: vitamin E (TOH) 
firstly intercepts an oxy radical and the tocopherol radical cation (TOH
.+
) formed is repaired by β-carotene 
(CAR), which in turn forms the carotenoid radical cation (CAR
.+
) latter repaired by ascorbic acid. 
 
Table 5- Examples of some lycopene interactions with other antioxidants (adapted from Kong et al. 
(105)). 
Examples References 
The combinations of lycopene with vitamins C and E and β-carotene have exhibited higher 
scavenging activity on 2,2-DPPH radical than their individual antioxidant activity. 
(135) 
Lycopene combined with other antioxidants gave a better inhibiting effect towards diene 
hydroperoxides produced from linoleic methyl ester with 2,2'-azobis (2,4-
dimethylvaleronitrile) (AMVN) induced oxidation. 
(108) 
Lycopene helps in repairing the vitamin E or α-tocopherol radical and the products from 
this reaction radical cation will  be repaired by vitamin C.  
Some researchers suggested that vitamin E could regenerate the intact lycopene.  
(102) 
(136) 
A study done using multilamellar liposomes showed that lycopene and lutein was the best 
combination toward AMVN-induced oxidation. Lycopene is the strongest reducing agent 
and able to reduce the radical cations of lutein and zeaxanthin, but not β-carotene. 
(6, 137, 138) 
 
There are additional reports that have analyzed the antioxidant or chemopreventive 
effects of lycopene in combination with cellular antioxidants, such as the ho rmone 
melatonin. Moselhy & Al mslmani (139) investigated the chemopreventive potential of 
lycopene and melatonin on 7,12-dimethylbenz(a)anthracene (DMBA)-induced 
mammary tumours in female rats. These authors reported that melatonin enhanced the 
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ability of lycopene to decrease the levels of both malondialdehyde (MDA), a marker of 
lipid peroxidation, and NO in the serum and breast tissues of DMBA-treated rats. 
Similarly, the co-administration of melatonin significantly increased the activity of the 
antioxidant enzymes (SOD, CAT and GPx) in this tissue. It was estimated that while 
lycopene, administrated alone, protected 66.5 % of the DMBA-injected rats from 
carcinogenesis, the co-administration with melatonin protected 80 % of the animals (3, 
139). 
Antioxidant Response Elements/Electrophile Response Elements (ARE/EpRE) are cis -
regulatory sequences at the promoter region of detoxifying enzymes. These elements 
allow the coordinated induction of these enzymes  (3). The major ARE transcription 
factor Nrf2 (nuclear factor) is a primary factor involved in induction of antioxidants and 
detoxifying enzymes, and is essential for the induction of several phase II cytoprotective 
enzymes, including glutathione S-transferases, NAD(P)H:quinone oxidoreductase which 
play a role in the detoxification of carcinogens. Carotenoids and their metabolites share 
with all other classes of phase II inducers a common chemical property, the ability to 
react with sulfhydryl groups (8, 140). Carotenoids activate the ARE transcription system 
by disrupting the cytosolic interactions between the major ARE-activating transcription 
Factor (Nrf2) and its inhibitor Kelch-like ECH-associated protein 1 (Keap1) (3, 141). Such 
effects on gene expression may be related to the protective or adverse properties of 
carotenoids (9). 
Evidence in recent years indicates that beneficial effect of lycopene may be due in part 
to the protection of the cells from ROS through induction of phase II detoxification 
enzymes (114, 142-144). 
Studies with β –carotene demonstrated that this carotenoid can act as pro-oxidants at 
high concentrations and as antioxidants at low concentrations. However, no conclusive 
evidence exists for a similar behaviour of lycopene (3). In addition, high lycopene 
concentrations in cell media may not be associated with its high intracellular 
concentrations because lycopene uptake by cells is relatively low, which would favour 
an antioxidant role for lycopene in vivo (21, 113). Eichler et al. (145) reported that the 
Tretinoin and Lycopene as Protectors against UV radiation:  






antioxidant and pro-oxidant behaviours of lycopene depend on the cellular level of this 
compound. Optimum protection of skin fibroblasts from UVR-induced formation of 
TBARS was observed at 0.15 nmol/mg protein and the pro-oxidant effect above 0.15 
nmol/ protein. Likewise, only low doses of β -carotene and lycopene were able to 
prevent cellular DNA damage (146). However, according to Young & Lowe (127), clear 
evidence for a pro-oxidant activity of carotenoids at physiological relevant pO2 is still 
missing. 
Although many in vitro and in vivo studies provided evidence for the antioxidant 
properties of lycopene, some doubt has recently emerged to whether the health 
benefits of lycopene really arise from its antioxidant activity. Moreover, most of the in 
vivo studies have been performed with lycopene extracts, so the contribution of other 
components remains unclear (3, 147). 
 
3.2.4.2  Induction of Gap-Junctional Communication 
Gap-junctional communication (GJC) allows small molecular signaling between cell -to-
cell through channels that are formed by gap junction proteins such as connexin 43 (Cx-
43). GJC has been implicated in the control of cell growth via adaptive responses, i.e., 
differentiation, proliferation, and apoptosis. It has already been evidenced that a loss of 
GJC is a hallmark of carcinogenesis (114, 148, 149). Lycopene has been shown to have a 
chemopreventive activity by inducing gap junctional communication (GJC) (3). Stahl et 
al. (150) demonstrated that in human fetal skin fibroblasts, lycopene significantly 
enhanced GJC after 1 and 3 days of treatment. In the same study, only high 
concentrations of acycloretinoic acid had a similar effect, supporting that this 
metabolite may not account for the GJC-inducible activity of lycopene (3).  
Cx-43 is the connexin most often induced by retinoids and carotenoids. Among 
carotenoids, lycopene and its oxidative and enzymatic cleavage metabolites modulate  
GJC in a differential and dose-dependent manner. The oxidative metabolite lycopene-
5,6-epoxide was shown to increase Cx-43 expression in human keratinocytes (114, 151). 
Livny et al. (152) found that the expression of Cx-43 in KB-1 human oral tumour cells 
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was up-regulated mainly after treatment with lycopene, and to a much lesser extent 
with β-carotene, thus inhibiting proliferation and enhancing GJC. However, only one in 
vivo study found a positive association between GJC or Cx-43 expression with lycopene 
consumption (147, 153). 
It has been hypothesized that lycopene derivatives may have hormone – like actions at 
low concentrations by acting as ligands for a nuclear receptor, similar to retinoic acid 
derived from carotene (154). Carotenoids were found to inhibit in a reversible manner 
the progression of carcinogen initiated fibroblasts to transformed ones, and this 
achievement was correlated to an increased GJC induced by these compounds. Non-
tumour cells are contact-inhibited and have functional GJC, but most tumour cells have 
dysfunctional homologous or heterologous GJC (9).  
 
3.2.4.3  Retinoid-like Activity 
Retinoids are the most important oxidative products of provitamin A carotenoids. 
Retinoids have been implicated in the management of several human diseases, 
including chronic diseases, by gene expression regulation at specific target sites (155). 
The growth inhibitory effects of retinoids in cancer cells  have been studied (156). 
However, it is unclear if non-provitamin A carotenoids, such as lycopene (Fig.6), and 
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Provitamin A Carotenoids  
                    β-Carotene                                                                         Ret inoic Acid  






Non Provitamin A Carotenoi ds 
                     Lycopene 




  Zeaxanthin  
 
Fig.6- Provitamin A and Non provitamin A Carotenoids structure (chemical structures from PubChem 
(109); figure adapted from Mein et al. (114)). 
 
Recently, it has been suggested (114) that the anti-proliferative effects of the cleavage 
product apo-10′-lycopenoic acid may be mediated through induced expression of the 
Cleavage 
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RAR-β receptor (and retinoid signaling). The latter has been hypothesized to be a 
tumour suppressor gene playing an important role in the retinoids growth inhibitory 
effects mediation, in several cancer cell lines.  
 
3.2.4.4  Cell Proliferation and Apoptosis Regulation 
In vivo studies (one with humans and six with animal models) have suggested that 
lycopene induces apoptosis of cancer cells (147).  
The growth inhibitory effect of lycopene was firstly demonstrated by Levy et al. (157), 
who showed that lycopene is a stronger cell growth inhibitor than β-carotene in 
endometrial, mammary, and lung human cancer cells . In contrast to cancer cells, human 
fibroblasts were less sensitive to lycopene. In addition, the growth inhibitory effect of 
lycopene may also be attributed to induction of apoptosis. Palozza et al. (158) 
reported that lycopene (0.5-2 mM) inhibited the growth of immortalized RAT-1 
fibroblast cells exposed to cigarette smoke by arresting cell cycle progression and 
inducing apoptosis. However, further investigation is needed into the dose-response 
effects of lycopene, especially concerning to smoke exposure and/or alcohol ingestion 
which can affect lycopene metabolism. In addition, a deeper understanding of the 
metabolism of apo-10´-lycopenoids on carcinogenesis is also needed (114).  
Lycopene also prevents carcinogenesis by affecting several cellular processes, such as 
cell cycle progression and signal transduction pathways modulation (Fig. 6) (3, 13).  
Carotenoids are able to induce apoptosis in several tumour cells, acting as potent 
antiblastic agents. Their ability to modify the expression of transcription factors and/or 
proteins involved in the apoptotic process depends on several factors (159). The 
transcription modulation may be due to direct interaction of the carotenoid molecules 
(or their derivatives) with transcription factors, such as ligand-activated nuclear 
receptors, or to indirect change of transcriptional activity, via variations in redox status 
of the cell. 
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The signaling pathways targeted by lycopene in different cancer cell lines were 
summarized by Kelkel et al. (3), and represented in Fig.7. Briefly, lycopene inhibits 
insulin-like growth factor (IGF-1R) and the related Ras signaling cascade. This inhibition 
involves the downstream signaling via the MAPK (ERK, JNK, p38) and PI3K/Akt 
pathways. Consequently, transcription factors (NF- κB, Sp1 and AP-1) cannot be 
activated, thus modulating target gene expression. Many of the target genes of these 
transcription factors are implicated in cell cycle regulation and proliferation (genes of 
cyclin and CDK families). Cyclins and CDK proteins influence the expression of 
retinoblastoma (Rb) expression. Unlike normal cells, these cascades are deregulated in 
tumor cells, allowing cells to continue cell cycle phase transition.  
Likewise the inflammatory cascade is repressed. It was demonstrated that lycopene 
effectively reduced inflammation by inhibiting the release of TNF-α and stimulating IL-
10 production. Moreover, lycopene, as other carotenoids, was shown to stimulate gap 
junctional communication, which is known to play an important role in cell growth 
control and carcinogenesis (3). This effect supports lycopene antiproliferative effects are 
also modulated by increasing gap junctional communication (Fig.7). 
 
 
Fig.7-  Scheme of the signaling pathways targeted by lycopene in different cancer cell  lines  and lycopene’s 
points of action (adapted (3)).  
Tretinoin and Lycopene as Protectors against UV radiation:  






We have obtained recent experimental results regarding the effects of UV-B irradiation 
on human keratinocytes (HaCaT cells) previously exposed to lycopene. According to 
these results, it seems that lycopene is playing a corrective role in photodamaged cells 
(unpublished data). However, numerous gaps still exist in understanding how 
carotenoids modulate the apoptosis process. Many of the results on the pro-apoptotic 
effects of carotenoids have been demonstrated only in vitro. Thus, improved knowledge 
of the role of carotenoids in apoptosis in vitro and in vivo will help in understanding 
their potential role in health and disease (159). 
 
 
3.2.4.5  Effect on Photocarcinogenesis  
Antioxidants can prevent cancer development by protecting DNA from oxidative 
damage (3). The photoprotection effect of carotenoids (including lycopene) has been 
studied in several in vitro/ in vivo studies, epidemiological studies and clinical trials. 
Current data remains however controversial, as some studies report a positive effect 
whereas others report opposite effects. 
In Vitro/ In Vivo Studies 
A combination of natural antioxidants has been proposed to be important for 
photoprotection according to in vitro and in vivo data (160). Kowalczyk et al. (160) 
found that several phytochemicals, including lycopene, protect against free radicals’ and 
cytochrome P450 superfamily´s (CYPs) activity in vitro. In in vivo studies, they also found 
that lycopene markedly decreased the epidermal thickness (antitumour promotion 
effect) compared with 7,12-dimethylbenz[a]anthracene-treated group. It also reduced 
percentages of mice with mutation in 61 codon of Ha-ras (anti-initiation effect). Based 
on the differential effects observed for the selected phytochemicals on events and 
processes critical for the growth inhibition of keratinocytes , these authors highlighted 
the need of phytochemicals synergistic combinations to neutralize detrimental effects 
of carcinogenesis and tumour promotion. Offord et al. (154) studied the 
photoprotective potential of dietary antioxidants tested in human dermal fibroblasts 
exposed to UV-A radiation. The carotenoids were prepared in nanoparticle formulations 
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combined with vitamin C and/or vitamin E. Lycopene and β-carotene alone showed no 
protection capacity, however, after the addition of vitamin E, their stability and cellular 
uptake were improved. In addition, the increase of collagenase metalloproteinase 1 
(MMP-1) mRNA expression was suppressed. Shixian et al. (131) suggested that the 
synergistic effects observed between lycopene and vitamin E may be related to: a) their 
differential membrane localization; b) their physicochemical properties that allow that 
one antioxidant may regenerate the second antioxidant; c) their differential 
interference with signal transduction pathways leading to the synergistic inhibition of 
cell proliferation. In addition, Afaq et al. (161) have shown in vitro that anthocyanidins, 
such as delphinidin, present in pomegranate and also in tomatoes fruits, may act as 
other photochemoprotective agents. 
Butnariu et al. (162) studied the photoprotective potential of lycopene alone against 
UV-A damage in in vivo conditions. The effect on the skin's protective mechanisms 
against UV-A radiation was evaluated by means of experimental acute inflammation on  
rat paw edema. Lycopene has been involved in the synthesis of prostaglandins and 
phospholipids components of cell membrane increasing skin protection mechanisms 
(162). Recently, we have also demonstrated that lycopene induced a therapeutic 
response by inhibiting mice ear edema (163). The results obtained with lycopene were 
statistically similar to those obtained with bethametasome (positive control). However, 
topical application of lycopene reduced inflammatory infiltrate in higher extension than 
bethametasone, which may support the beneficial potential of lycopene.  
Regarding UV-B effects, Fazekas et al. (47) demonstrated that topical application of 
lycopene inhibited UV-B induced ODC and myeloperoxidase activities . Additionally, it 
reduced significantly skin thickness in a dose dependent manner. Topical lycopene was 
able to prevent caspase-3 cleavage of and to reverse the UV-B-induced normal 
proliferating cell nuclear antigen (PCNA) inhibition. These authors suggested that 
lycopene may act as a protective and preventive agent against acute UV-B induced 
photodamage by: a) inhibiting the epidermal ODC; b) reducing inflammatory responses; 
c) maintaining normal cell proliferation, and possibly c) preventing DNA damage. 
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Lycopene ability to inhibit the formation of DNA damage may explain the absence of 
caspase-3 expression and, thus, by inhibiting caspase-3 lycopene prevents the 
occurrence of UV-B- induced apoptosis. 
Wu et al. (164) found that lycopene inhibited PDGF-BB (platelet-derived growth factor-
BB)-induced signaling and cell migration in human cultured skin fibroblasts through 
direct binding to PDGF-BB. PDGF-BB facilitates the growth, invasion and metastasis of 
melanoma. Inhibition of PDGF-BB effects can arrest melanoma progression. In vitro 
studies with human cell lines of foreskin fibroblast and metastatic melanoma shown 
that lycopene can inhibit PDGF-BB induced fibroblasts migration, attenuate PDGF-BB 
induced phosphorylation, and reduce PDGF-BB induced signaling (165). In addition, 
lycopene was shown to bind to PDGFBB also in human plasma (116). Melanoma-
induced fibroblast migration was compromised by trapping of PDGF by lycopene (164) 
suggesting that it may interfere with tumour-stroma interactions. This finding also 
suggests that lycopene may act as stromal cells and tumour cells inhibitor, contributing 
to its anti-tumour activity (164). 
However, other data contradict the putative inhibitory effects of lycopene on UVR 
damage, including tumor proliferation. For example, Burgess et al. (166) concluded that 
lycopene within physiological ranges did not affect cell proliferation in several human 
cell lines, including skin carcinoma and non cancerous skin. In addition, Borawska et al. 
(167) suggested that genistein and epigallocatechin-3-gallate but not lycopene could 
help maintaining or improving skin health through enhancing viability of skin fibroblasts . 
According to Yeh et al. (168) lycopene enhances UV-A induced DNA damage and 
expression of heme oxygenase-1 in cultured mouse embryo fibroblasts because 
carotenoids are unstable under light exposure and may have prooxidative effects. Apo-
6´-lycopene,2-methyl-hepte-6-one is one of the oxidative products formed during 
irradiation of lycopene. These in vitro studies were also supported by experiments on 
humans, which demonstrated that lycopene is more sensitive to UVR than other 
carotenoids (110). Curiously, Nagao (112) found that oxidized metabolites of lycopene, 
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but not lycopene itself, can inhibit cell growth and stimulate apoptosis in human 
promyelocytic leukemia cells (HL-60).   
These conflicting data supports that further studies on the pathways targeted by 
lycopene alone are needed, and raise the question of putative synergic effects of 
lycopene and other compounds.   
 
Epidemiological and Clinical Studies 
Few studies have examined the relation of carotenoid exposure and skin cancer in 
humans. In most of these studies, neither β-carotene nor lycopene appear to be 
protective for melanomas or non-melanomas skin cancers (51). However, these cohort 
studies reflect a small number of cases, limiting their power to detect an effect. In 
contrast, several clinical trials were conducted, but none has found an effect of β -
carotene supplementation on either skin cancer or skin cancer incidence (169). 
According to Black & Lambert (134), the diet was the main variable in epidemiological 
studies that showed photoprotective effects of β-carotene on carcinogenesis and those 
that showed no effects or even exacerbation. The studies in which a photoprotective 
effect was observed employed commercial, closed-formula rations whereas the other 
studies with opposite results employed semi defined diet. In fact, carotenoids or 
phytochemicals present in closed-formula diets might act to determine the UVR-
carcinogenic response in the presence of β-carotene. 
According to Heinrich et al. (170) a supplementation with a daily dose of 24 mg of 
carotenoid mix comprising the three main dietary carotenoids, β -carotene, lutein and 
lycopene provided photoprotection against UVR-induced erythema and this effect was 
comparable to that of β-carotene alone. Protection was correlated with an increase in 
the carotenoid levels in skin and serum. Long treatment period was required to achieve 
photoprotection. It should be pointed out that the protective properties of carotenoids 
are probably at least two-fold, consisting of their potent antioxidant activity and their 
ability to induce cellular protective responses. Wright et al. (171) also reported a 
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positive association between lycopene intake and a decreased risk of non-melanoma 
skin cancer. In addition, it was recently demonstrated that lycopene content in the skin 
was inversely proportional to skin roughness, supporting that lycopene may also be able 
to reduce skin aging (172). 
The source of lycopene (natural form vs. synthetic) may also influence its 
photoprotective properties. For example, Aust et al. (173) investigated the effects of 
synthetic lycopene (~ 10 mg/day) in comparison with a tomato extract and a drink 
containing solubilized lycopene. The protective effect was more pronounced in the 
tomato extract (38 %) and lycopene drink (48 %) groups. However, phytofluene and 
phytoene present in tomato extract and lycopene drink may have also contributed to 
observed protective effects, since both of these carotenoids exhibit absorption maxima 
at wavelengths of UVR (173). This study also points to synergic effects of different 
phytocompounds present in the tomato extract.  
Supporting some in vitro studies already mentioned, studies on humans also 
demonstrated that lycopene is able to protect the skin from the effects of UV-B rays, 
especially when used in association with vitamin C and vitamin E  (14). These protective 
effects have been attributed to redox reactions of carotenoids that may influence UVR 
carcinogenesis (14). 
Another important topic is the period of lycopene supplementation, i.e., prior or after 
the UVR exposure.  Rizwan et al.  (174) examined whether pre- and post-
supplementation with tomato paste rich in lycopene could protect human skin against 
UVR - induced effects partially mediated by oxidative stress, i.e. erythema, matrix 
changes and mitochondrial DNA damage. At the end of the study, these authors 
concluded that lycopene provided protection against acute and potentially longer-term 
aspects of photodamage. Moreover, studies looking at induced sunburn before and 
after supplementation with lycopene show a significant reduction in skin photodamage 
when an increased intake of lycopene was performed (175).  
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Human skin is constantly exposed to the UVR which may induce a number of 
pathobiological cellular changes, including carcinogenesis. The development of novel 
preventive and therapeutic strategies depends on our understanding of the molecular 
mechanism of UVR damage. In this review, the mechanisms of action and potentialities 
of one provitamin A (tretinoin) and one non-provitamin A (lycopen) active compounds 
were presented and discussed. 
Tretinoin can be used for photoaging treatment by different mechanisms, such as: 
reduction and redistribution of epidermal melanin, improved ultrastructural 
characteristics of the epidermis, increased anchoring fibrils, increased deposition of 
papillary dermal collagen, and increased vascularity in the papillary dermis. Moreover 
retinoids, such as tretinoin, are considered the first line treatment for acne, being also a 
maintenance therapy due to their anti–inflammatory and comedolytic actions. 
Lycopene has been proposed to play a critical role on anticarcinogenic action at 
different levels without exerting side-effects, as it was described for antioxidant, gap-
junction communication, cell proliferation and apoptosis properties. It is a powerful 
antioxidant both in vitro and in vivo at low concentration against the oxidation of 
proteins, lipids and DNA. However, several gaps remain on the clarification of the role of 
lycopene, and other carotenoids, as modulators of apoptosis. Thus, improved 
knowledge of the role of carotenoids and their oxidation products in apoptosis in vitro 
and in vivo is still needed. Even many studies regarded the influence of lycopene (and 
other carotenoids) on cancer risk reduction, this relationship mostly suggested by case-
control studies, should be confirmed by additional evidence from prospective studies . 
For comparison, the tested conditions should ideally be standardized (e.g. lycopene 
source, period of application, dose). This evidence becomes even more necessary when 
contradictory results are obtained.  
The skin protection against sunburn by these agents is not comparable to the use of a 
sunscreen, a suitable diet combining different natural antioxidants may contribute to 
basal protection, and thus increase the defense against UVR-mediated damage to skin. 
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AMVN: 2,2'-azobis (2,4-dimethylvaleronitrile) 
AP-1: Activator Protein-1  
ARE:  Antioxidant Response Elements  
ATRA:  All-Trans-Retinoic Acid  
BCC: Basal Cell  Carcinoma  
Bcl-2: B-cell  lymphoma 2  
Bid: BH3 interacting-domain death agonist   
BRAF: B-Raf proto-oncogene 
CAT: Catalase   
COX-2: Cyclooxygenase-2  
CPD: Cyclobutane Pyrimidine Dimmers   
CRABP: Cytosolic Skin Binding Proteins  
CTLA-4: Cytotoxic T Lymphocyte Antigen 4   
Cx-43: Connexin 43  
CYP: cytochrome P450 superfamily 
DMBA: Dimethylbenz(a)anthracene  
EpRE: Electrophile Response Elements   
FDA: Food & Drug Administration  
GJC: Gap Junction Communication  
GPx: Glutathione Peroxidise  
HO-1: Hemeoxygenase-1 
IFN: Interferon  
IGF: Insulin-like Growth Factors  
IL: Interleukin  
Keap1: Inhibitor Kelch-like ECH-associated protein 1  
LDL: Low Density Lipoprotein  
 
MAPKs: Mitogen – Activated Protein Kinases  
MDA: Malondialdehyde   
MED: Minimal Erythema Dose  
MEK: Mitogen-activated Extracellular signal-regulated Kinase  
MMPs: Metalloproteinases  
MMP-1: Collagenase  
MMP-3: Stromelysin-1  
MMP-8: Neutrophil Collagenase  
MMP-9: Gelantinase  
NF: Nuclear Factor  
NMSC: Non-melanoma skin cancers   
ODC:  Ornithine Decarboxylase  
8-OHdG : 8- Hydroxyl-2´-Deoxyguanosine  
PCNA: Proliferating Cell Nuclear Antigen  
PDGF-BB: Platelet-Derived Growth Factor-BB   
PDT: Photodynamic therapy  
PPE:  Palmar–Plantar Erythrodysesthesia 
RAR; RXR: Retinoic Acid Receptors  
RARE: Retinoic Acid Response Elements  
ROS: Reactive Oxygen Species  
SCC : Squamous Cell Carcinoma  
SOD: Superoxide Dismutase  
TGF: Transforming Growth Factor  
TNF: Tumour Necrosis Factor   
TRP: Tyrosinase related proteins  
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Topical Delivery of Antioxidants 
 
Abstract 
Reactive oxygen species (ROS) and free radicals have been implicated in a number of 
diseases and disorders, and the skin, for its localization, is exposed to a large number of 
environmental threats. Free radical scavengers and antioxidants have thus been 
proposed as protective or therapeutic agents against ROS-mediated injuries. Oral 
treatment with several antioxidants has been reported to provide skin protection 
against deleterious effects of ultraviolet radiation. Topical delivery of antioxidants has 
increasingly gained interest and development, especially by offering better targeting to 
the upper skin layer. However, the topical delivery of antioxidants for dermal action is a 
challenging research field since the molecules are, in general, susceptible to 
degradation. The search for a new delivery system that, simultaneously, preserves the 
antioxidant stability and enhances its deposition on the skin, opened a new chapter in 
drug delivery design. Nanocarriers have been successful in enhancing the clinical 
efficiency of several drugs. More recent approaches in modulating through the skin 
delivery led to the development of specialized nanoparticulated systems.  
The first part of this article presents a review of the potential of antioxidants as 
pharmacological agents in ROS related diseases, with a special focus on oxidative stress 
implicated skin pathologies: ROS formation and natural protection against ROS toxicity, 
ROS-mediated skin damage and skin protection by antioxidants. On the second part of 
this work, we present reported formulation strategies for dermal delivery of 
antioxidants focusing the nanoparticulated systems developed in recent years. 
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The human body suffers constant attacks from ROS, condition that can lead to a state of 
disease when the available supply of the body's antioxidants is insufficient to handle 
and neutralize ROS of different types. The result is massive cell damage, cellular 
mutations, tissue breakdown and immune compromise.  
ROS have been implicated in a number of pathologies (1). The over expression of 
antioxidant enzymes has been found in a number of diseases including infection, 
inflammation and cancer, either at systemic or at the skin levels (2,3,4). 
Skin, besides being the largest organ in human body, is also a major target of oxidative 
stress (OS). The knowledge of the deleterious effects of ROS led to the utilization of 
antioxidant therapy for systemic and for cutaneous diseases and disorders, both as 
prophylactic and therapeutic agents. The antioxidants global market has always been 
important because many of their constituents are present in traditional herbal 
medicine. More recently, epidemiological studies presented nutritional compounds 
involved in the prevention of several health problems. 
Topical antioxidant therapies could benefit significantly from the development of 
appropriate drug delivery systems in either of the following cases: to obviate the rapid 
absorption and degradation of antioxidants or to allow for the deep skin penetration of 
the referred antioxidants, and to potentiate antioxidant intracellular effectiveness. 
In the present paper, an overview on the formation of ROS in biological systems and the 
cellular systems of antioxidant defense will be presented. The role of ROS in systemic 
and in skin diseases will also be reviewed. The use of antioxidants for therapeutic 
purposes will be discussed. A special focus on new drug delivery systems for topical 
application is considered due to the potential therapeutic advantages of the delivery of 
antioxidants to the upper and deep skin. 
 
 





1. ROS formation and natural protection against ROS toxicity 
ROS are highly reactive molecules generated by the biochemical redox reactions that 
occur as part of normal cell metabolism, and by exposure to environmental factors such 
as ultraviolet (UV) light, cigarette smoke, environmental pollutants and gamma 
radiation. The use of some toxic compounds can result in the production of ROS, which 
include anticancer drugs, anaesthetics, analgesics, etc. However, ROS are also involved 
in many cellular functions, being a normal part of being alive. For example, ROS are 
generated when mitochondria oxidizes glucose. The release of free radicals and 
oxidants from the cells is a physiological process essential for the defense from 
infection: white blood cells use ROS to attack and destroy bacteria, viruses, and virus-
infected cells. The detoxifying actions of the liver also require ROS. Fig.1 summarizes the 




Fig.1- ROS formation and effects (adapted (5)). 
 





The main ROS, which occur in the human body, include: superoxide radical (O2
.-), 
hydroxyl radical (OH.), nitric oxide radical (NO.) and peroxyl radical (ROO.). Once formed, 
these species attack cell structures within the body. Primary targets of ROS attack are 
the polyunsaturated fatty acids in the membrane lipids, causing lipid peroxidation, 
which may lead to disorganization of cell structure and function. Furthermore, 
decomposition of peroxidized lipids yields a wide variety of end-products, including 
malondialdehyde (MDA). 
ROS have special target structures in the cells: the cell membranes, mitochondria, DNA, 
enzymes and lipids. In the case of cell membranes, ROS compromise the delivery of 
nutrients and the removal of waste. In the case of the mitochondria, ROS compromises 
cellular energy production. Oxidative damage to DNA impairs cell reproduction and 
leads to cancer and autoimmune disease. Oxidized low-density lipoproteins cause 
arterial hardening and clogging that leads to heart attacks and strokes.  
Therefore, ROS have been well studied and characterized (6). They are naturally 
controlled by the chemical or enzymatic detoxificant systems protecting the organism 
from its effects. However, the capacity of these systems is not always as efficient as 
desirable. Their protection decreases in many biological disorders and with aging.  
Free radicals are unstable because they have unpaired electrons in their molecular 
structure. This causes them to react almost instantly with any substance in their 
proximity. The hydroxyl radical is the most reactive radical. Hydrogen peroxide and 
peroxynitrite are degraded with .OH formation. .OH reacts preferably with membrane 
phospholipids. 
There are three free radical lipid peroxidation initiation mechanisms: 
1-Non-enzymatic process (irradiation, chemical toxicants); 
2-Semi-enzymatic process, with O2
.- radicals mediated by enzymes generation. After .OH 
formation the oxidation is processed in the non-enzymatic way; 
3-Enzymatic process, mediated by cycloxygenases or lipoxygenases. 





OS is a condition of pro-oxidant/antioxidant disequilibrium: the generation of 
potentially harmful ROS exceeds the quenching tissue’s antioxidant defense 
mechanisms. Many research works have been performed in order to understand, 
evaluate their consequences and to treat the damages caused by free radicals (7,8). 
However, when their production is higher than antioxidant protection, the OS 
phenomenon occurs, and the protective tools become self-damaging mechanisms: DNA 
and protein damage, lipid peroxidation, inactivation of anti-peroxidases, depletion of 
anti-oxidant defenses, activation of NF-kB and cytokines transcription. In sum, the 
mechanism of ROS formation is dangerous when out of control, making the production 
of radical species a cause of injury and disease.  
In healthy individuals, the antioxidant system defends tissues against ROS attack. The 
main antioxidants are vitamins A, E and C, β-carotene, glutathione, bioflavonoids, 
selenium, zinc, CoQ10 (ubiquinone), and various phyto-chemicals from herbs and foods. 
Biochemical antioxidants not only scavenge free radicals, but inhibit their generation 
from the body, as well. They include lipoic acid, enzymes such as superoxide dismutase 
(SOD), catalase (CAT), glutathione peroxidase, and other repair enzymes. Melatonin, a 
hormone produced by the pineal gland, is also a potent antioxidant. Cholesterol, 
produced by the liver, is another major antioxidant that the body uses to repair 
damaged blood vessels. Vitamin C is water-soluble and the most effective antioxidant 
within the plasma; it also regenerates vitamin E. Vitamin E is liposoluble and the most 
effective antioxidant within the cell wall.  
The body has the ability to make some of its own antioxidants, three of which are SOD, 
CAT, and glutathione peroxidase. However, the body is not able to produce enough 
antioxidants on its own to neutralize all of the ROS. The rest of these antioxidants are 
originated from food. α-lipoic acid, mixed carotenoids, Coenzyme Q10, cruciferous, N-
acetyl-N cysteine, lutein, and a host of bioflavonoids are examples of antioxidants 
obtained from food. 
The role of enzymes like SOD could not be separated from the relationship with other 
scavengers. SOD has a specific scavenger activity effective for superoxide ion. However, 





other low molecular components are useful to complete cell defense from free radicals 
attack. Copper bound at active site of SOD is claimed to play a role in main processes 
associated with inflammation: oxygen dismutation, prostaglandin synthesis and collagen 
cross-linking. 
Antioxidants work synergistically with each other. Glutathione peroxidase works in 
parallel with SOD and CAT and they could also work against different types of free 
radicals.  
For antioxidative action, antioxidants need adequate amounts of the so-called 
antioxidant minerals copper, zinc, manganese, and selenium, and adequate amounts of 
folic acid and vitamins B1, B2, B6, and B12, which are enzymes cofactors. These 
nutrients limit the antioxidant’s work. 
It is thus possible to describe a coordinated system composed by enzymes and proteins 
and also by low molecular weight compounds, both hydrophilic and hydrophobic. 
Different antioxidants play specific roles in different tissues and different organs. 
Antioxidant enzymes are present in the skin (9). SOD activity in the skin is 5-10 times 
lower than in other tissues and does not significantly differ from dermis to epidermis. 
The SOD activity appears increased in some skin diseases but unaffected in others. CAT 
activity in the epidermis varies in depth being smaller in the deep strata. Specific activity 
is lower than for the liver but comparable to the brain and the heart. CAT activity is 
significantly decreased in photo-OS. Glutathione peroxidase activity is more than twice 
as high in epidermis, compared with dermis, and vary in response to ROS induced by 
tumors. 
The scheme presented in Table 1 summarizes the various compounds involved in the 
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Carnosine various ROS quenching 
Taurine hypochlorite neutralization 
Uric acid  
Bilirubin 
lipid peroxidation prevention 
 
Antioxidant enzymes act as antioxidants in vivo. This is the case of SOD and CAT: their 
substrates are superoxide radical and hydrogen peroxide, respectively, to prevent 
accumulation of hydroxyl radical. A dismutation reaction involves one- or two-electron 
transfers, where the electrons are accepted from O2
.- or H2O2. On the other hand, lipid 
peroxyl radicals result from .OH reaction with polyunsaturated fatty acids of membrane 
phospholipids and can be inactivated by bioantioxidants such α-tocopherol and reduced 
form ubiquinon Q10, non-enzymatically. 
Other enzymes (10) participate in the regeneration of ascorbic acid involved in the 
reduction of radicals of antioxidants, such as α-tocopherol radical. Also glutathione–
dependent peroxidases using lipohydroperoxides prevent the production of 
alkoxylradical, contributing for the lipid peroxidation regulation. Proteins are 
responsible for chelating the transient metals and preventing electron donation. Low 





molecular weight compounds complete the depletion of the ROS not scavenged by 
antioxidant enzymes. 
 
2. ROS-mediated skin damage  
Human skin is responsible for protecting internal organs from the toxic external 
environment and, consequently, the major target candidate of OS. The skin protects 
from heat, cold, physical injuries and also provides the first defense against invasion by 
bacteria, viruses, and other toxic elements. The skin is also an excretory organ, 
removing toxins from the body via perspiration. 
The skin essential biomolecules can be severely damaged during photosensitization 
reactions. In these photodynamic reactions the activation of molecular oxygen is 
implicated, either by formation of ROS or singlet oxygen.  The OS can induce not only 
cellular death, but also DNA mutations (photogenotoxicity), which in the case of an 
inefficient DNA repair system can induce oncogenesis. Peroxidation of lipids may occur 
(photo-peroxidation), the reaction with proteins may induce cell death, 
immunosuppression or uncontrolled intracellular signalling (11). When associated to 
photogenotoxicity, it can induce irreversible metabolism and cause cellular 
transformation. 
There are many ROS implicated diseases that can affect the skin (12). Table 2 shows a 
possible classification of skin diseases associated with ROS. 
The skin protein collagen is particularly susceptible to ROS damage, causing the collagen 
protein molecules to break down and then link back up again in a different way, in a 
cross-linking process. Collagen cross-linking causes the normally mobile collagen to 
become stiff and less mobile. Sunlight also causes the messenger molecules present in 
skin cells to become active and create inflammatory products. Fisher et al. (13) have 
shown that multiple small exposures to UV irradiation lead to sustained elevations of 
enzymes that degrade skin collagen and contribute to photoaging. Skin aging 
accelerating factors produce an imbalance in the turnover of macromolecules in the 





dermis. Topical application of antioxidants is able to decrease the modification rate of 
skin elasticity and thickness (14). 
Table 2- Skin diseases associated with ROS (12). 
Physicochemical oxidative stress UV 
Heat 
Chemicals 
Neutrophilic oxidative stress Cutaneous vasculitis 
Behçet’s Disease 
Acne and Rosacea 
Psoriasis 




Skin inflammatory disorders 
 
Some factors can accelerate skin aging: sun exposure, active or passive cigarette smoke, 
environmental toxins, poor diet, excess alcohol consumption, stress, harsh soaps or 
detergent-based moisturizers, sleep deprivation. Skin cancer typically occurs in skin that 
is photo-aged. 
 
2.1. Photo-oxidative stress in the skin barrier: photo-induced skin lesions 
In the last years, with the changes in the ozone layer in the upper atmosphere, it is clear 
that the effects of UV radiation from the sun are much more dangerous than originally 
thought.  
The exposure of normal skin to UV contributes to well-known acute responses such as 
erythema and pigmentation, and also to chronic harmful effects such as photoaging and 
photocarcinogenesis. It is admitted that cutaneous photodynamic reactions resulting 
from the interaction of UV/visible radiation with endogenous cell photosensitizers 
generate ROS. The ROS are also involved in phototoxic reactions induced by the 





interaction of UV/visible light with drugs or other industrial or environmental chemicals, 
accumulated in the skin after topical or systemic administration. 
Elias and co-workers have provided a large body of evidence that the stratum corneum 
(SC)-the outermost skin layer - lipid composition is essential for maintaining the barrier 
integrity and suggested that perturbations of the SC lipid or protein architecture may be 
important for a number of dermatoses (e.g. atopic dermatitis), rather than merely the 
end result of processes initiated in underlying layers (15,16). The oxidative modification 
of lipids affects preferably unsaturated fatty acids and leads to their degradation. ROS 
could alter the lipid composition of the SC and thus potentially affect the barrier 
function.  
In addition to oxidative injury within the SC, the increased formation of stable lipid 
peroxidation end products (MDA) in the SC could trigger inflammatory responses in 
adjacent skin layers. A well-known example of such a mechanism, with UV radiation-
induced formation of a compound in the SC and subsequent inflammatory response in 
adjacent skin layers, is urocanic acid, in a process believed to take part in UV radiation-
induced immunosuppression (17).  
 
2.2. ROS-mediated skin cancer 
The contribution of ROS to skin carcinogenesis has been known for a long time, 
especially following UV irradiation (18). ROS induce DNA damage and 
immunosuppression contributes to the skin cancer appearance. 
Fig.2 represents the involvement of ROS in skin cancer induction. The DNA damage 
plays a central role expressed by immune system suppression (with an increase of 
Langerhans cell depletion, an increase of cytokine release and a decrease of antigen 
presentation) and by mutations in growth regulatory genes contributing to abnormal 
cellular physiology (19). The latter, contributes, on one hand, to an increase of cellular 
derived ROS, and consequently to maintain a cycle of DNA damage and, on the other 
hand, to potentiate skin neoplasia. 














Skin neoplasia Cellular derived ROS  
Fig.2- Mechanism of ROS-mediated skin cancer (adapted (19)). 
Young skin is also exposed to ROS potentially damaging changes but there is sufficient 
cellular energy (ATP) for DNA repair and cell renewal. Enzymes that provide antioxidant 
activity, such as SOD and CAT, are readily available. With aging, the energy for cell repair 
and renewal diminishes and the antioxidant enzymes are less available. Exposure of skin 
to solar UV radiation induces OS and suppression of cell-mediated immune responses. 
Reduction in UV-induced infiltration of CD11b+ cells may be a strategy to reduce solar 
UV light-induced ROS-mediated skin disorders, such as photoaging and 
photocarcinogenesis (20). 
 
2.3. Skin inflammatory disorders 
Inflammatory skin disorders representing a large proportion and the redox-modulated 
pathway in inflammatory skin diseases have been reviewed (21). 
Free radicals make the membrane more permeable, allowing the cells to dehydrate. 
Enzymes break down the lipid bilayer and cause inflammation. Chronic inflammation is 
an underlying cause of common degenerative diseases. Along with causing permanent 
gene mutations, free radicals activate signal transduction pathways that are related to 
growth, differentiation, senescence, and connective tissue degradation. 





SC of atopic dermatitis patients has a less pronounced oxidative state as a consequence 
of an increase in cutaneous antioxidant defenses due to the chronic inflammation (22). 
Occupational exposure to metal working fluids causes allergic and irritant contact 
dermatitis. OS can enhance dermal inflammation caused by this occupational 
exposure23. Studies demonstrated an enhancement in mast cell accumulation caused by 
topical exposure to metal working fluids (24). In childhood atopic dermatitis 
pathophysiology, results have shown an impaired homeostasis of oxygen/nitrogen 
radicals and increased OS, suggesting its suppression as a potentially useful strategy for 
treatment of this chronic inflammatory disease (25,26). 
Generalized severe OS of the skin is expressed as a consequence of contact dermatitis in 
a restricted area (27). 
A systemic unbalance of the antioxidants has been shown (28) and a common profile in 
patients with different forms of physical urticaria has been detected. These alterations 
may lead to an increased percentage of peroxidable compounds in skin and to the 
intracellular generation of ROS. 
Significantly elevated heme-oxygenase-1 mRNA levels were found in acute 
inflammatory illness of children, suggesting that monocyte heme oxygenase-1 
production could serve as an anti-inflammatory agent to control excessive cell or tissue 
injury in the presence of OS (29). 
Rosacea is a chronic inflammatory disease that affects predominantly the face. Authors 
found that in mild involvement stage of rosacea patients SOD activity was stimulated to 
protect the skin against ROS so that the MDA levels were maintained. In a more severe 
state of the disease, the MDA levels were increased, supporting the “antioxidant system 
defect hypothesis” in rosacea patients (30). 
ROS are also found to be involved in allergic skin diseases. The CAT activity of human 
skin with allergic contact dermatitis decreased both in young and old skin, suggesting 
that cutaneous CAT may play a role in the pathophysiology of this disease (31). 





Alterations in the oxidation products, antioxidant markers, antioxidant capacity and 
lipid patterns were found in plasma of patients affected by Pappilon-Lefèvre Syndrome 
(PLS) (32). PLS has been grouped with the palmoplantar ectodermal dysplasias. An 
imbalance in both oxidation product/antioxidant concentrations and essential fatty acid 
pattern was found. 
Alopecia areata is an autoimmune inflammatory disease. Some authors found an 
affected oxidative status in the disease, suggesting that lipid peroxidation and 
antioxidant enzymes may be involved in its pathogenesis (33). 
Numerous rodent models used in cutaneous inflammation research are based on the 
induction of acute or subacute vascular type of cutaneous inflammatory responses after 
the application of chemical agents such as croton oil, arachidonic acid and dithranol 
(34). Arachidonic acid-induced mouse ear inhibition test (AA-MEIT) is described as the 
most commonly used in vivo test for assessing the anti-inflammatory effects of drugs in 
the first stage trials. Since neuthrophil influx is a component of the inflammatory 
reaction, high levels of myeloperoxidase are expected as a reflex of neutrophil 
accumulation (35).  
Studies of dithranol-induced skin irritation in the mouse ear model reveal that the 
formation of free radicals is essential for dithranol inflammation (36). Significant 
reductions of Cu,Zn-SOD (37), and of gluthatione S- transferases levels were induced by 
dithranol. 
An acute model of skin inflammation induced by ROS, generated by glucose oxidase as a 
producer of H2O2, has been described to test the anti-inflammatory action of enzymes. 
The inflammatory response was inhibited predominantly by CAT and to a lower extent 









3. Skin protection by antioxidants 
From a pharmacological point of view, ROS have been seen as a basis for drug design for 
a long time. However, the study of the skin ROS pharmacology is still in the beginning 
(39). Skin is easily reached for topical applications, which makes the topical route a 
preferential strategy for such therapy.  
As ROS mediate pathological and toxicological processes, several pharmacological 
strategies exist and can be classified as different groups (40): 
1- Natural or synthetic antioxidants (gluthatione - GSH, flavonoids, butylhydroxytoluene, 
butylhydoxyanisole, N-acyl dehydroalanines); 
2- Enzymes and enzyme mimetics (SOD, CAT, GSH peroxidase, Ebselen®, copper 
diisopropyl salicylate); 
3- Vitamins – A, E, C;  
4- Scavengers of O2
- - derived radicals – mannitol, glucose, dimethylsulfoxide; 
5- Chelators - Desferal®; 
6- Precursors of intracellular antioxidants – aminothiols, N-acetylcysteine, selenium. 
In terms of mechanistic basis for strategies applicable to control ROS, such strategies 
can be classified as: 
1- Enzymatic redox reaction 
2- Non-enzymatic redox reactions 
3- Radical scavenging 
4- Precursors of intracellular antioxidants 
5- Metal ion chelation 
6- Energy quenching 
 
The use of antioxidant enzymes, as an adjuvant therapy, able to intercept ROS formed 
and able to increase the natural antioxidant cells defenses (detoxifying enzymes (41), 
vitamins E and C, carotenoids, whose presence has individual variability) is probably the 
most challenging strategy. The presence of exogenous antioxidant enzymes could 
prevent the formation of locally produced ROS (42). SODs and CAT are metalloproteins 
that use efficient dismutation reactions in their mechanisms to detoxify ROS (8). A large 
number of studies have shown the advantages of antioxidant enzymes in the treatment 





of numerous pathologies. Cuzzocrea et al. (8) comprehensively reviewed the use of 
antioxidants for therapeutic purpose. In treatment of various fibrotic skin diseases, 
modulation of skin SOD activity to inhibit some OS damages has been described, with 
clinically varying success (43).  
The use of SOD and CAT as therapeutic agents to attenuate ROS induced injury 
responses, other than skin related, has been reported (44,45). Limitations of enzymes 
use are their large size limiting cell permeability, short circulating half-life, 
immunogenicity and cost. For example, the clinical use of SODs has been limited due to 
the lack of cellular membrane permeability, short plasma half-lives, solution instability, 
bell-shaped dose response curve and high susceptibility for proteolytic degradation. 
Enzymes, which can exhibit their pharmacological activity in plasma or on tissue surface, 
benefit from prolongation of plasma half-life. Liposomes have been extensively studied 
as carriers for antioxidant enzymes, especially for SOD. 
Novel synthetic catalytic scavengers were developed to inactivate toxic oxygen radicals 
and other reactive oxygen species, including oxygen radicals and hydrogen peroxide, to 
reduce damage caused in various autoimmune, cardiovascular, neurological, 
inflammatory and infectious diseases, and studied in animal models (46).  
Antioxidant therapy strategies include drug administration via the skin for local 
therapeutic effect, both on diseased or healthy skin (topical delivery), and for systemic 
effect (transdermal delivery).  Furthermore, many attempts have thus been made to 
overcome the skin permeability barrier for large molecules. Early studies have shown 
that skin fluidizers can facilitate permeation of small drugs across the intact skin but it 
remained practically impossible to deliver a significant amount of large drugs, such as 
proteins, through the skin without major organ disturbance (47). 
Although the skin selectively excludes the passage of proteins, optimized mixed lipid 
colloidal vesicles, Transfersomes®, are able to mediate the transport, even of 
macromolecules, through the skin and can ensure targeted drug delivery deep below 
the application site, as demonstrated in previous studies (48). This is very important 
since numerous attempts have been made to find acceptable alternatives to an 





injection and the use of antioxidant enzymes is limited by the outermost layer of the 
skin.  
 
3.1. Use of natural or synthetic antioxidants 
This dichotomy has relative importance in the food industry, in the addition of 
antioxidants to food. The so- called natural antioxidants are synthesized most often by 
plants and also by various microorganisms, fungi and animals. Antioxidants can be also 
obtained by the synthesis or biosynthesis in the industry. These are called synthetic 
antioxidants. The former type exists for own producers benefit. Synthetic antioxidants 
production follows well-defined industrial procedures. They are tested for safety in 
human health and can be produced in large scale. Other group of antioxidants are 
identical to the natural antioxidants found in food, but synthesized in the industry and 
called nature-identical antioxidants. They combine the advantages of synthetic and 
natural antioxidants: they are pure substances, relatively cheap, easily available, and of 
reproducible properties, including the antioxidant activity (49). 
3.2. Use of low molecular weight antioxidants 
Photochemopreventive effects of selected botanical antioxidants have been extensively 
reviewed (50,51).  
Silymarin, a flavonoid antioxidant, possess high protective effect against tumour 
promotion involving inhibition of promoter–induced oedema, hyperplasia proliferation 
index and oxidant state (52). Prevention of UV-B-induced immunosuppression and ROS 
by silymarin may be associated with the prevention of photocarcinogenesis in mice (53). 
Studies demonstrated that activin, a grape seed-derived proanthocyanidin extract, 
reduced the inflammatory response and the ROS developed in systemic sclerosis (54). 
Soybean isoflavone genistein inhibits UV-B-induced skin tumourigenesis in mice by 
selective inhibition of oxidative DNA damage (55). Paradoxical effect has been found 
after oral vitamin C supplementation: the supplementation had no effect on UV 





radiation-induced erythermal response with no reduction in skin content of total 
glutathione and protein thiols (56). A reason for this finding might be the fact that skin 
bioavailable vitamin C is replacing other reductants of skin cells. 
Vitis vinifera (grapes) was proposed as a chemopreventive agent against skin ROS and 
carcinogenesis (57). 
Novel chemopreventive agents as FA15 derived from natural sources and a hydrophobic 
derivative of ferulic acid, produce suppression of inflammation and skin tumour (58). 
The role of antioxidants on cutaneous photodamage has been recently reviewed (59). 
The combination of topical vitamin C and E produced appreciable photoprotection in 
pigs (60). Studies suggest that α-tocopherol (vitamin E) protection against UV-B-induced 
lipid peroxidation is a consequence of both its ability to scavenge peroxyl radicals and 
its UV-B absorbance resulting in a sunscreen effect (61). Both mechanisms would 
provide photoprotection in adjacent epidermal layers. α-tocopherol could also regulate 
the SC lipid homeostasis and thus maintain the physical integrity of the penetration 
barrier. 
Vitamin E is probably the most studied low molecular weight antioxidant. Topical 
administration of α-tocopherol protects cutaneous tissues against UV-induced oxidative 
damage in vivo, in murine skin and suggests that the underlying mechanism of such 
effect is related to the up-regulation of a network of enzymatic and non-enzymatic 
antioxidants (62). High doses of vitamin E significantly lower the urine porporphyrin 
excretion in studied patients affected by porphyria cutanea tarda (63). Topical 
application of α-tocopherol was also demonstrated to reduce UV radiation-induced 
immunosuppression and to prevent UV-B induced carcinogenesis in hairless mice (64). 
The associated mechanism appears to be via preventing epidermal lipid peroxidation 
(65).  
The study of the mechanisms of UV radiation induced damages has led to the 
development of skin models for short-term studies. This is the case of ex vivo pig skin 
model used to test the protective effect of topical application of antioxidants (66). 





The mechanism for immunosuppression induced by UV-B has been studied (67) and it 
was demonstrated that chronically applied vitamin E can effectively reduce cancer 
formation and immunosuppression induced by UV irradiation (64). Topically applied 
vitamin E scavenges UV radiation-generated lipid peroxides and ROS. This may inhibit 
loss of membrane integrity protection from local immunosuppression (65). 
Identification of common dietary substances with photocarcinogenesis protective 
effects has been made. Dietary administration of butylated hydroxytoluene inhibits UV 
radiation induction of carcinogenesis (68). Dietary photoprotection by ω-3 
polyunsaturated fatty acids against photocarcinogenesis in animals has been described 
(69). In healthy humans, there is evidence of protection by dietary EPA (eicosapentanoic 
acid, a ω-3 polyunsaturated fatty acid) against a range of early genotoxic markers (70). 
Lycopene lacks provitamine A activity, but it is a powerful antioxidant both in vitro and 
in vivo against the oxidation of proteins, lipids and DNA. Lycopene has been identified as 
one of the most potent scavengers of singlet species of oxygen free radicals – the 
highest among the carotenoids (twice as potent as β-carotenoid perhaps because of the 
greater number of conjugated double bonds in the lycopene structure: 11 vs 9) and, 
approximately, 100 times more powerful than Vitamin E (71-74).  
 
3.3. Use of high molecular weight antioxidants 
Among many others, antioxidant enzymes are effective cellular catalysts responsible for 
controlling a great number of reactions in the cells. These special active proteins have 
been employed in many studies as antioxidant therapeutic agents with restricted 
success related to its in vivo behavior. However, successful antioxidant enzyme therapy 
has been reported for treatment of experimental arthritis (75) and for the treatment of 
cutaneous lesions (76) when enzymes are delivered by means of colloidal carriers.  
Because ROS are responsible for the biological effects of the photo-OS, it may be 
thought that the use of antioxidants, including the enzymes SOD and CAT, may be a 
promising strategy for preventing or alleviating these effects. UV-B exposure increases 





intra- and extracellular H2O2 production (77). However, it is important to improve the 
skin penetration of these macromolecules, enhancing their ability to repair and/or 
prevent skin damages induced by absorption of visible and/or UV-A light by drugs or 
other chemicals (called photosensitizers) accumulated in sunlight exposed areas of the 
skin. This objective can be achieved with an appropriate carrier mediate regio-specific 
delivery of molecules and enhance enzyme skin penetration into skin and deep below 
the application site. This would be a relevant goal if we consider the large number of 
drugs (antibiotics, neuroleptics and anti-arrhythmics) that can induce exacerbated 
cutaneous reactions in skin areas exposed to solar radiation, mainly radiation UV-
A/visible, due to photo-OS induced by these photosensibilizer molecules. This photo-
toxicity can be so severe that hospitalization may be needed. 
Topical application of a SOD containing gel, on the human normal skin surface, was able 
to inhibit the acute inflammatory response induced by a locally applied solution of 8-
methoxypsoralen followed by UV-A irradiation (78). In parallel, after the application of a 
hydrogel containing a fluorescently labeled SOD on the human skin surface, the labeled 
SOD was localized in the upper epidermis and in the epidermal cell layer surrounding 
the lumina of the hair follicles (42). These results are in accordance with results of other 
authors, which evidences that the delivery of proteins into the skin has been achieved 
predominantly by means of accumulation of liposomes in the hair follicles (79).  
Studies demonstrated the radiation damage modification in various systems by means 
of antioxidant enzymes and have suggested the protective role of Cu,Zn-SOD against 
UV-B-induced injury of the human keratinocyte cell line HaCaT (80). 
Topical application of SOD was proposed and investigated for the treatment of skin and 
mucous membrane lesions (81), with differing and even contradictory results. A lipid 
peroxidation study in burned patients suggested that polyethylene glycol-conjugated 
SOD can prevent the conjugated dienes formation by suppressing oxygen radical 
production (82). Using an acute localized gamma irradiation pig model, it was shown 
that a successful treatment of fibrosis, involving skin and skeletal muscle, with liposomal 
SOD might be possible (83). In most studies dealing with the topical application of SOD, 





however, the skin was not intact and enzyme delivery through the skin was by diffusion, 
permeation or using shunts, such as hair follicles and glands. 
In the case of thermal injury to the skin, skin SOD activity decreased immediately after 
experimental burns and topical administration of SOD (84). 
Topically applied SOD encapsulated in liposomes reduced the size of post-burn wounds 
and the formation of oedema in rabbits, compared to pure and intralesionally injected 
SOD (76). 
Using an in vivo skin inflammation model, induced by ROS generated by glucose oxidase 
as a producer of H2O2, the inflammatory response was inhibited predominantly by CAT 
and in lower extent by SOD, both attached to polyethylene glycol (38). 
 
4. Pro-oxidant activity 
Almost all antioxidants have pro-oxidant effects in vitro in high concentrations or under 
special conditions because they are by nature quite unstable molecules (85,86). Also 
many products contain ester derivatives of the antioxidants or non-natural isomer 
forms that cannot be absorbed and/ or metabolized by the skin (86).  
Several of these antioxidants may auto-oxidize readily to free radicals like hydroxyl 
radical and semiquinone radical. Such species are known to be toxic and are reported to 
bind irreversibly to various cell constituents by the formation of covalent binding with 
sulfhydryl groups and/or other essential groups producing secondary free radicals. The 
formation of these secondary free radicals is responsible for the pro-oxidant activity of 
these agents (85). The capacity of carotenoids to act as pro-oxidants has been noted in 
model systems by an increased formation of thiobarbituric acid-reactive substances 
(TBARS) as a marker of lipid peroxidation (87). Carotenoids act as pro-oxidants at high 
concentrations and as antioxidants at low concentrations. High carotenoid 
concentrations in cell media may not be associated with high intracellular 





concentrations because lycopene uptake by cells is relatively low, which would favor an 
antioxidant role for lycopene in vivo (88). 
A study in C3H cells (71) demonstrated that lycopene possesses prooxidant activity 
when exposed to UV-A and the oxidative derivatives of lycopene, like Apo-6´-lycopene 
and 2-methyl-hepte-6-one, rather than itself may be responsible for the increased OS, 
enhancing the UV-A-induced lipid peroxidation and the subsequent activation of the 
heme oxygenase-1 cascade.  
Lycopene in combination with vitamin E, glabridin, rosmarinic acid or carnosic acid 
synergistically inhibits the oxidation of LDL, and it has been suggested that the 
synergistic effects may be attributed to the interaction of these antioxidants with 
lycopene-derived radicals and/ or with oxidative products of lycopene. Indeed it has 
been envisioned that a combination of natural antioxidants, including lycopene, may be 
required for effective photoprotection. These results suggested that it may be 
premature to use lycopene as a component of cosmetics and further studies are needed 
to ascertain the safety of using lycopene, and perhaps other carotenoids in cosmetics. 
Apart from other mechanisms, pro-oxidative effects have been discussed as a possible 
reason for an increased risk for lung cancer observed in two intervention studies with -
carotene. In these studies the incidence of lung cancer was about 20% higher than in 
controls, when -carotene was supplemented at high doses over an extended period of 
time to individuals at an elevated risk for this disease. Vitamin E and vitamin C influence 
the levels of pro-oxidant carotenoid radical cation which could be pro-carcinogenic in 
nature (85). 
Eichler et al. (87) reported that the antioxidant and pro-oxidant behaviors of -carotene, 
lycopene, and lutein depend on the cellular level of the compounds. Optimum 
protection was observed at 0.4, 0.05 and 0.3 nmol/ mg protein, respectively and the 
pro-oxidant effect above 6 and 0.15 nmol/ mg protein for -carotene and lycopene. 
To overcome the vitamin C instability, the more stable esterified derivatives ascorbyl-6-
palmitate and magnesium ascorbyl phosphate are often used, but these derivatives are 





not well absorbed and are only minimally metabolized by the skin to the active free 
ascorbic acid form (86). Besides, other authors (85) reported that ascorbic acid-6-
palmitate strongly promoted UV-B induced lipid peroxidation and may intensify skin 
damage following physiological dose of ultraviolet radiation. In order to achieve the 
benefits to the skin with topical vitamin C, the formulation must contain at least 10 % of 
L-ascorbic acid, be stable and be at an acid pH, about 3.5 less than the pKa of vitamin C 
(4.2) (86). 
The synthetic isomers of vitamin E are esterified to acetates and succinates for use in 
commercial vitamins and some topical formulations because of its higher stability. 
However, the skin has only a limited capacity to cleave the esterified forms of vitamin E 
to achieve free tocopherol form. Furthermore, the all-rac form of vitamin E has been 
reported to cause allergic contact dermatitis and erythema multiforme when applied 
topically. No such adverse reactions have been reported with d--tocopherol (85).  
High concentrations of -tocopherol (>> 0.005 mol tocopherol/mol unsaturated fatty 
acid) accelerated lipid auto-oxidation in vitro. By the mechanism of its own recycling, 
tocopherol depletes other antioxidants, such as ascorbate, thiols and ubiquinols, in this 
way acting as pro-oxidant. The antioxidant efficiency of ascorbate is strongly dose 
dependent and ascorbate has the potential to generate pro-oxidant effects in cells and 
cell free systems (86).  
In cells, vitamins C and E interact synergistically to provide antioxidant protection: 











5. Topical delivery systems 
The skin receives an extraordinary interest as a site of application of drugs both for 
antioxidant and other molecules. The skin is much more than a body container: it is the 
biggest (around 7 kg and 18000 cm2) and elaborate, multilayer functional unit capable 
of performing multiple and fundamental roles. The skin exhibits a complex structure 
and a great capacity of regeneration being made up of several layers including SC, viable 
epidermis and dermis, and appendages that include sweat glands, sebaceous glands, 
and hair follicles. The SC is the outermost desquamating ‘horny’ layer of skin, 
comprising about 15-20 rows of flat, partially desiccated, dead, keratinized epidermal 
cells. The skin acts as a barrier, avoiding the penetration of foreign bodies (toxins, 
pathogens, etc) and simultaneously maintaining the body’s ingredients, including water. 
Paradoxically, the cutis, the most exposed layer, still holds many secrets concerning the 
mechanisms of transcutaneous permeation (89). The hydrophobic parts of SC are one 
key to the understanding of this process. A substance with molecular weight higher than 
300 Da is too large to penetrate the skin. The skin entry is generally described as 
intercellular or transcellular, but the latter apparently is of little, if any, practical 
importance. Skin surface differs from the deep skin regions and acts as a semi-
permeable barrier. Permeation and penetration through nanopores can be described by 
equations. The transport of material through a barrier is proportional to a driving-force 
difference that varies for different permeants. Strictly speaking, permeation relates only 
to diffusion of molecules through a barrier. Fick’s law of diffusion can be generally 
applied to estimate the transcutaneous material flow. Flow is proportional to the 
system permeability value, the involved area and the driving-force difference, across 
the skin barrier. Barrier penetration by a carrier, a macromolecule or molecule 
aggregates is not sensitive to transbarrier permeant concentration driving-force. 
Carriers and aggregates can only cross a barrier penetrating the latter. This concept is 
applicable to the skin barrier. Once applied on the intact skin, low-molecular-weight 
molecules generate a transcutaneous concentration gradient capable of pushing 
molecules into the skin. The idea is to simplify the enormous complexity of the skin and 
to consider diffusion through the skin governed by Fick’s law of diffusion. In the case of 





penetration of vesicles, an externally created water activity difference through the pore 
is needed for the motion (90).  
Penetration enhancement techniques based on delivery systems have been 
considerably exploited. However, each drug enhancement strategy may differ and 
requires optimization. 
It is important to restrict the term transdermal delivery to the passage of solutes 
through the various layers of the skin to reach the systemic circulation and to exert 
systemic effect. Dermal or topical delivery should be addressed to the local skin delivery 
that is performed with the aim of targeting the skin and minimizing the systemic 
absorption. Topical delivery thus permits to extend antioxidant skin deposition and 
promoting skin antioxidant enrichment.  
 
5.1. Prodrugs and skin penetration modifiers 
The chemical approach has contributed to the introduction and commercialization of 
several permeation enhancers. A chemical enhancer is usually defined as a substance 
that reversibly alters the skin barrier function in order to permit the drug permeation 
into the skin faster or better than otherwise in a non-invasiveness approach. Chemical 
enhancers act mainly at intercellular level. To this moment only few results on the 
permeation of macromolecules by means of chemical enhancement were obtained. It is 
the case of the permeation enhancer effect of Azone on in vitro percutaneous 
absorption of heparin (91,92). Furthermore, heparin, a charged macromolecule can 
serve as a chemical modifier for transdermal ion and molecule transport associated with 
high-voltage pulsing, suggesting that heparin may stabilize electroporation pathways 
(93). 
Prodrugs can be used as permeation enhancement strategy (94) or, if the prodrug 
diffuses worst through the skin, a reservoir effect can be achieved with gradual delivery 
of free drug. This strategy is very interesting for topical antioxidant administration since 
it could generate a continuous delivery of antioxidants in the skin (95). For topical 





delivery of a pro-drug it is important to evaluate in vitro degradation and chemical and 
enzymatic hydrolyses of the prodrug (96). 
Soy isoflavones can be used to protect skin from OS induced by UV-B radiation. Using 
solvents as the vehicle significant amounts of isoflavon were delivered into the skin (97). 
It is necessary to find an appropriate vehicle to test the lipophilic antioxidants 
internalization. Solvents, lipoproteins and proteins are able to solubilize the 
antioxidants and to promote its delivery to cells (98).  
 
5.2. Conventional delivery systems 
Over the past few decades there have been many advances in our understanding of the 
physicochemical properties of both formulation systems and their ingredients. Dosage 
forms for dermatological drug therapy are intended to produce a desired therapeutic 
action at specific sites in the epidermal tissue. A drug’s ability to penetrate the skin’s 
epidermis, dermis, and subcutaneous fat layers depends on the properties of the drug 
(physicochemical properties), the carrier base and skin condition. Gels, lotions and 
creams play an important role as vehicles for the topical treatment of the skin. Both 
topical and transdermal drug products are intended for external use. However, topical 
dermatologic products are intended for localized action on one or more layers of the 
skin (e.g. sunscreens, keratolytic agents, local anaesthetics, antiseptics and anti-
inflammatory agents). In modern-day pharmaceutical practice, semisolid formulations 
are the preferred vehicles for dermatological therapy because they remain in situ and 
deliver the drug over extended time periods. In most cases, therefore, the developed 
formulation will be an ointment, emulsion, or gel. Concerning antioxidant properties, 
most of the research papers refer gels and emulsions formulations as vehicles. 
Depending on the lipophilicity of the antioxidant, the chosen vehicle can enhance or 
reduce its skin deposition being an important factor in the selection of a suitable 
formulation (99). 





The common characteristic of all gels is that they contain continuous structures that 
provide solid-like properties. Depending on their constituents, gels may be clear or 
opaque, and be polar, hydroalcoholic, or nonpolar. The simplest gels comprise water 
thickened with natural gums, semisynthetic materials, synthetic materials or clays. Gel 
viscosity is generally a function of the amount and molecular weight of the added 
thickener. 
Cassano et al. (100) refer a dextran hydrogel linked with ferulic acid for the delivery of 
vitamin E.  Their results showed that ferulate hydrogel was a more effective carrier in 
protecting vitamin E from photodegradation than hydrogel without antioxidant 
moieties. Then, the antioxidant hydrogel could be of potential use for cosmetic and 
pharmaceutical purposes as carrier of vitamin E which can reduce erythema, 
photoaging, photocarcinogenesis, oedema, and skin hypersensitivity associated with 
exposure to UV-B radiation (100). Epigallocatechin-3-gallate, a catechin from green tea, 
has been tested for transdermal delivery and topical application. Catechin gel 
formulation resulted in prolonged levels in plasma tissues (101). Topical application of 
resveratrol was tested in a series of hydrogel formulations and solutions, and it was 
concluded that delivery via a skin route may be a potent way to achieve the therapeutic 
effects of resveratrol (102). 
The most common emulsions used in dermatological therapy are creams, both oil-in-
water (O/W), or water-in-oil creams (W/O) emulsions.  
To diminish oxidative injury, topically applied antioxidants must reach the susceptible 
cells. The use of α-lipoic acid and proanthocyanidin significantly enhances collagen 
synthesis and deposition when used in a standard cosmetic composition (103). 
Flavonoids and polyphenols were formulated into an O/W emulsion showing a 
photoprotective effect when applied into the skin with sunscreens (104). 
Zhai et al (105) evaluated and proved the antioxidant capacity and preventive effects of 
a topical emulsion of vitamin E on the response to UV exposure. Other authors 
(106,107) showed also the protective effect of topical formulations containing 
antioxidant agents – vitamin C, vitamin E, ferulic acid against UV damage. 





Isoflavones (genistein, equol, daidzein, biochanin A, and formononetin) were 
formulated as 0.5 % individual isoflavone solutions, and the photoprotection effect in a 
pig skin model was compared to an antioxidant combination solution of 15 % vitamin C, 
1 % vitamin E and 0.5 % ferulic acid. The results showed that the protection was less 
than that provided by the topical antioxidant combination, but nevertheless the 
isoflavones provided effective photoprotection, and were considered as good candidate 
ingredients for protection against UV photodamage (108).  
Gaspar & Campus (109) evaluated the influence of two different UV-filters 
combinations, a photostable and a photounstable one, on the photostability as well as 
on the efficacy of a formulation based on a phosphate-based self-emulsifying wax and 
on hydroxyethilcellulose, containing vitamin A, C and E derivatives. They concluded that 
both UV filters combinations did not influence the hydration and anti-aging effects of 
the formulations containing vitamins, and that the skin irritation was reduced in the 
presence of these vitamins. In addition, the photostable UV-filters combination had the 
highest recovery of vitamin A in the photostability studies. Finally, they suggested that 
the most suitable formulation was the one containing the combinations of vitamins A, C 
and E with photostable UV-filters.  
A commercially available cream containing 0.4 % hydroquinone and 0.15 % retinol with 
antioxidants was used successfully for topical treatment of melasma (110). 
Water-in-oil microemulsions containing quercetin significantly prevented UV-B 
irradiation-induced skin damages due to the increased penetration into the SC (111).  
The effectiveness of topical non-ionic emulsion formulations containing quercetin to 
inhibit the UV-B irradiation-induced skin damages was previously demonstrated by 
other authors (112). Combined therapy using at least two antioxidants was tested in 
different microemulsions type (113). 
In conclusion, the regular application of skin care products containing antioxidants may 
be a benefit to efficiently prepare our skin against exogenous oxidative stressors 
occurring during daily life. Furthermore, sunscreen agents may also benefit from 





combination with antioxidants resulting in increased safety and efficacy of such 
photoprotective products (114). 
 
5.3. Complexation with Cyclodextrins 
Cyclodextrins (CyDs) are cyclic water-soluble, non-reducing, macrocycle carbohydrate 
polymers (115). These starch derivatives are non-toxic ingredients, are not absorbed in 
the upper gastrointestinal tract, and are completely metabolized by the colon 
microflora. Besides this, -CyD, -CyD and -CyD enjoy GRAS status (FDA) for use as an 
additive in food products, as a flavor carrier and protectant (116,117). Worldwide there 
are several commercial pharmaceuticals with CyDs based formulations. In topical 
dosage forms, -CyD and methylated--CyD have more often been used (118-120). 
 
Fig.3- -Cyclodextrin toroidal structure 
CyDs are shown to have a toroidal, hollow, truncated cone structure (Fig.3), where the 
polar sugar hydroxyl groups are oriented to the cone exterior, and consequently the 
external faces of CyDs are hydrophilic.  The result of this amphipathic property is that 
CyDs can form soluble, reversible inclusion complexes with water-insoluble compounds 
resulting in compound solubilization (121). 
Encapsulation may be a method of protecting molecules as CyDs behave like an empty 
molecular capsule with the ability to entrap “guest” molecules of appropriate geometry 
and polarity. The guest molecules (such as antioxidants) are protected from light, heat 
and oxidation. The entrapped molecules are released from the molecular-inclusion 
system on contact with water or by exchange with another guest. The method of 





encapsulation can also be applied to achieve controlled release in topical formulations. 
Some of the release mechanisms involves: a change in temperature, moisture or pH; the 
application of pressure or shear; and the addition of surfactants (122). The method of 
preparation can affect the effectiveness of the complex (123,124). Accelerated and 
long-term storage stability of CyD entrapped topical ingredients surpassed that of the 
traditionally formulated ones (125-128).  
Due to their size and hydrophilicity only insignificant amounts of CyDs and drug/CyD 
complexes are able to penetrate into lipophilic biological barriers, such as intact skin. In 
general, CyDs enhance topical drug delivery by increasing the drug availability at the 
barrier surface. At the surface the drug molecules partition from the CyD cavity into the 
lipophilic barrier. Thus, drug delivery from aqueous CyD solutions is both diffusion 
controlled and membrane controlled. It appears that CyDs can only enhance topical 
drug delivery in the presence of water (129). 
HP-β-CyD was found to be an effective permeability enhancer for 17-β-oestradiol (130).  
Methylated CyDs are expected to promote transdermal drug absorption, because they 
are highly surface active (131). 
The entrapment of CyD-drug complexes into liposomes is not a new strategy (132). 
However, more recently, drug-in-CyD-in-deformable liposomes has been developed for 
topical delivery (133). 
CyDs have been used in formulations for dermal and transdermal delivery (129) and 
have been used for antioxidant formulation for food industry (134), mainly to promote 
antioxidant solubilization and chemical stability (135).  
Low aqueous solubility of melatonin was significantly increased in a mixture of 
propylene glycol and HP-β-CyD, motivating enhanced percutaneous absorption of 
melatonin (136). In the same way the complexation of 4-nerolidylcatechol and HP-β-CyD 
led to higher drug solubility and stability (137). 
Poly(ethylene glycol) citrate (6-armPEG) and its inclusion complex with α-CyD were 
prepared and used for preparation of vitamin C transdermal patches with stabilization 





of vitamin C in topical formulations. The release / diffusion of ascorbic acid across 
synthetic membrane were considerably enhanced in the presence of 6-armPEG-α-CyD 
complex (138). 
Permeation assays in pig ear skin clearly demonstrated the enhancer effect of β-CyD on 
3-O-methylquercetin (3-MQ) permeation. The hydrophilic matrix used controlled 3-MQ 
release from the β-CyD complex, demonstrating the influence of the inclusion 
phenomena on 3-MQ diffusion through the gel and partition toward the SC (139). 
A topically applied 2 % hydroquinone–CyD formulation significantly reduced the 
pigmentation of actinic lentigines in Asian subjects by enhanced penetration, 
bioavailability, and efficacy (140). 
Inclusion complex between β-CyD and astaxanthin found to greatly enhance its heat 
stability under light (141). 
Ferulic acid physico-chemical stability was improved by complex formation. Ferulic 
acid/α-CyD complex showed the most promising properties (high association constant, 
high degree of photostability, slower drug release) as sunscreen delivery system (142). 
Problems associated with sunscreen agents (UV-A and UV-B filters) are their poor 
solubility and photo degradation which undergoes marked decomposition under 
sunlight exposure leading to a decrease of its expected UV-protective capacity. It is also 
desirable to minimize skin penetration of some sunscreens. The inclusion of sunscreen 
agents into the CyD cavity can suppress their photosensitizing potential and increase 
their solubility (143). 
In spite of a large number of studies dealing with CyD stabilization of antioxidants and 
topical delivery using CyD containing formulations, antioxidant complexation with CyD 









5.4. Nanoparticulated delivery systems 
Novel drug delivery systems have been introduced in the topical delivery of drugs with 
special incidence on particulate carriers. Particulate type carriers are also known as 
colloidal carrier systems. Much has been written about the ability of liposomes and 
other vesicular colloidal carriers to penetrate the SC. The possibility of using such 
vesicles for transdermal drug delivery was also widely discussed (144-147).  
To improve the transdermal drug delivery using lipid-based-aggregates, specialized 
carriers have been developed, some of which are claimed to cross the skin intact. 
Drug association to the carrier can be of three basic different types: encapsulation 
/inclusion in internal carrier space or carrier core; adsorption to the external surface of 
the carrier; or covalent association to the membrane or carrier surface.  
5.4.1. Liposomes 
Liposomes are typically hollow spheres surrounded by a lipid bilayer. Other shapes have 
also being known and documented (148,149). The hydrophilic parts of lipids, most often 
of phospholipids, are oriented to the inner and to the outer bilayer surface (Fig. 4). 
Liposomes may be affected by the preparation method as much as this affects the 
lamellarity and drug distribution, and can be loaded with drugs in vesicle interior or lipid 
bilayer. Hydrophilic substances are encapsulated in the inner aqueous space and 
lipophilic compounds are integrated into or on the bilayer (Fig.4). 
 
Fig.4- Liposome cartoon. Schematic representation of molecular partition into a bilayer. 





Liposome carriers are used in several controlled or targeted release pharmaceuticals. In 
the cosmetic field, phospholipid liposomes, but also niosomes, i.e. vesicles made of non-
ionic surfactants, or sphingosomes, made of sphingolipids, are occasionally used. For 
transcutaneous delivery, the idea of making vesicles with membranes similar to those 
present in the SC, led to the preparation of non-phospholipid liposomes, starting with 
Gray et al. in 1973 (150), and many others since then. 
Mezei & Gulasekharam (151) were the first to report that liposomes loaded with 
triamcinolone acetonide facilitate the accumulation within the epidermis and dermis 
with low systemic levels. Similar results were obtained with local anaesthesia: liposomal 
tetracaine compares favorably with that mediated by a cream (152). 
The years following 89 were rich on topically applied liposome research. Some of the 
most relevant studies include phospholipids interactions with the skin, lipid vesicle 
transport through SC, and dermatologically relevant studies with liposomes. Many of 
these studies revealed interactions between lipid vesicles and the skin via high surface 
absorption, lipid incorporation or deposition between the intercellular lipid lamella or 
between the poorly organized lipid regions, and even more likely among themselves, 
liposomes can also fuse with intercellular lipids (153). In fact, liposomes may affect SC 
permeability. The basic mechanisms by which this occurs are still uncertain. Two 
possibilities are proposed: 1) molecules penetrate into the skin associated with intact 
liposomes; 2) molecules cross the skin, which is affected by the interaction with 
liposomes or liposome ingredients. In any case, liposomal lipids are incorporate into SC 
lipid bilayers, and thus facilitate drug transport by changing the lipid layers properties. 
When this happens, liposomal lipids act as chemical enhancers. Liposomes either act 
after fusion on the skin via hydration increase or through the action of surfactant or 
enhancer-like components, such as hydrolyzed fatty acids (Fig.5-III)) (145). 
 
Drug deposition is affected by formulation and processing variables involved in 
liposome preparation. Drug deposition in the skin was studied using a factorial approach 
to demonstrate the influence of formulation variables. This study explored the topical 





delivery of vitamin E acetate (154). Liposomal encapsulation of phycocyanin improved 
its topical anti-inflammatory activity in cutaneous inflammation models (155). 
Verbascoside, commonly used in Chinese medicine, was incorporated in large liposomes 
and resulted in the dermal but not transdermal delivery of the drug (156). Topical 
application of the antioxidant rh-SOD incorporated in liposomes reduced successfully 
wound size edema formation in thermally injured tissues comparatively to enzyme 





























































































Fig.5- Skin drug delivery: I) drug delivery from a conventional delivery system; II) drug-loaded vesicular 
carrier with non flexible membrane; III) drug delivery after carrier adsorption and/or fusion with the 
stratum corneum; IV) drug delivery from a formulation containing a permeation enhancer; V) drug 
delivery by means of deformable intact vesicle penetration into and through the intact skin; and VI) 
transappendageal penetration of drug-loaded deformable carriers. (adapted (145)) 












5.4.2. Deformable vesicles 
The hypothesis that liposomes could cross intact SC is very controversial. Liposomes can 
cross the skin through the pilo-sebaceous units, which are widely open shunts (157) 
(Fig.5-VI)). Carriers with flexible membranes are more deformable than rigid ones, thus 
penetration of colloidal particles is a function of membrane flexibility. Ideal vesicles for 
penetration work should pass through pores without suffering extrusion. To ensure 
vesicle’s motion, a strong external driving force must act on the vesicle’s components. 
Naturally occurring transcutaneous hydration gradient is presented as the biophysical 
mechanistic explanation for spontaneous deformation and passagework (even accepted 
with some skepticism) (90). 
The introduction of special vesicles, which are deformable enough to penetrate even 
narrow pathways between cells in the skin, started a new chapter in the transdermal 
delivery field. In recent years, specially designed carriers cross the skin intact and deliver 
the loaded drugs into the systemic circulation, being at the same time responsible for 
the percutaneous absorption of the drug within the skin. To differentiate them from the 
more conventional liposomes are named as deformable vesicles or Transfersomes. With 
Transfersomes, the concept of permeability and penetrability was reviewed. It has now 
been proven that intact Transfersomes, in contrast to liposomes, penetrate the skin 
without its disruption (48). Transfersomes® (a trademark of IDEA, AG) composed of 
highly flexible membranes are the result of combining into a single structure 
phospholipids (that give the bilayers structure and stability) and an edge-active 
component (to increase the bilayer flexibility) in order to move spontaneously against 
water concentration gradient in the skin.  These carriers comprise at least 
phosphatidylcholine and an edge-active molecule acting as the membrane softener. The 
vesicles have typically 150 ± 50 nm. Many of the techniques used for liposome 
preparation and characterization can be used for Transfersomes as well. Carrier 
properties are responsible for membrane flexibility and consequently for vesicle 
deformability necessary for through-the-skin passagework. This vesicle characteristic is 
assessed using membrane penetration assays. The transport does not rely chiefly on 
annexial route but rather is fairly uniform through the entire intact SC.  





Simões et al. (75) developed and characterized SOD-loaded Transfersomes and have 
shown for the first time that SOD incorporated into Transfersomes and applied onto a 
skin area not necessarily close to the inflamed tissue, and is able to promote non-
invasive treatment of induced arthritis. Studies demonstrated that this antioxidant 
enzyme delivered by means of ultradeformable lipid vesicles can serve as a novel 
region-specific treatment of inflammation after topical application (158). 
The driving force for skin penetration by lipid vesicles was firstly argued to be the 
hydration gradient, or hydration potential difference, across non-occluded SC, and more 
recently the transepidermal electrical potential was postulated to be the driving force 
for barrier penetration (144). Additional requirements for successful skin penetration 
are: 1) lipid vesicles deformability sufficient to allow carriers squeezing through “holes” 
in the intercellular lipid layers; 2) non-occlusive application which maintains the driving 
force across the skin. The natural hydration then forces carriers through weak junctions 
between lipid structures in intercellular space in SC.  
The rate of barrier penetration is proportional to the transbarrier water activity 
difference, which is in turn proportional to the carrier hydrophilicity. Intercolloidal 
repulsion is essential for carrier penetration. In addition, colloid deformation is needed 
in order to move particles from high-stress to low-stress sites through pores in a barrier. 
This transbarrier stress difference can be generated, e.g. when a external pressure 
produced by a gas stream, is applied on a suspension and this is filtered through narrow 
pores, or when a vesicle suspension is applied onto the skin, under non-occlusive 
conditions, and is left to dry out. In this case, a transbarrier hydration gradient is 
responsible for transbarrier stress difference. The external pressure is then responsible 
for the vesicle’s motion. Fig.5 illustrates different possibilities for skin drug delivery. 
Fig.5-V is a schematic representation of the fate of a deformable vesicle suspension on a 
barrier with narrow pores (145). 
Ethosomes are a special kind of unusually deformable lipid vesicles in which the 
abundant ethanol makes lipid bilayers very fluid (159). This improves delivery of various 
molecules into deep skin layers such as cannabinoids, testosterone, minoxidil, 





propranolol and trihexyphenidil (160). Ethosomes are composed of phospholipid, 
ethanol and water. The exact process of drug delivery by ethosomes is not completely 
clear. Ethanol, responsible for the flexibility of the vesicles, evaporates from the 
formulation once applied on skin surface under non-occlusive conditions. On the other 
hand, the influence of total ethosomal composition on the bilayer structure of the SC is 
not yet fully understood.  
Regarding the comparison between systems as topical vehicles, the major difference is 
not technological but in terms of release rate: the diffusional performance through 
barriers (commonly Franz cells) is, in general, higher for flexible liposomes than for 
conventional ones (161). 
Fang and co-workers developed a new liposomal system which is a mixture of 
Transfersomes and ethosomes to enhance the skin permeation of cathechins (162). 
Other so-called “elastic vesicles” were found to be responsible for major morphological 
changes in the intercellular lipid bilayer structure comparatively to rigid vesicles. The 
structures are liquid state vesicles made of L-595/ PEG-8-L/sulfosuccinate (50/20/5), 
and have an average size of 100-120 nm. A two-photon excitation microscopy study has 
shown that after treatment with “elastic vesicles”, thread-like channels were found 
within the entire SC (163). Fluorescent label incorporated in rigid vesicles was confined 
to the intercellular spaces of the upper SC.  
Deformable vesicles are, thus, alternative and promising drug delivery systems for 
antioxidant topical delivery, presenting a strategy to overcome the skin barrier. 
Amongst the various drugs that have been tested, only a few studies present 










5.4.3. Non-ionic surfactant vesicles (NSVs) 
Niosomes or non-ionic surfactant vesicles, consisting of non-ionic surfactants, are a 
special example of (non-phospholipid) liposomes. They have vesicular structure, most 
often stabilized by cholesterol, and have been tested as drug carriers (164). The findings 
resemble those made with phospholipid vesicles: gel-phase vesicles do not affect 
transdermal transport and do not cross the skin, whereas fluid phase vesicles can affect 
molecular diffusion into the skin more strongly. However, no evidence was presented to 
date that such vesicles could cross SC intact. 
NSV can be formulated mainly by lipid layer hydration method, reverse phase 
evaporation method, or by transmembrane pH gradient uptake process.  
NSV alleviate the disadvantages associated with liposomes such as chemical instability, 
variable purity of phospholipids and high cost, which makes it suitable for industrial 
manufacture. Besides, NSV are quite stable structures, even in the emulsified form, 
require no special conditions such as low temperature or inert atmosphere for 
protection or storage, and provide a large amount of surfactant classes available for the 
design of this vesicular system (165-167).  
NSV appear to have application in topical products containing both hydrophilic and 
hydrophobic drugs. These vesicles have been applied for cosmetic purposes very 
successfully and have been experimentally evaluated as carriers of many antiblastic 
drugs, such as methotrexate, doxorubicin and cisplatin, haemoglobin, indomethacin and 
the antipsoriatic dithranol. The encapsulation of drugs in NSV can decrease drug 
toxicity, increase drug absorption and delay removal of drug from circulation due to 
slow drug release (167). Besides, NSV have also been used to encapsulate lidocaine, 
estradiol, cyclosporine, erythromycin, α-interferon, plasmid DNA for the human 
interleukin-1 receptor for topical delivery (168). In fact, topically applied NSV can 
increase the residence time of drugs in the SC and epidermis, while reducing the 
systemic absorption of the drug (169).   





NSV were used as carriers for tretinoin (TRE), and for selected formulations, niosomes 
retarded the drug photodegradation (169). Manconi et al. (166) evaluated the potential 
of alkyl polyglucosides (APGs) NSV as topical delivery systems capable of improving the 
cutaneous delivery of TRE by measuring the influence of drug thermodynamic activity 
and niosome composition, size, lamellarity and charge on the (trans)dermal delivery of 
TRE. For this purpose, TRE was incorporated at saturated and unsaturated 
concentrations in both multilamellar and unilamellar vesicular formulations using two 
different commercial mixtures of APGs: octyl-decyl polyglucoside and decyl 
polyglucoside and with a polyoxyethylene lauryl ether (Br30). In recent years, attention 
has been focused on sugar-based surfactants like APGs for several types of applications, 
including dermatological ones. Overall, obtained results showed that TRE cutaneous 
delivery is strongly affected by vesicle composition and thermodynamic activity of the 
drug. In fact, very hydrophilic surfactants may improve diffusion of TRE through the pig 
skin. Brij® 30 or Oramix NS 10 (hydrophilic-lipophilic balance (HLB) 9 and 11, 
respectively) NSV have shown to be able to greatly enhance drug cutaneous retention, 
especially if compared to the commercial formulation RetinA® and P90 liposomes. On 
the other hand, small negatively charged niosomal formulations, which are saturated 
with TRE, have shown to give higher cutaneous drug retention than both liposomes and 
commercial formulation (RetinA®) (166). Moreover, interactions between skin and 
vesicles seem to depend on physicochemical properties of the main component of the 
vesicular bilayer. However, these results are strongly affected by the thermodynamic 
activity of the drug. Vesicular formulations, which are saturated with TRE have shown to 
highly promote drug accumulation in the pig skin, while the same does not occur when 
the vesicular bilayer is not saturated with the drug. Therefore, these results showed an 
interesting advantage of vesicular systems: once drug saturated vesicular formulations 
are prepared, they can be diluted to reach the desired drug concentration without 
losing the saturation of the vesicular bilayer, and therefore, maintaining the same 
thermodynamic activity of the drug and the same driving force for skin permeation 
(166).  





Another example (167) is the solubilization and stabilization of -carotene in NSV. The 
authors found that the maximum entrapment efficiency for -carotene was reached by 
the use of Tween® 60, while the lowest was observed in the presence of Tween® 20 
probably due to a different HLB. Besides, NSV which contained cholesterol and Tween® 
60 in a 1:1 ratio strongly increased their ability in trapping the carotenoid. On the other 
hand, the addition of cholesterol in a higher ratio decreased the niosomal efficiency in 
trapping the carotenoid, which could be explained by a possible competitive carotenoid 
and cholesterol incorporation into NSV. The maximum hydrodynamic diameter of the 
vesicles was reached by the addition of 0.5 mg/ mL of -carotene. -carotene contained 
in NSV was highly resistant to sunlight, high temperatures and OS induced by different 
sources of free radicals. They also investigate the behavior of -carotene in NSV in a 
highly malignant colon cancer cell line and found that the niosomal formulation strongly 
inhibited tumour cell growth in a dose-dependent manner. Therefore, NSV provided a 
convenient, non toxic and inexpensive vehicle for -carotene in cell culture (167). 
Caraf et al. (170) showed that NSV could be obtained from polyoxyethylene sorbitan 
monolaurate-cholesterol in aqueous environment. These authors investigated the 
delivery of lidocaine HCl and lidocaine base from vesicles through silicone membrane 
and nude mice skin. The amount of lidocaine permeated through nude mice skin from 
these NSV was similar to liposomes and only about 2-fold greater than from a micellar 
system. 
NSV were also investigated for their ability to deliver drugs to hair follicles. Niemiec et 
al. (171) investigated the deposition of two polypeptide drugs, interferon- and 










5.4.4. Solid Lipid Nanoparticles (SLN) 
Solid lipid nanoparticles (SLN) dispersions introduced in 1991 have been proposed as a 
new type of colloidal drug carrier system (172-174). The system consists of 0.1-30% 
(w/w) solid lipid particles in the nanometer range (40-1000 nm), which is dispersed in 
water, and if necessary, stabilized with preferably 0.5-5 % (w/w) surfactant (173). 
Generally, they are made of solid hydrophobic core having a monolayer of surfactant 
coating. The solid core contains the drug dissolved or dispersed in the solid high melting 
fat matrix. In general, solid lipids can be triglycerides (e.g. tristearin), glycerides (e.g. 
glyceryl behenate; glycerol tripalmitate), fatty acids (e.g. stearic acid), steroids (e.g. 
cholesterol) and waxes (e.g. cetyl palmitate).  All classes of emulsifiers have been used 
to stabilize the lipid dispersion. It has been found that the combination of emulsifiers 
might prevent particle agglomeration more efficiently (175,176). 
SLN have different advantages including: good tolerability (avoidance of organic 
solvents), simple and cost effective large scale production, stability (conferred by 
surfactants or polymers), site-specific targeting, controlled drug release and protection 
of liable hydrophilic or hydrophobic drugs from degradation (172,176). However, there 
is also the insufficient drug loading, drug expulsion after polymorphic transition on 
storage and relative high water content of the dispersions. To overcome some of the 
limitations of SLN, nanostructured lipid carriers (NLC) were introduced. NLC are 
composed of solid lipids and a certain amount of liquid lipids, showing an improved drug 
loading and increased stability on storage thereby reducing drug expulsion. 
Furthermore, it is possible to control the drug release from the matrix. NLC have been 
explored for dermal delivery in cosmetics and dermatological preparations (173,175). 
Lipid Drug Conjugate (LDC) nanoparticles were introduced to overcome the limitation 
of some drug types incorporated in the solid lipid matrix. Lipophilic drugs are usually 
incorporated in SLN but due to partitioning effects during production, only high potent 
hydrophilic drugs effective in low concentrations are incorporated in SLN. LDC enables 
the incorporation of both hydrophilic (e.g. doxorubicin and tobramycin) and lipophilic 
(e.g. progesterone and cyclosporine A) drugs (175). 





Most SLN dispersions are produced by high pressure homogenization (HPH). Hot 
homogenization is the most frequently applied technique, even in temperature 
sensitive compounds because the exposure time is relatively short. Other production 
procedures are based on the use of organic solvents (HPH/ solvent evaporation/ 
diffusion), dilution of microemulsions, w/o/w double emulsion method, membrane 
contractor technique, phase inversion or also by high speed stirring and/or 
ultrasonication technique.  
Although many different drugs have been incorporated in SLN, there are only few 
studies about drug release. SLN have been studied and developed for parenteral, 
dermal, ocular, oral, pulmonary and rectal routes of administration. The results with 
dermal application are encouraging and probably, this will be the main application of 
SLN. The dermal administration route further reduces the risks of cytotoxicity or 
systemic toxicity. The excellent tolerability of the lipid nanoparticles is supported by 
many available cosmetic dermal products already being introduced to the market 
fulfilling the regulatory requirements towards tolerability and nanotoxicity. Thus, it 
seems justified to call the lipid nanoparticles a “nanosave” carrier (173).  
In most cases, the incorporation of the SLN dispersion in an ointment or gel is necessary 
in order to achieve a topical formulation. For dermal application, burst release as well as 
sustained release (already reported for SLN suspensions) are of interest. Burst release 
can be useful to improve the penetration of a drug. Sustained release becomes 
important with active ingredients that are irritating at high concentrations or to supply 
the skin over a prolonged period of time with a drug. 
Hsu et al. (177) have reported the preparation of CoQ10 nanoparticles engineered from 
microemulsion precursors. It was also demonstrated that CoQ10 was more stable within 
polymeric nanoparticles over dispersion and oil-based formulation when exposed to UV 
and high temperatures (178). The release profile of Q10-loaded NLC and nanoemulsion 
was compared (179) and the Q10-loaded NLC exhibited a biphasic release pattern. 
Liu et al. (180) showed that isotretinoin-SLN formulation with skin targeting may be a 
promising carrier for topical delivery of isotretinoin. The in vitro permeation studies 





showed avoidance of the systemic uptake of isotretinoin, a high accumulative amount 
of isotretinoin in skin and a significant skin targeting effect. Castro et al. (181) 
demonstrated by X-ray powder diffraction that the formation of ion pairing is an 
interesting alternative for retinoic acid encapsulation in SLN. SLN containing all-trans-
retinoic acid (ATRA) were developed and evaluated for topical delivery (182). Authors 
concluded that the photodegradation of ATRA was reduced, the loading capacity of 
ATRA in SLN was higher than 95 % (w/w) and the amount of ATRA released from SLN at 
4 C and 37 C were less than 15 % and more than 60 % (w/w) for 96h, respectively. 
Jenning et al. (183) evaluated the potential use of glyceryl behenate SLN loaded with 
vitamin A (retinol and retinyl palmitate) and incorporated in a hydrogel and O/W cream. 
Vitamin A concentrations in the porcine skin tissue suggested a certain drug localizing 
effect. High retinol concentrations were found in the upper skin layers following SLN 
preparations. Because of a polymorphic transition of the lipid carrier with subsequent 
drug expulsion following the application to the skin, the drug localizing action appears 
to be limited for 6-24h. Best results were obtained with retinol SLN incorporated in the 
O/W cream retarding drug expulsion. The penetration of the occlusion sensitive drug 
retinyl palmitate was even more influenced by SLN incorporation. SLN of tretinoin were 
successfully developed with the help of emulsification-solvent diffusion technique, and 
the capability of an SLN based gel in improving topical delivery of tretinoin has also 
been evaluated (184). Drug encapsulation in SLN resulted in a significant improvement 
in its photostability in comparison to methanolic solution, and also prevented its 
isomerization. Furthermore, the skin irritation studies carried out on rabbits showed 
that SLN based tretinoin gel is significantly less irritating to skin as compared to 
marketed tretinoin cream and clearly indicated its potential in improving the skin 
tolerability. In vitro permeation studies through rat skin indicated that an SLN based 
tretinoin gel has a permeation profile comparable to that of the marketed tretinoin 
cream (184). 
Souto et al. (185) prepared and characterized SLN containing the novel anti-aging 
substance -lipoic acid. An entrapment efficiency of 90 % was obtained for all 
developed formulations using Miranol Ultra C32 as emulsifying agent. DSC analysis 





confirmed that these systems are characterized by a solid-like behavior, even with a 
very low crystallinity index. Recent studies with SLN and NLC of α-lipoic acid 
demonstrated an antioxidant activity in developed water-soluble formulation for topical 
administration (186). 
It has been found in vitro that SLN have UV reflecting properties. The use of 
physiological components in SLN is a clear advantage over existing UV protective 
systems (UV blockers or TiO2) with respect to skin penetration and potential of skin 
toxicity (176). In addition, it was found that a combination of molecular sunscreens and 
SLN showed a synergistic effect (172). Wissing et al. (187) studied the comparison of 
two different formulations (SLN and conventional O/W emulsion) as carrier systems for 
the molecular sunscreen oxybenzone. The release rate was strongly dependent upon 
the formulation and could be decreased by 30–60 % in SLN formulations. In all test 
models, oxybenzone was released and penetrated into human skin more quickly and to 
a greater extent from the emulsions. UV absorption properties of 3,4,5-
trimethoxybenzochitin-loaded SLN and SLN free system were also compared (188). 
Comparing SLN to a conventional emulsion, the amount of molecular sunscreen can be 
reduced by 50 % in the SLN formulation maintaining the protective level of the 
conventional emulsion.  
5.5. Others 
More recently, pharmaceutical foams appeared as the solution for skin drug deposition 
of drugs (189). In order to overcome the poor drug release from the particles, a recent 
study investigated the capability of dynamic foam to break open nanoparticles upon 
application to the skin and enhance drug delivery efficiency (190). The study was 
performed with vitamin E acetate and the results shown that dynamic foam can 
enhance the release of vitamin E acetate from lipid nanoparticles upon dose 
application. It is still not clear whether a similar strategy is suitable and effective for 
other agents. Tocols and derivatives are widely used as antioxidants in food industry 
and in pharmaceutical compositions, and have been also proposed as drug carriers for 
topical delivery (191). 






ROS are produced by various causes, which can produce lipid peroxidation and other 
cellular injuries. This production, if excessive, could cause autoxidative damage. It has 
been demonstrated that oxidative mechanisms are involved in the pathogenesis of both 
systemic and skin disorders and diseases. An increased interest in antioxidant 
protection against ROS effects is present in dermatology research and, especially, an 
increasing focus on the therapeutic topical application of antioxidants has emerged in 
the last years. However, the real potential of topical antioxidant therapy for the 
treatment of OS-related skin disorders has not been yet fully recognized. The 
development of an appropriate and efficient antioxidant delivery for the treatment of 
OS related diseases is an important goal for the pharmaceutical technology and 
dermatology fields. The comprehension of ROS role in pathologies, such as skin 
inflammation and skin cancer could contribute for the establishment of therapeutic 
strategies involving antioxidant therapy. In the particular case, special emphasis was put 
on the drug delivery systems of antioxidants and radical scavengers for prophylactic or 
therapeutic action, to solve problems related to antioxidant skin bioavailability. 
Incorporation of antioxidants in suitable carrier bases or topical delivery systems could 
provide a comprehensive solution for OS-related skin diseases.  






ROS: reactive oxygen species 
OS: oxidative stress 
UV: ultraviolet 
MDA: malondialdehyde 
SC: stratum corneum 
CyD: cyclodextrin 
3-MQ: 3-O-methyl-quercetin 
NSV: nonionic surfactant vesicles 
APGs: alquyl polyglucosides 
SLN: solid lipid nanoparticles 
NLC: nanostructured lipid carriers 
LDC: lipid drug conjugate 
HPH: high pressure homogenization 
ATRA: all-trans-retinoic acid 
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Novel Tretinoin Formulations:  a Drug-in-Cyclodextrin-in-Liposome 
Approach  
Abstract 
Purpose: The aims of this experimental work were the incorporation and full characterization of 
the system Tretinoin-in-dimethyl beta cyclodextrin-in-ultradeformable vesicles (Tretinoin-CyD-
UDV) and Tretinoin-in-ultradeformable vesicles (Tretinoin-UDV). 
Methods: The Tretinoin-CyD complex was prepared by kneading and the UDV by adding 
soybean phosphatidylcholine (SPC) to a nonionic surfactant followed by an appropriate volume 
of sodium phosphate buffer solution to make a 10 % - 20 % lipid suspension. The resulting 
suspension was brought to the final mean vesicles size, of approximately 150 nm, by sequential 
filtration.  
The physicochemical characterization was based on: the evaluation of mean particle size and 
polydispersity index (PI) measured by photon correlation spectroscopy (PCS) and atomic force 
microscopy (AFM) topographic imaging; zeta potential (ζ-potential) and the SPC concentration 
determined by Laser-Doppler anemometry and an enzymatic-colorimetric test, respectively. The 
quantification of the incorporated Tretinoin and its chemical stability (during preparation and 
storage) was assayed by HPLC at 342 nm.  
Results: It was possible to obtain the system Tretinoin-CyD-UDV. The mean vesicle size was the 
most stable parameter during experiments time course. AFM showed that Tretinoin-CyD-UDV 
samples were very heterogeneous in size, having three distinct subpopulations, while Tretinoin-
UDV samples had only one homogeneous size population. The results of the ζ-potential 
measurements have shown that vesicle surface charge was low, as expected, presenting 
negative values. The incorporation efficiency was high and no significant differences between 
Tretinoin-CyD-UDV and Tretinoin-UDV were observed. However, only Tretinoin-UDV with 20 % 
lipid concentration formulation remained chemically stable during the evaluation period. 
Conclusion: According to our results, Tretinoin-UDV with 20 % lipid concentration seems to be a 
better approach than Tretinoin-CyD-UDV, attending to the higher chemical stability. 
Keywords: Tretinoin; Dimethyl-β-cyclodextrin; Ultradeformable Vesicles; Photon 
Correlation Spectroscopy/ Laser-Doppler Anemometry; Atomic Force Microscopy 






Tretinoin, a trans-isomeric form of retinoic acid, is effective in the topical treatment of 
different proliferative and inflammatory skin diseases, such as acne vulgaris, ichtiosys, 
psoriasis, epidermotropic T-cell lymphomas or epithelial skin cancer. Although the exact 
action mechanism of tretinoin is unknown, current evidences suggest that topical 
tretinoin decreases the cohesiveness of follicular epithelial cells with decreased 
microcomedones formation in acne vulgaris. Moreover, tretinoin stimulates the mitotic 
activity and the turnover of follicular epithelial cells causing comedones extrusion. Until 
now, this is the most effective topical comedolytic agent for the treatment of acne (1). 
The formulations may contain 0.025-0.1 % of drug on topical creams and 0.01-0.025 % 
on gels. Unfortunately, this drug presents some technical drawbacks such as chemical 
instability in the presence of oxygen, light and heat and poor water solubility. 
Additionally, its topical application may cause irritation and peeling of the treated areas 
(2-5).  
Numerous drug delivery strategies, like conventional liposomes, ultradeformable 
vesicles (UDV), niosomes, solid lipid nanoparticles (SLN), cyclodextrins (CyD), 
microemulsions and hydrogels have been studied to overcome some drug formulation 
drawbacks (4). Micro/nano encapsulation of drugs, such as tretinoin (3, 6, 7), has been 
proposed in order to improve dermal tolerability, encourage adherence, and contribute 
to better long-term therapeutic outcomes, by facilitating a controlled release (8). For 
example, Mandawgade et al. (9) developed SLN to delivery tretinoin, and more recently 
Castro et al. (10) demonstrated that SLN were efficient as a vehicle to reduce retinoic 
acid skin irritation, keeping its efficacy. A recent report (6) has presented a new 
designation of vesicles - permeation enhancer containing vesicles (PEV) and the 
promotion of dermal delivery of tretinoin by means of such carriers. However, 
information concerning the drug stability of this drug-carrier association still remains to 
be clarified. 
Phospholipid vesicles, colloidal particles composed of concentric bilayers formed from 
self-assembly of amphiphilic lipids (e.g., soybean phosphatidylcholine), can act as skin 





permeation enhancers as well as drug carrier agents. Their composition affects physico-
chemical properties such as size, charge and bilayer elasticity. Several types of vesicles 
have been described in literature (11). Liposomes, in particular, are nontoxic and 
biodegradable vesicles, easy to scale up for manufacturing and enabling the 
encapsulation of both water- and lipid-soluble active components. Besides their unique 
benefits, liposomes show some disadvantages, such as low stability, low encapsulation 
efficiency, high cost of manufacturing, degradation by hydrolysis or oxidation, 
sedimentation, aggregation or fusion during storage (12). Conventional liposomes have 
been generally reported to remain confined to the upper layer of the stratum corneum 
(SC) and to accumulate in the skin appendages, with minimal penetration to deeper 
tissues, owing to their large minimum size and lack of flexibility (13). This characteristic 
has limited their application in delivering drugs to deeper layers of the skin; 
nevertheless, they were proven to protect tretinoin from light (14, 15).  
Recent approaches in modulating vesicle compositions have been conducted in order to 
develop systems capable of carrying low molecular weight drugs and macromolecules to 
deeper tissues. Deformable liposomes or ultradeformable vesicles (UDV), termed as 
Transfersomes® (a trademark of IDEA AG, Germany), are the first generation of elastic 
vesicles introduced in the early 1990s. These vesicles are constituted by phospholipids 
and an edge activator, which is frequently a single chain surfactant that destabilizes the 
vesicles lipid bilayers, and consequently increases the bilayers deformability (16). While 
conventional liposomes were reported to have mainly local or rarely transdermal 
effects, UDV are considered a carrier for dermal and transdermal drug delivery. They 
have been proven to be superior to conventional gel-state and even liquid-state vesicles 
in terms of both enhancement of drug permeation and interactions with human skin 
(17, 18). 
The UDV’s action mechanism was investigated, and two hypotheses were proposed 
(19):  first (mechanism 1), intact vesicles may enter the SC carrying vesicle-bound drug 
molecules into the skin, acting as drug carrier systems. The driving force for the vesicles 
to enter the skin could be the transcutaneous osmotic, hydrostatic and electrical 





gradients (20, 21). Accordingly, vesicles applied on the skin surface follow 
spontaneously the local hydration gradient, moving into the deeper skin strata (Fig.1). 
This highlights another important difference between deformable and conventional 
liposomes, the high and stress-dependent adaptability of such UDV, which enables them 
alone to squeeze between the cells in the SC. Second (mechanism 2), vesicles may enter 
the SC and change the intercellular lipid lamellae, acting as penetration enhancers of 
free drug molecules into and across the SC (19, 22, 23).  
 
Fig.1 - Deformability-driven movement of Transfersomes through small pores. Adapted from Simões (24). 
Accommodation of a poorly water-soluble drug in the lipid bilayer of liposomes is often 
limited in terms of drug–to-lipid mass ratio. Thus, the entrapment of water-soluble 
drug/cyclodextrin inclusion complexes in the aqueous phase of liposomes has been 
proposed in order to avoid such drawbacks, besides the chemical stability (25). 
Although “drugs-in-cyclodextrin-in-liposome” systems have been previously studied by 
some authors with other derivatives (β- and hydroxypropyl-β-CD) (25-27), only few 
studies concern topical formulations (28, 29). 
The aim of this study was to formulate tretinoin and fully characterize the resulting 
drug-carrier systems (Fig.2): Tretinoin-in-dimethyl beta cyclodextrin-in- ultradeformable 
vesicles (Tretinoin-CyD-UDV) and Tretinoin-in-ultradeformable vesicles (Tretinoin-UDV) 
in order to compare their physicochemical parameters during preparation and storage 





in use and sterile conditions. In fact, Tretinoin-in-dimethyl-beta-CyD complex has 
already been studied in previous work (30). 
            
Fig.2- Schematic representation of drug-in-cyclodextrin-in-liposomes (left side) and phospholipid 
structure and interaction with actives (right side). Adapted from Simões (24). 
 
This experimental work emphasizes the potential of the double vectorization of 
tretinoin. Theoretically, the entrapment of CyD drug complexes into UDV will increase 
the advantage of both of them: while the CyD seems to be a solubilizer agent, a 
chemical protector and sometimes a permeation enhancer (2, 30), one the other hand, 
the UDV seems to be able to penetrate into the intact skin when administered under 









Materials and Methods 
Materials 
Tretinoin was purchased from Fagron (Terrassa, Spain) and dimethyl-β-cyclodextrin 
(degree of substitution: 1.8) was a generous donation from Wacker 
(Stuttgart, Germany). Soybean phosphatidylcholine (S100: 62% Linoleic Acid; 15% 
Palmitic Acid; 12% Oleic acid and isomers; 5% Linolenic Acid; 3% Stearic Acid) and 
Tween 80® were purchased from Lipoid AG (Steinhausen, Switzerland) and Sigma-
Aldrich (St. Louis, MO, USA), respectively. All other reagents were of analytical grade. 
 
Methods 
Preparation of Tretinoin Dimethyl-β-Cyclodextrin Complex (Tretinoin-CyD) 
The Tretinoin-CyD complexes were prepared by kneading (mortar and pestle) in 1:4 
molar ratio and protected from light and air. 
Preparation of Formulations 
Three batches of each formulation were prepared according to Table 1. 
Soybean phosphatidylcholine (SPC) was added to the bilayer softening agent (Tween 
80®) and stirred with 50 mM sodium phosphate buffer solution, pH 7.4, to make a 10 – 
20 % lipid suspension. Firstly, the crude suspension was filtered to prepare 100 ± 50 nm, 
assumedly unilamellar vesicles (32). In order to obtain larger vesicles, it was frozen and 
re-thawed repeatedly (5 cycles). The resulting suspension was brought to the final mean 
vesicle size, of approximately 150 ± 50 nm, by sequential filtration under nitrogen 
stream.  
The addition of the complex was made in the beginning of the mixture (Tretinoin-CyD-
UDV) and, in another similar formulation, only tretinoin was added (Tretinoin-UDV).  





At the end of the formulation process, three batches of each one were sterilized by 
filtration through a 0.22 µm pore filtered and stored at 4 C. 
The formulations were always protected from light and air. 
Table 1 – Tretinoin-CyD-UDV and Tretinoin-UDV formulations. 










Topical treatment of 








































Hydrating medium qs 100  qs 100  qs 100  
DM--CyD = Dimethyl-β-Cyclodextrin 
 
Characterization of Vesicles Formulations before and after centrifugation 
Non-incorporated tretinoin was separated from incorporated one by ultracentrifugation 
(L8 - 60M ultracentrifugeTM Beckman Instruments Inc., Fullerton, CA, USA). The 
centrifugation was performed using the following conditions: 180,000 g at 15 C during 
2 hours. 
Mean Vesicle Size Determination 
The mean vesicle size (hydrodynamic diameter) and the mean size distribution in terms 
of polydispersity index (PI) were measured by photon correlation spectroscopy using 
Nano-S equipment from Malvern® (Worcestershire, UK). The mean particle diameter 





was obtained by averaging three measurements at an angle of 90 in 1 cm diameter 
cells at 25 C. All the samples (10 µL) were diluted with 1 mL of filtered distilled water.  
 
Atomic Force Microscopy (AFM) Studies 
A NanoWizard II equipment (JPK Instruments®, Berlin, Germany) mounted on the top of 
an Axiovert 200 inverted microscope® (Carl Zeiss, Jena, Germany) was used for imaging 
the samples. The AFM head is equipped with a 15-mm z-range linearized piezoelectric 
scanner and an infrared laser. Samples were diluted to 1/100 (Tretinoin-CyD-UDV) and 
to 1/50 (Tretinoin-UDV) in Milli-Q water and deposited on freshly cleaved muscovite 
mica for 20 min. After subsequent washes, the samples were allowed to air dry at room 
conditions. Imaging of the samples components were performed in air, in tapping 
mode. Oxidized sharpened silicon tips (ACL tips® from Applied Nanostructures, CA, USA) 
with a tip radius of 6 nm, resonant frequency of about 190 kHz and spring constant of 
45 N/m were used for the imaging. Imaging parameters were adjusted to minimize the 
force applied on the scanning of the topography of the complexes. Scanning speed was 
optimized to 0.5 Hz (Tretinoin-UDV) and 2 Hz (Tretinoin-CyD-UDV) and acquisition 
points were 512 × 512. Imaging data were analyzed with the JPK image processing v.3 
(JPK Instruments®). The width and height of the samples were calculated from cross-
section plots. All dimensions measurements were performed using the Gwyddion 
software version 2.19® (Czech Metrology Institute, Brno, Czech Republic). The 
histograms of the structures width for each sample were constructed choosing the ideal 
bin size to achieve the best-fitted Gaussian model peak width. The selected binning size 
was approximately 5 nm. The maximum values of the Gaussian peaks represent the 
different statistical measures of the width of the samples. 
 
Zeta Potential Determination 
Zeta potential values of empty and loaded vesicles were measured by Laser Doppler 
Anemometry (Malvern Zetasizer 2000®, Worcestershire, UK) after diluting the samples 





in sodium phosphate buffer solution pH 7.4 with 10 mM Tween 80® in order to 
investigate the effect of drug loading on vesicles surface charge.  
 
Pressure Driven Transport 
The flow of loaded vesicles was determined with a 1 mL-filtration unit that miniaturizes 
the commercial available pressure filtration device. The flow of suspension was driven 
by an external pressure of 0.7 MPa created by a nitrogen stream and measured as a 
function of time. Track-etched polycarbonate membranes with 30 nm mean pore 
diameter were used. The suspension was collected into a container on a Sartorius 
LA620P scale® (Sartorius, Göttingen, Germany). The data were collected with the 
Wedge software® for Windows (TAL Technologies Inc., Philadelphia, PA, USA). 
 
Incorporation Efficiency (IE) determination 
Tretinoin quantification was determined using a validated HPLC method (33, 34). A 
HPLC system consisting of a 32 Karat Software (Beckman Instruments®, Palo Alto, CA, 
USA), a Midas Spark 1.1 autoinjector (Spark®, AJ Emmen, The Netherlands) and a Diode-
Array 168 detector (Beckman Instruments®) was used for this drug assay. The injector 
was fitted with an injection loop of 50 μL. Chromatographic separations were 
performed using a reversed-phase chromatography column (Lichrocart® 250-4, 5 μm 
C18, 200 mm x 4 mm, Merck Millipore, Darmstadt, Germany). The detection wavelength 
was 342 nm and the mobile phase was composed of 0.01 % trifluoroacetic acid and 
acetonitrile (15:85, v/v, %) at a flow rate of 1.0 mL/min. 
SPC quantification was made by an enzymatic colorimetric assay (Phospholipids kit, 
Spinreact®, Sant Esteve de Bas (GI), Spain). Phospholipids are hydrolyzed by 
phospoliphase D and the liberated choline is subsequently oxidized by choline oxidase 
to betaine with the simultaneous production of hydrogen peroxide. In the presence of 
peroxidase, the hydrogen peroxide couples oxidatively the 4-aminophenazone (4-AP) 





and dichlorophenol to forms a quinonemine dye. The intensity of formed color is 
proportional to the phospholipids concentration and measured spectrophotometrically 
at 505 nm (UV-VIS spectrophotometer Shimadzu® UV-160A, Kyoto, Japan).  
The IE was then calculated according to the following equation: 
Eq. 1.  IE (%) = ([drug]final  [lipid]initial) / ([drug]initial  [lipid]final)  100 
 
Stability studies  
Stability studies were performed in 6 independent batches of each formulation in use  
(3 batches) and sterile (3 batches) conditions stored at 4 C during 90 days. The 
formulations parameters were determined in each six time points, as described before.  
 
Statistical Analysis 
The results are reported as mean ± standard deviation (SD) of at least three replicates 
for each batch. The results of all these experiments were statistically analyzed by 
analysis of variance (ANOVA) using SigmaPlot 11.0 software®. The Holm-Sidak Test was 
used whenever possible (i.e. when the normality and equal variance tests pass) for all 
pairwise comparisons for stability results. It is more powerful than the Tukey and 
Bonferroni tests and is recommended as the first line procedure for most multiple 
comparison testing. The overall significance level is 0.05 and statistical differences were 











Mean Lipid Vesicles Size 
The mean vesicles size results obtained for the two formulations tested (Tretinoin-CyD-
UDV and Tretinoin-UDV) are represented in Fig.3 and Fig.4. 
 
Fig.3 - Mean size distribution by intensity of Tretinoin-CyD-UDV after preparation (n = 3 independent 
batches). 
          
Fig.4 - Mean size distribution by intensity of Tretinoin-UDV after preparation (n = 3 independent batches). 
The final mean size distribution obtained for both formulations was approximately 150 
 50 nm, as expected for midfielders unilamellar UDV. The polydispersity index (PI) was 
used as a measure of a unimodal mean diameter distribution. Small values of PI (< 0.1) 
indicate a homogenous population, while higher values (> 0.3) indicate a higher 





heterogeneity. All the results met quality criteria and the respective PI was also 
acceptable (below 0.2). Literature data concerning the influence of CyD presence on 
liposomal vesicle dimensions are controversial. On one hand, some authors did not find 
significant differences between the mean size of liposome containing the drug-CyD 
complexes and the liposomes containing drug alone (27, 35). On the other hand, other 
authors reported the opposite (36, 37). These contrasting results may depend on the 
different experimental conditions.  
 
AFM results 
Tretinoin-CyD-UDV and Tretinoin-UDV formulations were possible to image by AFM. 
Fig.5 shows isolated discoid structures on both types of sample, but with differences in 
size and height. Fig.5A and 5D are examples of the images analyzed for each Tretinoin-
CyD-UDV and Tretinoin-UDV samples, respectively. After conducting width and height 
measurements with cross sections for each complex imaged, width frequency count 
histograms (Fig.5 C and 5D, respectively) and a height frequency count histograms (data 
not shown) were built. The total number of analyzed particles was 110 for Tretinoin-
CyD-UDV samples and 193 for Tretinoin-UDV samples. Tretinoin-CyD-UDV has a 
homogeneous height distribution of 0.954  0.005 nm, while Tretinoin-UDV samples 
have two different height groups: 1.05  0.07 nm (group 1) and 2.37  0.18 nm (group 
2). 
The results acquired from the width histograms (Fig.5C), after applying the Gaussian 
model, showed exactly the opposite. Tretinoin-CyD-UDV is a heterogeneous sample, 
with 3 distinguishable subpopulations with different average cross-section widths: 45.0 
± 0.7 nm (subpopulation 1), 75.9 ± 1.3 nm (subpopulation 2) and 109.4 ± 1.8 nm 
(subpopulation 3). These subpopulations presented different relative frequencies on the 
whole sample constitution: 61 %, 24.5 % and 14.5 % for subpopulations 1, 2 and 3, 
respectively.  





For the Tretinoin-UDV formulation, Gaussian fitting of the width histogram showed only 
one homogeneous population, with an average cross-section width of 38.8 ± 0.3 nm 
(Fig.5F).  
 
Fig.5- Atomic force microscopy results for Tretinoin-CyD-UDV (A to C) and Tretinoin-UDV (D to F) samples. 
A, D – height images (A - 1 × 1 μm
2
, height relative scale of 0.616 nm; D - 0.85 × 0.85 μm
2
, height relative 
scale of 1.855 nm); B, E – error images (of the same areas); and C, F – width frequency count histograms. 
Samples imaged on air in tapping mode. 
 
Zeta Potential 
The zeta potential characterizes the surface charge of the particles, giving information 
about repulsive forces between particles or vesicles, and makes a prediction about the 
stability of colloidal dispersions (38).  
The zeta potential was measured for both formulations and also for the respective 
controls (Fig.6). 























Tretinoin-CyD-UDV CyD-UDV Tretinoin-UDV empty UDV
 
Fig.6- Zeta potential of the two loaded formulations: Tretinoin-CyD-UDV and Tretinoin-UDV before 
centrifugation and the respective controls (CyD-UDV and empty UDV). (mean ± SD, n =3 independent 
batches, statistical differences marked by different letters) 
 
The results of the zeta potential measurements revealed that vesicles surface present 
negative charge values, as expected attending to the use of a nonionic surfactant in the 
formulation (Tween 80®) and also to the neutral pH of the buffer. There were 
statistically significant differences between the mean zeta potential values of Tretinoin-
CyD-UDV and Tretinoin-UDV besides empty UDV (p<0.05). One possible explanation for 
the drug-induced-vesicle negative zeta potential values may be related to the changes 
on the vesicles surface structure due to the complex incorporation, a phenomenon also 
observed by other authors (39). This may result in the change of the 
phosphatidylcholine head groups orientation at the surface of vesicles, with the choline 
group plane lying below the phosphate group plane, contributing to the negative 
surface potentials measured. This measurement was higher for Tretinoin-CyD-UDV 











Pressure Driven Transport Measurements 













Ci Ti Cf Tf
 
Fig.7 - Flows of the two formulations: Tretinoin-CyD-UDV before centrifugation (Ci), after centrifugation 
(Cf) and of Tretinoin-UDV before centrifugation (Ti), after centrifugation (Tf). (mean ± SD, n=3 
independent batches, statistical differences marked by different letters) 
 
It can be observed in Fig.7 that after centrifugation and the consequent separation of 
the non-incorporated drug fraction from the vesicles, they became more flexible. The 
flow was higher for Tretinoin-CyD-UDV perhaps due to the weak intermolecular 
interactions (CyD non-covalent interactions). In fact, CyD-UDV (control) had the highest 
flow (0.022 ± 0.100 g/s) which may justify the flow differences obtained between the 
two formulations. However, the differences between the median values among the 
formulations are not large enough to exclude the possibility that the difference is due to 
random sampling variability. There is not a statistical difference, except for Tretinoin-
CyD-UDV before and after centrifugation (Ci vs Cf, p<0.05).  
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   b 
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Incorporation Efficiency  
Incorporation efficiency (IE) is the percentage fraction of the total drug incorporated 
into UDV. This is a crucial parameter in the evaluation of vesicular formulations, as 
vesicles with maximum IE would improve drug bioavailability. This parameter 
represents the degree of interaction between the carrier and the drug (32). 















Fig.8 - Incorporation Efficiency (IE) of the two formulations: Tretinoin-CyD-UDV and Tretinoin-UDV. (mean 
± SD, n=3) 
The IE was high, approximately 90 %, and no significant differences were observed 
between Tretinoin-CyD-UDV and Tretinoin-UDV (p = 0.305).   
 
Stability studies  
Stability studies were performed in both formulations in use and in sterile conditions, 
during 90 days, regarding the following parameters: vesicles size, drug content, and 
incorporation efficiency. The results are presented in Table 2. 
 a 
  a 





The mean vesicle size was checked at different time points and the results obtained 
were around 120 nm for both formulations (Tretinoin-CyD-UDV and Tretinoin-UDV), as 
theoretically expected (32). According to the size results obtained, it is possible to 
conclude that the vesicle’s diameter was a very stable parameter during stability study 
time course. 
In general, there were no significant differences between both formulations (Tretinoin-
CyD-UDV and Tretinoin-UDV) in use and in sterile conditions concerning the 
incorporation efficiency during study time course, which reflected the good stability of 
these formulations regarding this parameter. However, considering the chemical 
stability, the drug assay varied significantly over time for both formulations, especially in 
use conditions (p<0.05). In fact, some chromatograms (Fig.9 and Fig. 10) of the 60th day 
showed a great increase of the isomers peaks areas for these formulations, which led us 
to consider the tretinoin degradation.  The drug assay was lower for Tretinoin-CyD-UDV 
due to a possible lost during the complexation process. 





Table 2- Stability study of Tretinoin-UDV (Tret-UDV) and Tretinoin-CyD-UDV (Tret-CyD-UDV) with 10 % 
lipid concentration, in use and sterile conditions (mean values of 3 independent batches ± SD). 
   Parameters 
Formulation Storage conditions Time period Vesicle size (nm) Tretinoin (mM) IE (%) 
Tret-UDV 
In use conditions 
0 129 ± 2 4.5 ± 1.8 77.8 ± 14.6 
7 126 ± 3 4.0 ±  1.5 63.9 ± 1.7 
15 128 ± 3 3.6 ± 0.9 93.9 ± 8.0 
30 127 ± 3 3.2 ± 0.9 78.9 ± 15.6 
60 125 ± 1 2.8 ± 1.8 87.0 ± 4.3 
90 129 ± 4 2.8 ± 0.8 62.2 ± 2.7 
Sterile conditions 
0 128 ± 2 4.5 ±  1.8 85.2 ± 16.4 
7 124 ± 1 4.3 ± 1.5 76.2 ± 15.0 
15 128 ± 3 4.4 ± 1.4 82.6 ± 8.0 
30 126 ± 1 3.9 ± 1.3 93.4 ± 11.3 
60 129 ± 9 3.5 ± 1.5 87.1 ± 0.1 
90 126 ± 5 2.3 ± 1.1 90.3 ± 16.8 
Tret-CyD-UDV 
In use conditions 
0 117 ± 1 3.4 ± 2.4 88.7 ± 6.7 
7 122 ± 4 2.9 ± 2.0 77.7 ± 11.1 
15 120 ± 2 2.9 ± 2.0  66.0 ± 8.4 
30 122 ± 0 2.4 ± 1.7 62.9 ± 9.2 
60 125 ± 3 2.0 ± 1.5 89.9 ± 14.3  
90 126 ± 1 1.8 ± 2.2 91.5 ± 1.4 
Sterile conditions 
0 117 ± 1 3.4 ± 2.4 88.7 ± 6.7 
7 119 ± 0 3.1 ± 2.3 81.4 ± 11.2 
15 120 ± 3 3.0 ± 2.2 88.2 ± 3.9 
30 122 ± 2 2.6 ± 1.8 82.2 ± 5.2 
60 124 ± 4 1.3 ± 2.0 80.5 ± 1.5  
90 121 ± 3 0.6 ± 0.6 80.7 ± 16.7 
 






Fig.9 - Chromatogram of Tretinoin-UDV formulation (10 % lipid concentration) in use (at left) and in sterile 
(at right) conditions, after 60 days of storage. AU = Arbitrary units. Tretinoin standard presented a 
retention time of 8.4 min. 
             
Fig.10- Chromatogram of Tretinoin-CyD-UDV formulation (10 % lipid concentration) in use (at left) and in 
sterile (at right) conditions after 60 days of storage. AU = Arbitrary units. Tretinoin standard presented a 
retention time of 8.4 min. 
Taking into consideration the results obtained in this comparative study, an attempt 
was made to prepare a formulation with higher phospholipid content in order to 
achieve a Tretinoin-carrier system with suitable physical characteristics and proper drug 
chemical stabilization. Fig.11 and Table 3 present the results obtained with the increase 
of total lipid concentration from 10 to 20 % in Tretinoin-UDV formulation regarding its 
stability. In this case, five parameters (vesicles size, zeta potential, drug content and 














Fig.11 - Chromatogram of Tretinoin-UDV formulation (20 % lipid concentration) in use conditions, after 60 
days of storage. AU = Arbitrary units. Tretinoin standard presented a retention time of 8.4 min. 
In general, this formulation presented around 130 nm of vesicles size and low negative 
zeta potential. However, although the vesicles size remained stable over time, the same 
did not happen with zeta potential. In fact, this parameter decreased during 90 days. In 
terms of colloidal systems, this variation was not important since there was no evidence 
of particles aggregation according to the size evaluation. Nevertheless, important 
parameters such as IE and drug loading remained quite stable (approximately higher 
than 90 % and 13 µg/ mg SPC, respectively). 
In summary, the incorporation of tretinoin in UDV with total 20 % lipid concentration 
(IE> 90 %), resulted in adequate physicochemical parameters of the system and higher 














Table 3- Stability study of Tretinoin-UDV (Tret-UDV) with 20 % lipid concentration in use and in sterile 
























Drug Loading  
(µg/ mg SPC) 
Tret-UDV 
In use 
0 127 ± 2 -6.5 ± 0.3 2.3 ± 0.4 113.0 ± 24.9 13.4 ± 2.4 
7 135 ± 2 -3.4 ± 0.2 ND ND ND 
15 129 ± 1 -3.0 ± 0.0 2.0 ± 0.0 68.7 ± 12.3 14.4 ± 6.3 
30 134 ± 1 -1.6 ± 0.4 2.0 ± 0.0 98.0 ± 6.8 13.2 ± 1.5 
60 135 ± 2 -1.3 ± 0.3 2.2 ± 0.2 97.1 ± 25.5 14.1 ± 2.3 
90 132 ± 0 -2.0 ± 0.7 2.0 ± 0.6 ND 13.1 ± 3.3 
Sterile 
conditions 
0 131 ± 10 -5.9 ± 0.6 2.4 ± 0.4 104.0 ± 19.3 14.7 ± 3.0 
7 135 ± 6 -3.9 ± 0.7 ND ND ND 
15 132 ± 4 -2.6 ± 0.1 2.1 ± 0.1 84.5 ± 9.0 13.0 ± 1.2 
30 136 ± 6 -1.3 ± 0.3 2.3 ± 0.5 95.9 ± 18.0 15.3 ± 3.1 
60 135 ± 4 -1.5 ± 0.2 2.2 ± 0.3 92.3 ± 14.8 15.4 ± 0.7 
90 135 ± 5 -1.4 ± 0.3 1.6 ± 0.7 ND       14.9 ± 5.4 






In this research work, the stability of six independent batches of each Tretinoin-CyD-
UDV and Tretinoin-UDV formulations prepared in the same conditions were fully 
analyzed.  
Transfersomal or UDV formulations were prepared according to Simões et al. (40, 41). 
Transfersomes preparation method permits the formulations to be handled without 
temperature, organic solvents or drastic mechanical conditions (40, 42). Taking 
temperature as example, this is a factor that could have a negative influence on 
tretinoin stability because of its high susceptibility. In fact, high temperatures used in 
other methods represent an obstacle to laboratory handling and industrial production 
of tretinoin formulations.  
The preparation method involves a stirring step, after which midfielders unilamellar 
UDV are obtained (Fig.12). 
 
Fig.12 – Scheme of vesicle size and lamelllae variation during midfielders unilamellar vesicles production. 
MLVs (multilamellar vesicles); SUVs (small unilamellar vesicles); LUV (large unilamellar vesicles). 
 
After stirring, and in order to obtain small size unilamellar vesicles (SUVs), the 
formulations were filtered under pressure through decreasing pore size membranes. 
Formulations were then freeze-thawed, so that vesicle fusion occurred and large 
unilamellar vesicles (LUVs) were formed (32). To get the desired vesicle size of 
unilamellar structures (150 ± 50 nm), a last sequential filtration was made. Although the 
filtration steps were time consuming, the relatively simple method used proved that it is 





possible to produce nanovesicles with uniform characteristics. In fact, the average size 
of the vesicles did not oscillate much, being quite stable during the 90 days of storage. 
This is an important indicator of the formulation stability since if aggregation of UDV has 
occurred, the average size would have increased. It is also important to state that the 
resulting size is necessary to ensure vesicles deformation, and for further skin 
penetration (32, 43). Moreover, the size obtained is also dependent on the formulation 
composition. In fact, the results confirmed an appropriate composition to produce 
nanovesicles, and the vesicle size was the most stable physical parameter obtained from 
the stability studies.  
The differences between Tretinoin-CyD-UDV and Tretinoin-UDV size could be due to the 
different molecular interaction that might occur in these two different UDV 
formulations. Cyclodextrins, particularly the methylated derivatives, are known to 
remove lipid components from cell membranes and liposomes by forming inclusion 
complexes with the lipids, especially with cholesterol. It is thus possible that, during or 
after entrapment of the drug/cyclodextrin complex solutions, lipids enter the 
cyclodextrin cavity, replacing the drug. This could destabilize the bilayers to some 
extent, enabling partial or complete leakage of drug content from vesicles and varying 
the vesicles size (higher PI) (44). Another hypothesis is the different localization of the 
two Tretinoin forms inside UDV. Tretinoin-CyD might be located in the UDV aqueous 
lumen (the complex was added at the beginning of the vesicles preparation).  On the 
contrary, the free Tretinoin form will be located within the UDV lipid bilayers.   
From subsequent AFM scanning images one can also conclude that the isolated species 
on both formulations were stable and do not change their structure upon scanning with 
the AFM tip. The results obtained for Tretinoin-CyD-UDV samples showed 3 different 
subpopulations, in terms of width, instead of only one. Although it was observed a 
subpopulation with larger size due to sample aggregation, it had the lowest frequency 
of occurrence. For Tretinoin-UDV formulation, AFM width results showed only one 
homogeneous population, but with lower width/diameter value (38.8 ± 0.3 nm). The 
differences on the diameter of the particles measured by AFM and DLS could be 





explained by different factors: (i) sample preparation (dryness and consequent vesicles 
shrinkage in AFM, in contrast to DLS); (ii) with AFM, after sample deposition on mica, it 
gains a semi-discoid shape and the tip only could scan over the surface of the attached 
particles, while on DLS the particle size is determinate by the light intensity of the 
sample in colloidal suspension; (ii) DLS may have technical limitations for bi- or trimodal 
samples, as it has been reported that DLS is inappropriate to accurate measure particle 
mixtures with a large difference at the ratio between the diameters of the particles (45). 
Hoo et al. (46) made a comparison of AFM and DLS methods to characterize 
nanoparticle size distributions, and concluded that heterogeneous samples in size could 
not be accurately characterized using conventional DLS due to the intensity difference 
of the light from the small particles versus large particles.  Thus, AFM was used here to 
further observe the size homogeneity since a complex system is being characterized 
(CyD + Drug + UDV).  
Zeta potential is another parameter that can help determining the physical stability of 
liposomal formulations. Tretinoin formulations used in this study presented a negative 
charge just after preparation. Soybean phosphatidylcholine (SPC) is a phospholipid often 
used in topical dosage forms due to the presence of oleic and linoleic acids in its 
compositions, both permeation enhancers (40, 47). Sinico et al. have shown that 
negatively charged liposomes strongly improved newborn pig skin hydration and 
tretinoin retention in the skin (48). However, Kitagawa and Kasamaki found that cationic 
liposomes consisting of double-chained cationic surfactant, phosphatidylcholine 
increased the delivery of retinoic acid about two-fold (12, 49).  
In the tested formulation, Tween 80®, a non-ionic surfactant, acts as an edge activator 
to provide high deformability to the vesicle (40, 50). In addition, soybean 
phosphatidylcholine (SPC), is a neutral or zwitterionic phospholipid over a pH range 
from strongly acid to strongly alkaline (47). Thus, the low vesicles surface charge is an 
expected result. Interestingly, in spite of a low surface charge (especially, nearly zero) 
which in theory is prone to vesicle aggregation and fusion (6), such phenomenon did not 
occurred, as it was demonstrated by the vesicle size evaluation during the stability 





studies. The absence of this phenomenon may be explained by steric stabilization, 
which in this case is obtained from Tween 80®, a bulky surfactant that prevents vesicle 
fusion. 
The incorporation efficiency (IE) was high for both Tretinoin-CyD-UDV and Tretinoin-
UDV formulations. According to Maestrelli et al. (51), multilamellar vesicle liposomes 
(MLV) containing ketoprofen-CyD complexes exhibited reduced IE in comparison with 
those containing drug alone, which was explained by the drug location inside the 
vesicles. In the case of MLV, the volume occupied by the aqueous phase is smaller than 
that occupied by the lipidic phase. Thus, when the drug is added to the organic phase, it 
is entrapped in greater amounts in the multi-layer liposomal membrane, when 
compared to the hydrophilic complex into the aqueous lumen. However, in this work, 
this difference was not the same as the UDV prepared were midfielder unilamellar 
vesicles. In addition, the CyD derivative used, dimethyl-β-CyD, was added in the 
beginning of the suspension formation, as already mentioned. Therefore, the complex 
entrapment into the aqueous core of these vesicles was probably more favorable 
attending to the higher water solubility and stability of the complex (30), and to the 
UDV preparation method. UDV have already been proven to be a versatile system for 
the incorporation of both hydrophobic and large hydrophilic entities (52).  
Regarding chemical stability, several attempts have been made to incorporate Tretinoin 
in pharmaceutical dosage forms in order to achieve an effective and stable drug 
delivering system (2, 3, 6, 53). Some of these approaches, such as liposomes, niosomes 
and nanocapsules or complexation with cyclodextrins, have showed some improvement 
of topical application of Tretinoin, either by actually enhancing the bioavailability of the 
drug or by slightly improving Tretinoin chemical stability (6, 30, 53-55). However, until 
now, none of those formulations can do both things successfully enough. In this 
research work, Tretinoin was entrapped in one of the most promising vesicles in 
nanotechnology, Transfersomes (56). The aims were to achieve both drug bioavailability 
and chemical stability. However, it was observed that only Tretinoin-UDV formulation 
with 20 % lipid concentration assured drug chemical stability when stored protected 





from light at 4 C. Considering that the other UDV formulations with 10 % lipid 
concentration, even in the presence of CyD, were not sufficient to stabilize this drug, 
the lipid concentration was found to be the most important formulation requisite in our 
experimental conditions.  
 
Conclusions 
In the present work, we investigated the use of the combined approach of CyD 
complexation and UDV entrapment in order to obtain adequate physicochemical 
parameters, including drug loading capacity. Although the enhanced water solubility of 
the Tretinoin-CyD complex may allowed its entrapment in the internal aqueous lumen 
of the vesicles instead of drug incorporation into the lipid bilayers, the results from 
stability studies showed, in general, no significant differences between the two different 
formulations, including the chemical stability. However, increasing the total lipid 
concentration from 10 to 20 % allowed getting comparable results in terms of vesicle´s 
characteristics and reducing Tretinoin isomerization in storage. This last formulation 
also showed high and stable incorporation efficiencies, which means it could be a good 
candidate to improve topical bioavailability of this drug. This study also showed that 
sterilization by filtration did not change vesicle and/or vesicle-drug system 
characteristics, especially regarding the lipid-concentrated formulation. After these 
characterization and stability studies, future work will continue with Tretinoin-UDV with 
20 % lipid concentration concerning the topical delivery of the drug. 
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Introduction: Ultradeformable vesicles are highly promising tools to enhance the 
percutaneous transport of different drugs such as tretinoin across the skin barrier, alter 
the drug bioconversion in viable skin, and also to increase the formulation stability at 
absorption site and reduce the drug induced irritation.  
Methods: Topical delivery of tretinoin - loaded ultradeformable vesicles (tretinoin-UDV) 
was evaluated concerning different studies, such as: the release and permeation 
profiles (tape stripping); skin penetration (fluorescence analysis); induced electrical 
changes in skin barrier properties; cytotoxicity (MTT and Trypan Blue assays) and skin 
irritation in in vivo conditions (Draize test). The novel formulation performance was also 
compared to a commercial tretinoin formulation regarding in vivo studies. 
Results: Results with synthetic membranes indicated a sustained and controlled drug 
release, as expected for this formulation. Regarding the permeation study, a dermal 
delivery was obtained since it was not detected any drug amount in the receptor phase 
after 24 h. Nile Red-UDV stained intensively mostly in the stratum corneum, 
corroborating the tape stripping results. Tretinoin-UDV decreased skin resistance, 
suggesting its ability to induce skin barrier disruption. Finally, the formulation vehicle 
(empty UDV) and tretinoin-UDV were not toxic in in vitro and in vivo conditions, at least, 
at 510 -3 mg/mL and 0.5 mg/mL of tretinoin, respectively.  
Conclusion: Tretinoin-UDV is a promising delivery system for tretinoin dermal delivery 
without promoting skin irritation (unlike other commercial formulations), which is quite 
advantageous for therapeutic purpose. 
Keywords: Tretinoin; Ultradeformable Vesicles; Topical Delivery; Skin Barrier Function; 
Toxicity 






Tretinoin has long been considered the gold standard, being the most common retinoid 
used for treatment of skin diseases (1). However, retinoids have the potential to cause 
troublesome dose-dependent irritation and dryness (2), and  are usually associated with 
poor tolerability, resulting in limited patient compliance (3). In addition, the tretinoin 
teratogenicity is the most serious side effect. This teratogenic effect is caused by the 
interference of the exogenous retinoic acid with endogenous retinoic acid signaling, 
which plays a role in patterning the developing embryo (4). However, the transdermal 
penetration and systemic bioavailability of topical retinoids are not yet completely 
clarified. Thus, there is not a consensual opinion about the use of topical retinoids 
during the pregnancy (5). 
In order to exert its action, tretinoin must overcome the main physiological barrier of 
human body – the skin. The skin consists of 250 μm thick inner skin region (dermis) and 
of 500 μm thick outer skin region (epidermis). The barrier function is mainly due to the 
outermost part of the epidermis, the stratum corneum (SC), which is composed of 
approximately 90 % corneocytes. These cells are tightly packed in stacks that run 
perpendicular to the skin surface, and clusters of which are responsible for skin 
permeation resistance and reservoir effect. Quality and crystallinity as well as total 
quantity of lipids in the SC  determine the skin barrier perfection (6, 7). There are 
several natural pathways through the skin barrier, such as sweat ducts, sebaceous 
glands, hair follicles, clusters-junctions, inter-cell-clusters and inter-corneocyte paths. 
Small hydrophilic entities have the propensity to cross normal skin between corneocytes 
clusters (20-30 nm diameter), molecules heavier than 400-500 Da are nearly completely 
confined to skin surface (6, 8).  
Dermal and transdermal drug delivery is problematic because skin has a low 
permeation rate. However, skin delivery offers the advantage of enhanced local effect 
(dermal),  elimination of first pass hepatic metabolism and sustained drug release for a 
prolonged period of time (transdermal) (7).  
Considering skin properties and tretinoin physical and chemical characteristics, besides 
its irritation potential, it becomes clear that it is extremely difficult to formulate this 






drug in a way that can, at the same time, overcome the skin barrier without irritation 
and provide the necessary stability to the drug. In recent years, technological advances 
have been made, aiming to overcome skin barrier, which can generally be divided into 
physical and chemical methods (9). Physical methods employed for increasing transport 
across the skin may use some form of mechanical, electrical (e.g. electroporation and 
iontophoresis), magnetic (e.g. magnetophoresis) or thermal energy to disrupt the skin 
(transiently), and are much more invasive then chemical methods. Chemical methods 
use permeation enhancers such as alcohols, fatty-acids, amines, surfactants and others. 
These chemicals may be included in various types of vesicles, helping those vesicles 
penetrating the skin (7-9).  
Numerous drug delivery strategies such as liposomes have been studied to overcome 
some drug technical drawbacks (10). Liposomes were shown as an interesting carrier for 
tretinoin in skin disease. In a comparative clinical evaluation of liposomal gel of benzoyl 
peroxide and tretinoin for acne, it was concluded that the liposomal tretinoin gel was 
shown to have better response in the treatment of comedones, whereas the liposomal 
benzoyl peroxide gel of this investigation showed a predominant response in the 
treatment of papules and pustules (11). Hence, concomitant therapy with liposomal 
tretinoin and liposomal benzoyl peroxide gel is expected to give more effective 
treatment of acne (11, 12). In vitro permeability experiments with [3H]trans retinoic acid 
showed that its encapsulation into SC lipid liposomes not only prolongs drug release but 
also promotes drug retention by the viable skin in order to reduce systemic absorption 
and the side effects associated with topical application (11, 13). 
Transfersomes®, also known as ultradeformable vesicles (UDV), result from the 
combination of phospholipids with surfactant in the right proportion to make them 
highly deformable, and to have one single bilayer. They were first introduced in the 
early 90s by Cevc & Blume (14) and, in contrast to liposomes which cannot penetrate 
the skin (only passing through the most favorable pathway), Transfersomes actually 
penetrate skin, by self-modifying their form and passing through pathways much 
narrower than their own diameter. Shape variation is only possible because the 
surfactant moves all the way through the bilayer into the zones of major tension. The 





quantity of lipid determines the extension of Transfersomes penetration (8, 15). The 
surfactant is often a single chain edge activator, such as sodium cholate, Span® 60/65/80 
or Tween® 20/60/80, and at the concentrations normally used, there is no toxicity 
associated (6, 7, 16, 17). The type and quantity of surfactant determines the 
transfersomal stability and permeability, and thus UDV must be designed and optimized 
on a case-by-case basis (9, 17). 
Applied on the skin surface under non-occlusive conditions, these elastic vesicles are 
able to squeeze through intercellular regions of the SC under the influence of the 
transepidermal water-activity gradient, which creates very strong force acting on the 
skin via vesicles (18). This enforces widening of the weakest intercellular junctions in the 
barrier and creates 20-30 nm wide transcutaneous channels. The channels allow 
sufficiently deformed lipid vesicles to cross the skin along the hydration gradient. 
Spontaneous motion of the highly deformed, hydrophilic entities through the skin 
barrier is consequently based on barrier penetration rather than on trans-barrier 
permeation (8). Therefore, it is not the ideal situation to apply the diffusion concept to 
vesicle transport across the skin (19). Transfersomes can effectively protect the drug 
against undesired rapid clearance into cutaneous blood vessels and are capable of 
retaining the drug long enough on, in and below the skin barrier. Furthermore, they can 
across the SC independently of the drug concentration (20), and may improve the 
dermal drug delivery while reducing systemic absorption. Therefore, the therapeutic 
dose could be reduced and, consequently, also the dose dependent side effects (11). 
The ability of Transfersomes to deliver drugs across the skin is therefore well-
documented and widely accepted. Transfersomes have been used as carriers for various 
compounds, amongst which are proteins and peptides (21) such as insulin (22), 
corticosteroids (23), nonsteroidal anti-inflammatory drugs such as ketoprofen (20) and 
anticancer drugs (24). 
The aim of this research work was to study the topical delivery of tretinoin in 
ultradeformable vesicles (tretinoin-UDV), a stable formulation already successfully 
characterized in previous experiments (25). The drug topical delivery was achieved by 






combining different experimental techniques: by combining different experimental 
techniques: in vitro release and permeation/penetration studies; electrical resistance 
measurement; skin cells viability/cytotoxicity and the in vivo evaluation of skin irritation. 
 
Materials and Methods 
 
Materials 
Tretinoin was purchased from Fagron (Terrassa, Spain). Soybean phosphatidylcholine 
(S100) was purchased from Lipoid AG (Steinhausen, Switzerland). Tween 80®, Nile Red, 
Phospate Buffer Saline PBS 7.4, Thiazolyl Blue Tetrazolium Bromide (MTT), Dimethyl 
Sulfoxide (DMSO) and Trypan Blue were purchased from Sigma-Aldrich (St. Louis, MO, 
USA), respectively. All other reagents were of analytical grade. 
 
Methods 
Preparation of Tretinoin Loaded Ultradeformable Vesicles  
Phosphatidylcholine (SPC) was added to the bilayer softening agent (Polysorbate 80) and 
stirred with 50 mM sodium phosphate buffer solution pH 7.4, to make a 15 and 20 % of 
lipid suspension. Tretinoin was added (0.05 %) to the lipid suspension since the 
beginning of preparation, always protecting samples from light and air. 
Firstly, the crude suspension was filtered to prepare 100 ± 50 nm, assumedly unilamellar 
vesicles. In order to obtain larger vesicles, suspension was frozen and re-thawed (5 
cycles). The resulting suspension was brought to the final size, of approximately 150 ± 50 
nm, by sequential filtration. 
 
Tretinoin Analysis 
Tretinoin quantification was determined using a validated HPLC method (26, 27). An 
HPLC system consisting of a 32 Karat Software (Beckam Instruments®, Palo Alto, CA, 
USA), a Midas Spark 1.1 autoinjector (Spark®, AJ Emmen, The Netherlands) and a Diode-





Array 168 detector (Beckman Instruments®) was used for this assay. The injector was 
fitted with an injection loop of 50 μL. Chromatographic separations were performed 
using a reversed-phase chromatography column (Lichrocart 250-4, 5 μm C18, 200 mm 
 4 mm, Merck Millipore, Darmstadt, Germany). The detection wavelength was 342 nm. 
The mobile phase used was composed of 0.01 % trifluoroacetic acid and acetonitrile 
(15:85, v/v, %) at a flow rate of 1.0 mL/min. 
Topical Delivery 
All topical delivery experiments were performed under light protection.  
Regarding the release study, two tretinoin-UDV formulations with 15 and 20 % of lipid 
concentration were tested. However, considering previous stability data (see results and 
discussion), only the selected formulation (tretinoin-UDV with 20 % of lipid 
concentration) was used for the following topical delivery experiments. The in vivo skin 
irritation potential of tretinoin-UDV was also compared to the marketed 0.05 % 
tretinoin formulation (Ketrel, Saninter, Lisbon, Portugal). 
 
In Vitro Release Study with Synthetic Membranes 
In vitro release profile was determined by using vertical Franz diffusion cells with a 
diffusion area of 1.0 cm2. About 0.25 g sample was spread over the donor side of the 
membrane (Polysulfone, Tuffry 25 mm, 0.45 m, Pall Corporation, Port Washington, 
NY, USA) under non-occlusive conditions. Polysulfone membranes were soaked for 
thirty minutes in isopropyl myristate, a skin enhancer. 
The receptor phase contained a 3.7 mL mixture of 0.01 M saline phosphate buffer (pH = 
7.4) and 0.1 % PEG-40 (m/v) in order to solubilize tretinoin in the receptor solution 
maintained at 32-37 C under stirring (Julabo U3 Thermostat and Multimagnetic stirrer 
SBS®, Labexchange, Paris, France). Care was taken to remove any bubbles between the 
underside of the diffusion membrane and the solution in the receiver compartment. 
At pre-determined times (2.0, 3.0, 4.0, 5.0 and 6.0 h), samples (200 µL) were collected 
and the same volume was replaced with fresh solution. The drug solubility in the 
receptor phase was 0.0061 mg/mL, thus assuring the maintenance of sink conditions 






during the diffusion experiments. The tretinoin amount in the receptor phase was 
quantified by HPLC, as described above. Data was expressed as cumulative amount of 
tretinoin permeated through the membrane filter, considering the total amount of drug 
applied for each formulation. 
 
In Vitro Skin Permeation/Penetration Studies 
In vitro skin permeation study was performed according to the method described by 
OECD Guideline 428 (28) at the same conditions as described before, except the use of 
fresh pig ear skin. Tretinoin-UDV formulation (200 μL) was spread over the skin (1.77 
cm2) in contact with 7 mL of receptor phase, and 24 h later, the skin samples were 
rinsed to remove excess formulation and dried with filter paper. After the skin samples 
had been attached and fixed on a smooth surface, the SC was removed using 10 
adhesive tapes (Scotch® 3M, S. Paulo, Brazil).  In order to improve the reproducibility of 
the tape stripping technique, a cylinder (2 kg) on a foam and an acrylic disk (both with 
an area of 5.73 cm2) was used resulting in a pressure of 349.3 g/cm2. This pressure was 
applied for 10 sec for each tape. All the tapes (including the first one) with the stratum 
corneum (SC) removed and the remaining skin (viable epidermis and dermis, ED) were 
cut into small pieces used for the extraction process, previously validated. In this 
extraction process, 5 and 1 mL of tetrahydrofuran (THF) 70% were added to the SC 
tapes and ED pieces, respectively. Both samples were stirred for 2 min in a vertical 
mixer, and sonicated for 20 minutes in order to obtain the cell lysis. After filtration (0.45 
μm), the supernatant was injected on HPLC to quantify the amount of tretinoin retained 
in each skin layer. 
 
In Vitro Skin Penetration Study with Nile Red 
Nile Red was incorporated in the UDV formulation instead of the drug and then applied 
to the donor compartment of Franz diffusion cells. Fresh skin sections treated with PBS 
pH 7.4 were used as control to determine tissue autofluorescence. After 24 h, the 
surface of the skin was carefully cleaned, and the diffusion area of skin samples was 
completely frozen using isopentane at  -30 C with liquid nitrogen, embedded in 





CryomatrixTM (Shandon, Thermo Scientific, Runcorn Cheshire, UK) and sectioned using a 
cryostat microtome (Shandon 5030). The longitudinal skin sections (8 µm) were 
mounted on positively charged microscope slides (Superfrost® Plus, Shandon). The slides 
were visualized without any additional staining or treatment using a fluorescence 
microscope (Olympus BX60®, Tokyo, Japan) equipped with a camera (Olympus DP50®) 
and filters for Nile red, excited at 530 nm with emission fluorescence at 550 nm 
(adapted from Lopes et al. 2009 (29)). 
 
In Vitro Skin Electrical Resistance 
To evaluate the effect of tretinoin-UDV on the skin barrier function, the electrical 
resistance of the tissue was measured before and after application of this formulation 
and water (control). Resistance across each membrane was measured by passing a fixed 
electrical current across the skin sample using a LCR multimeter (Tenma T.M. 72-960®, 
Taiwan, China) connected to two stainless steel electrodes, using a setting of 100 Hz. 
Skin samples were mounted in diffusion cells, and the donor and receptor 
compartments were filled with PBS pH 7.4. The cells were maintained at 32-37 C under 
stirring (Julabo U3 Thermostat and Multimagnetic stirrer SBS). 
After 20 min of equilibration, the electrodes were inserted in the donor and receptor 
compartments to measure the baseline skin resistance, taking care not to touch the skin 
membrane. At 4, 8 and 24 h, the skin samples were rinsed with water and carefully 
blotted dry. The donor compartment was then refilled with PBS, and electrical 
resistance was measured after about 20 min of equilibration (adapted from Lopes et al. 
2009 (29)). 
 
In Vitro Cytotoxicity in Human Keratinocyte Cell Line HaCaT  
The cytotoxicity potential of tretinoin-UDV was evaluated in HaCaT cell line, a non-
tumorigenic immortalized human keratinocytes cell line obtained from Cell Lines 
Services - CLS® (Eppelheim, Germany). Thus, the handling of these cells culture was 
always according to CLS protocol procedures. These cells were grown in Dulbecco's 
modified Eagle's medium (DMEM), rich in glucose, supplemented with 10 % fetal bovine 






serum (FBS), 2 mM L-glutamine, 1% penicillin–streptomycin (10000 U/mL) and 1 % 
fungizone (250 U/ mL) (Gibco®, Grand Island, NY, USA) at 37 °C in a humidified 
incubator with 5 % CO2 atmosphere (adapted (30, 31)). 
Tretinoin-UDV formulation was previously sterilized by filtration (0.2 μm) and diluted in 
culture medium at 5, 10 and 15 µg/mL. The osmolarity (automatic osmometer, Knauer®, 
Berlin, Germany) of the sample with the highest concentration was also measured. 
Beside the negative control (non exposed cells), both assay results were also compared 
to empty UDV formulation and tretinoin (complexed with cyclodextrin) aqueous 
solutions (32) with the same dilution factors.  
Cell metabolic activity 24 h after tretinoin-UDV formulation exposure was assessed as 
described below by the MTT assay (often used as viability method). The cells were 
seeded at a density of 7,000 cells/well and the culture medium was added until 200 μL 
to a cluster plate of 96-well. After incubation, the cell culture was exposed and 
incubated again for a period of, approximately, 24 h. The MTT assay was performed 
according to the following conditions (33): after exposure, cells were immediately 
washed with PBS and incubated with new culture medium (200 μL) containing 50 μL of 
MTT (1 mg/mL in PBS pH 7.2) during 4 h at 37 C, 5 % CO2. After this time, the medium 
was carefully removed and the same volume of DMSO was added to each well to 
solubilize the crystals. The plate was gently shaken for 2 h and protected from light. The 
optical density of reduced MTT was measured at 570 nm by spectroscopy on an 
automatic microtiter plate reader (Synergy™ HT Multi-Mode from BioTeK® Instruments 
Inc., Winooski, VT, USA) equipped with a specific software (Gen5, Biotek®). At least, 
three independent assays with six replicates of each sample were performed, and the 
cell metabolic activity (MA viability/proliferation characteristics) was calculated 
according to Eq.1.  
Eq.1  MA (%) = (Abs 570 nmsample – Abs 570 nm DMSO)/ Abs 570nm negative control – Abs 570 nm DMSO)  100 
MTT is a yellow water-soluble tetrazolium dye that is reduced by mitochondrial reductase of only 
metabolically active live cells, in part by the action of dehydrogenase enzymes, to generate reducing 
equivalents such as NADH and NADPH. The resulting intracellular purple formazan can be solubilized (in 
DMSO) and quantified by spectrophotometric means. Regarding the Trypan Blue assay, it relies on the 
breakdown in membrane integrity determined by the uptake of a vital dye to which the cell is normally 
impermeable (34).  





The cell viability after tretinoin formulation (and the respective controls) exposure was 
also confirmed by Trypan Blue assay and calculated according to Eq.2. The cells were 
incubated in a cluster plate of 12 wells. After trypsinization according to Boukamp et al. 
(35) and resuspension of the cells, an aliquot was taken and vortexed with 0.4 % trypan 
blue solution (1:1). After 5 min of incubation at 37 C, the cells were counted with the 
hemacytometer. 
Eq.2  Cell Viability (%) = [viable cells / (viable cells + non viable cells)]  100 
 
In Vivo Skin Irritation Potential and Histological Assessment  
The skin irritation potential of tretinoin-UDV was also compared to the marketed 
tretinoin formulation (Ketrel) when applied to back skin of shaved BALB/c female mice 
(20-25 g). Animals were housed in separate polypropylene cages of suitable size and 
kept under standardized environmental conditions throughout the study.  
Mices were divided into three groups of three animals each and treated daily by 
topically applying to the back (6 cm2), for 10 days, 100 µl of: group a) empty UDV; group 
b) 0.05 % tretinoin-UDV; and group c) 0.05 % Ketrel. Animals were examined for signs 
of skin irritation each day before treatment throughout the treatment period and given 
an overall “irritation score” defined by Draize (36): 0 = no differences, 1 = light 
erythema, 2 = well defined erythema, 3 = strong erythema, and 4 = very strong 
erythema with presence of a scar. At the end of tenth day, the animals were sacrificed. 
Skin biopsies (1 cm2) were taken from all treated areas, preserved in 10% formalin 
solution and processed for histopathological studies. Tissue sections were stained by 
hematoxylin and eosin standard procedure, and finally examined under a light 
microscope (Olympus, AH-2 Vanox, Tokyo, Japan).  
All animal experiments were carried out with the permission of the local animal ethical 
committee in accordance with the EU Directive (2010/63/UE), Portuguese law (DR 
129/92, Portaria 1005/92) and all relevant legislations. The experimental protocol was 
approved by Direcção Geral de Veterinária (DGV). 
 
 







The results are reported as mean + standard deviation (SD) of at least three replicates/ 
treatment. The results of all these experiments were statistically analyzed by Analysis of 
Variance (ANOVA) using SigmaPlot 11.0 software®. The differences were considered 




In Vitro Release Study with Synthetic Membranes 
Lipid composition, size and surface charge of liposomes, and drug solubility can affect 
stability and pharmacokinetic profiles of liposomes and drug release pattern (11, 37).  
The release profiles of tretinoin-UDV formulations (with 15 % and 20 % of lipid 
concentration) are described in Fig.1.       
 
                
 




) of tretinoin-UDV formulated with 15 and 20 % lipid 
concentration during 6 h (mean ± SD, n= 3 for each formulation).  





The release study of these formulations revealed a sustained and controlled profile, as 
theoretically expected attending to the formulation carriers (UDV) and to the increasing 
lipid concentration. Although the release rate was significantly higher for tretinoin-UDV 
with 15 % of lipid concentration (p = 0.012), this formulation was unstable at the 7th 
month (data not shown) unlike tretinoin-UDV formulation with 20 % of lipid 
concentration. Thus, this last formulation was chosen for the following topical 
experiments. 
 
In Vitro Skin Permeation/Penetration Study  
The in vitro skin permeation study was carried out through the whole skin also under 
non-occlusive conditions. After 24 h, no drug was detected in the receptor phase. 
Regarding the tape stripping experiments, 70 % tetrahydrofuran (THF) was selected as 
the extraction solvent due to its greater reproducibility among the samples and 
higher recovery rate of tretinoin in SC and ED samples, when compared with mobile 
phase. In fact, a greater drug retention in SC (~ 10-25 µm of thickness) was obtained 
than in epidermis and dermis (Table 1), as theoretically expected.  All measurements 
also showed low coefficient of variation indicating good reproducibility.  
Table 1- Tretinoin quantification (µg/cm
2
) in stratum corneum (SC) and epidermis + dermis (ED) samples 
(n = 6). 
Tretinoin Assay SC ED 
Mean (µg/cm
2
) 0.372 0.050 
Standard Deviation (±) 0.018 0.008 
Variation Coefficient (%) 4.926 15.730 
 
 
In Vitro Skin penetration study with Nile Red-UDV 
The skin penetration of Nile Red previously incorporated in the same UDV formulation 
was visualized by fluorescence microscopy. In general, untreated skin presented some 
autofluorescence (Fig.2A and C), especially in the SC. Nile Red incorporation resulted in 
a strong fluorescent staining of SC, epidermis and dermis, but especially of the first ones 






(Fig.2B and D). In this case, the fluorescence seemed fairly homogenously dispersed 
into the skin. 
 
Fig.2- Light microscopy (A and B) and corresponding fluorescence microscopy (C and D) of skin sections 
untreated (A,C) and treated with Nile Red-UDV formulation (B,D), 24 h after formulation topical 
application (original magnification 10x20x). 
 
 
In Vitro Skin Electrical Resistance (ER) 
Electrical resistance (ER) is a quick, safe and valuable tool for measuring the integrity of 
skin membranes. Ensuring that the skin barrier maintains its integrity is an essential 
factor to the successful performance of such experiments, as specified in test guideline 
OECD 428 (28).  





Compared to water (control) which maintained the skin electrical resistance until 24 h 
(20.8 ± 3.4 k), tretinoin-UDV decreased the skin electrical resistance to 88.5 % and 
59.3 % after 8 and 24 h, respectively.  This data suggests the ability of this nanocarrier 
formulation to induce skin barrier disruption, which was also confirmed by the skin 
penetration study.  
 
Cytotoxicity Assay 
The growth curve for MTT-formazan absorbance was analyzed to ensure that 
absorbance was proportional to the number of cells (Fig.3). Attending to the 
recommended absorbance range (between 0.75 and 1.25 values), it was chosen a 
seeding density of ~ 7,000 cells/well.  
 
 
Fig.3- Growth curve of HaCaT cells for MTT-formazan absorbance at 572 nm (mean ± SD). 
 
In preliminary studies it was observed that the formulation toxicity was highly variable 
and strongly dependent on cell confluence, being much lower when the cell confluence 
was higher (Fig.4a and b). According to this observation and also to usual exposure 
procedures, the cells were only exposed after achieving more than 50 % of confluence. 
In addition, all the samples had a mean osmolarity lower than 300 mOsm/ Kg.  
 









(P < 0.05) 
 
Significant 
(P < 0.05) 
Between the vehicles to each dose Between the doses to each vehicle 
T 5 µg/mL vs T_UDV 5 µg/mL Yes                 T_UDV 5 µg/mL vs. T_UDV 15 µg/ mL  Yes 
UDV 5 µg/mL vs T_UDV 5 µg/mL Yes T_UDV 10 µg/ mL vs. T_UDV 15 µg/ mL No 
T 5 µg/mL vs UDV 5 µg/mL Yes T_UDV 5 µg/mL vs. T_UDV 10 µg/mL Yes 
    
T 10 µg/mL vs T_UDV 10 µg/mL Yes T_5 µg/mL vs. T_15 µg/ mL Yes 
T 10 µg/mL vs UDV 10 µg/mL No T_10 µg/ mL vs. T_ 15 µg/ mL Yes 
UDV 10 µg/mL vs T_UDV 10 µg/mL No T_5 µg/mL vs. T_10 µg/mL No 
    
T 15 µg/mL vs T_UDV 15 µg/ mL Yes UDV 5 µg/mL vs. UDV 15 µg/ mL Yes 
UDV 15 µg/mL vs T_UDV 15 µg/mL Yes                     UDV 10 µg/ mL vs. UDV 15 µg/ mL  No 
T 15 µg/mL vs UDV 15 µg/mL Yes UDV 5 µg/mL vs. UDV 10 µg/mL Yes 
 






Comparison Between the Doses  
Significant 
(P < 0.05) 
               T_UDV 5 µg/mL vs. T_UDV 15 µg/ mL  Yes 
T_UDV 10 µg/ mL vs. T_UDV 15 µg/ mL Yes 
T_UDV 5 µg/mL vs. T_UDV 10 µg/mL Yes 
 
 
Fig.4- Determination and statistical analysis of MA (mean ± SD) by MTT assay 24 h after exposure to 
tretinoin-UDV (T-UDV), tretinoin aqueous solutions (T) at 5, 10 and 15 µg/mL and empty UDV (UDV) at 
the same concentration range under cell confluence: a) lower than 50 %; b) higher than 50 %. Data 
expressed as a percentage of control (non exposed cells). 
 
The cell viability assessed by the Trypan Blue assay is expressed in Fig.5. In general, a 
highly decrease of cell viability was found when using both empty UDV (the formulation 
vehicle) and tretinoin aqueous solutions (T). There are only significant differences of cell 
viability between the three tretinoin concentrations in T-UDV formulation and there are 
no significant differences between the empty diluted UDVs, except for the highest 




























Fig.5- Determination and statistical analysis of cell viability (mean ± SD) by Trypan Blue assay 24 h after 
exposure to tretinoin-UDV (T-UDV), tretinoin aqueous solutions (T) at 5, 10 and 15 µg/mL and empty UDV 
(UDV) at the same concentration range under cell confluence higher than 50 %. Non exposed cells are 





(P < 0.05) 
 
Significant 
(P < 0.05) 
Between the vehicles to each dose Between the doses to each vehicle 
T 5 µg/mL vs T_UDV 5 µg/mL No             T_UDV 5 µg/mL vs. T_UDV 15 µg/ mL  Yes 
UDV 5 µg/mL vs T_UDV 5 µg/mL No T_UDV 10 µg/ mL vs. T_UDV 15 µg/ mL Yes 
T 5 µg/mL vs UDV 5 µg/mL No T_UDV 5 µg/mL vs. T_UDV 10 µg/mL Yes 
    
T 10 µg/mL vs T_UDV 10 µg/mL No T_5 µg/mL vs. T_15 µg/ mL No 
T 10 µg/mL vs UDV 10 µg/mL No T_10 µg/ mL vs. T_ 15 µg/ mL No 
UDV 10 µg/mL vs T_UDV 10 µg/mL No T_5 µg/mL vs. T_10 µg/mL No 
    
T 15 µg/mL vs T_UDV 15 µg/ mL Yes UDV 5 µg/mL vs. UDV 15 µg/ mL Yes 
UDV 15 µg/mL vs T_UDV 15 µg/mL Yes           UDV 10 µg/ mL vs. UDV 15 µg/ mL  No 
T 15 µg/mL vs UDV 15 µg/mL Yes UDV 5 µg/mL vs. UDV 10 µg/mL No 
Comparison with control 
Significant 
(P < 0.05) 
T_UDV 5 µg/mL vs Non Exposed Cells No 
T_UDV 10 µg/mL vs Non Exposed Cells No 
T_UDV 15 µg/mL vs Non Exposed Cells Yes 






In both cytotoxicity assays (Fig.4 and 5), the tretinoin-UDV (T-UDV) formulation was not 
cytotoxic at the lowest concentration, 510 -3 mg/mL, and the differences between the 
all three concentrations were statistically very significant (p ≤ 0.001) in T-UDV 
formulation under cell confluence higher than 50 %.  
Some heterogeneity among replicates was mostly observed in the Trypan Blue assay 
shown by the SD bars (Fig.5). In addition, this method provided higher cell viability 
values than the MTT assay due to technical differences between them.  
 
In Vivo Skin Irritation Potential  
Data obtained from the skin irritation experiments with mice are represented in Fig.6, 
and as it can be observed, there are significant differences between the commercial 
(Ketrel) and tretinoin-UDV formulations (p < 0.05). In fact, the UDV formulation had 
the lowest skin irritation potential.  
 
Fig.6- Skin Irritation Potential of tretinoin-UDV and a marketed tretinoin formulation in shaved mice 
(mean ± SD, n = 3 for each formulation). Irritation score: 0 = no difference between the tretinoin-treated 
animals and control, 1 = light erythema, 2 = well defined erythema, 3 = strong erythema, and 4 = very 
strong erythema with presence of a scar. 
 
The epidermal width was augmented after treatment with both tretinoin formulations. 
Tretinoin–UDV treated skin showed irregular hyperkeratosis and hyperplasia of 






sebaceous glands and presence of fibroblast proliferation on superficial dermis (Fig.7B). 
For Ketrel®- treated skin, hyperplasia of the epidermis and superficial perivascular 
dermitis were observed (Fig.7C). 
 
 
Fig.7- Sections of mouse skin A) untreated (serving as the control)  or treated with B) Tretinoin-UDV or C) 
Ketrel
®





The observed release profiles of tretinoin formulations, and especially, their respective 
chemical stabilities were the basis of the selection of tretinoin-UDV formulation with 
20 % of lipid concentration to perform the following studies. In fact, this formulation 
had also a sustained release (Fig.1) and higher chemical stability when compared to 
other formulation prepared in previous studies: tretinoin hydrogel formulation, in which 
tretinoin was in free form or complexed with dimethyl-beta-cyclodextrin (38).  
The in vitro skin permeation study was carried out through the whole porcine ear skin 
also under non-occlusive conditions which are more suitable to improve the UDV flux 
under the transepidermal water-activity gradient (8). On the other hand, occlusive 
conditions would not only eliminate the osmotic gradient (19), but also improve drug 
accumulation into the skin layers (39, 40). In addition, porcine ear skin was selected as a 
C) B) 
A) 





model because of the similarities with human skin regarding biochemical properties, 
hair follicle density and thickness of SC (41). The drug concentrations in SC and 
epidermis/dermis are indicative of topical delivery, whereas the concentration in the 
receptor phase is indicative of transdermal delivery. In fact, no drug amount was 
detected in the receptor phase after 24 h. Thus, the results showed that tretinoin-UDV 
formulation has a dermal instead of a transdermal delivery, which will serve the 
therapeutic purpose since the tretinoin receptors, such as RAR-, are mainly located in 
epidermis layer (42). In addition, tretinoin transdermal delivery is not desirable as long 
as tretinoin teratogenic effect should be avoided. 
According to Manconi et al. (10), tretinoin cutaneous delivery is strongly affected by 
thermodynamic activity of the drug and vesicle composition (charge, structure and size) 
and, therefore, amphiphile physico-chemical properties. Moreover, interactions 
between skin and vesicles seem to depend on physico-chemical properties of the main 
component of the vesicle bilayers. In this case, the vesicles surface charge was low (due 
to the use of a nonionic surfactant in the formulation (Tween 80®) and the neutral pH), 
and the vesicles final size was approximately 150  50 nm (25).  
In tape stripping experiments, the amount of SC removed by a single adhesive tape strip 
depends on several intrinsic and extrinsic factors. Extrinsic factors that have been 
reported to affect the amount of SC removed by tape stripping are the type of adhesive 
tape (43), the force of removal from the skin (44, 45), the duration of pressure onto 
the skin (46) and topically applied formulations which may interfere with the 
disorganization level of SC and the skin hydration (47). Even constant extrinsic factors 
following a strict standard protocol, would not lead to a constant amount of SC in each 
tape strip, due to the various intrinsic parameters (e.g. corneocytes size). Therefore, all 
the procedures of the tape stripping experiment were previously validated. In this case, 
the SC was removed only with 10 adhesive tapes, and the tretinoin UDV formulation 
was mainly retained in this skin layer (Table 1), as theoretically expected from to the 
formulation composition and lipophilicity of SC layer.  






To evaluate whether penetration of the lipophilic drug (tretinoin) from UDV formulation 
was homogenous throughout the surface of the skin or was limited to certain skin 
structures, the skin penetration study and distribution of a fluorescent lipophilic 
compound (Nile Red) was performed (29). Nile Red was chosen as a model compound 
because it is a well-known fluorophore, and presents relatively high absorptivity and 
good fluorescence quantum yield. Its affinity to the intercellular lipids and lipophilic 
solvents is also well-known (48), and therefore it will readily stain the hydrophobic UDV 
membranes. Nile Red incorporation was predominant in SC and epidermis (Fig.2), rather 
than in dermis, which is desirable because retinoic acid receptors are mainly located in 
epidermis, as already mentioned before (42). These results are quite consistent with 
others obtained from previous skin penetration studies with another different 
hydrophilic fluorophore (Fluorescein, FITC) incorporated in the same formulation, and 
with the lag phase obtained in the releasing profile and the tape stripping results.  
Some delivery systems that contain penetration enhancers and/or surfactants can 
increase the skin penetration of drugs by reversibly decreasing the skin barrier function, 
and consequently, the Electrical Resistance (ER) (29). Rachakonda et al. (49) showed a 
significant agreement between the resistance technique and the standard permeation 
experiments, thus confirming the efficacy of resistance technique for screening 
potential chemical penetration enhancers. Lipids of the SC provide the principal 
transport and electrical resistance in the skin. It has been reported by others (50) that 
ER is dependent on skin hydration state, ionic strength of the receptor phase, 
alternating current frequency and current density. An increase in hydration of the SC 
results in decrease of ER. The most dramatic changes in ER have been observed with 
different ionic strength medium and alternating current frequency. Thus, the variability 
in these ER measurements was reduced by certain precautions as recommended by 
Rachakonda et al. (49), such as: 1) using skin samples with the same characteristics 
(previously stored at -20 C instead of -70 C); 2) maintaining the skin hydration; 3) 
using PBS pH 7.4 as the receptor phase; 4) using a setting of 100 Hz; 5) maintaining the 
temperature of the receptor compartment at about 32-37 C. This last condition is 





important because at lower temperature, the skin resistance might be higher due to 
increased rigidity of the lipid bilayers, and at higher temperature, the individual lipid 
molecules may have more vibrational energy, which makes the lipid bilayers more 
fluidic and may offer less resistance. Even taken all these precautions for ER 
measurements, a high variability was obtained, perhaps due to the ionic strength and 
zeta potential of the UDV formulation. However, tretinoin-UDV decreased the skin 
electrical resistance especially after 24 h, suggesting its ability to induce skin barrier 
disruption, also confirmed by the penetration study.  
Attending to the importance of developing safe, non-irritating topical delivery systems, 
the cytotoxicity potential of tretinoin-UDV was determined by the MTT and Trypan Blue 
assays. However, the drug concentration (Fig.4 and 5) must be much lower since the 
cells do not mimic the complex structure of the skin tissue. Thus, the tretinoin-UDV 
formulation was diluted at 5, 10 and 15 µg/mL. Measurement of cell viability and 
proliferation is the basis for numerous in vitro assays of a cell population’s response to 
external factors.  
Both cytotoxicity assays confirmed that the tretinoin-UDV (T-UDV) formulation was not 
cytotoxic at the lowest concentration. The differences between all the values obtained 
from the two assays are probably due to the respective assay procedure, such as the 
trypsinization during the Trypan Blue assay in which most of dead cells are removed, 
thus leading to higher cell viability values. The tretinoin-UDV formulation cytotoxicity 
observed at the highest concentration (15 µg/mL) may be due to the combination of 
two main components: tretinoin and surfactant, since the cell viability slightly decreases 
with increasing concentrations of these components. The discovered correlation 
between surfactant and UDV toxicity seems not to be surprising since all other 
remaining components (e.g. lipids) are considered as non-toxic. The toxic effect of 
surfactants is mainly explained by different hypothesis related to their chemical nature. 
The hydrophilic and lipophilic parts of surfactant molecule interact with polar head 
groups and lipophilic tails of cellular lipid bilayer respectively, resulting in a disruption of 
the plasma membrane (51, 52). Therefore, long hydrophilic chains could prevent the 
destabilization of the cell membrane by limiting the penetration of surfactant into the 






lipid bilayer, and in contrast, the hydrophobic part would promote the disruption of the 
membrane.  One critical point is still the fact that some of the surfactants contain 
unbound PEG chains that do not contribute to the surface activity (52). Maupas et al. 
(52) have established the toxicity of different pure surfactants in cultured HaCaT cells: 
TPGS1500 > Solutol® HS15 > Tween® 20  > Tween® 80 > Cremophor® EL > Simulsol® 4000. 
Tween® 80 (the surfactant used in UDV formulation) is a PEG sorbitane monooleate and 
has short PEGylated hydrophilic chains with approximately 20 units (52).  
The higher cytotoxicity of tretinoin-UDV formulation relative to empty UDV may be 
explained by the interaction between this lipophilic drug and the UDV lipids, which 
could probably alter the surfactant surface activity and, consequently, destabilize the 
cell membrane, especially when the cells confluence is lower and there are many empty 
spaces between them. Díaz et al. (53) tested the cytotoxic effect induced by retinoic 
acid (50 and 25 µg/mL) loaded into galactosyl-sphingosine containing liposomes on 
human hepatoma cell lines, and their results showed that even though liposomes could 
be a good delivery system for this drug, the study of the interactions between lipids and 
the drug and lipids and the membranes, as well as the specific mechanisms of 
internalization (simple endocytosis or receptor-mediated endocytosis), could predict the 
effect that this agent would have in cells.  
Although tretinoin has many therapeutically advantages, the skin irritation after its 
topical application limits significantly the patient compliance. Controlled drug delivery 
systems such as UDV can be an interesting alternative to protect the skin from direct 
contact with the drug which is incorporated in the lipid matrix and, consequently, 
gradually released (54). In addition, these vesicles help to reduce skin irritation by 
hydration of the epidermis due to contributing vesicular lipids to SC and water content 
(55). The search for a tretinoin formulation that could be therapeutically active and 
without skin irritation problems is a matter of interest in dermatotherapy. Here, we 
have demonstrated that the developed UDV formulation had the lowest skin irritation 
potential (erythema and scaling) (Fig.6 and 7). Castro et al. (54) have also obtained 
similar results with retinoic acid (RA) loaded in solid lipid nanoparticles (SLN), when 
compared to conventional formulations (gel or cream at 0.01 % and 0.05 %) using rabbit 





and rhino mouse models. Moreover, our histological results observed for keratinocytes 
proliferation and compaction of the skin barrier support other findings in literature (56, 
57), and clearly indicate the potential of UDV formulation in improving the skin 




Nanotecnology is not only used to protect unstable drugs but also to modify the drug 
permeation and/ or penetration by controlling its release rate and increasing the period 
of permanence on the skin, besides ensuring a direct contact with SC and skin 
appendices (58). Based on our results, we propose that tretinoin-UDV formulation has a 
suitable dermal delivery, with special targeting to SC and epidermis layers. In addition, 
the formulation vehicle (empty UDV) and tretinoin-UDV were not toxic under in vitro 
and in vivo conditions, at least at 510 -3 mg/mL and 0.5 mg/mL, respectively.  
In fact, Tretinoin-UDV can be considered as a promising delivery system for tretinoin 
dermal delivery without promoting skin irritation (unlike other commercial 
formulation), which is quite advantageous for therapeutic purpose for different skin 
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The Effect of UV-B Irradiation on Human Keratinocytes  
after Lycopene Exposure 
Abstract 
Introduction: Human skin is constantly exposed to the UV irradiation that may induce a number 
of pathobiological cellular changes. Lycopene has been reported as the antioxidant most quickly 
depleted in skin upon exposure to solar radiation, and thus might play a role against UV 
radiation. Regarding this, our goal was to investigate the effects of pre-exposure to lycopene in 
UV-B-irradiated skin cells (human keratinocytes HaCaT cells line).   
 Methods: Thiazolyl Blue Tetrazolium Bromide viability assay was firstly used to set the protocol 
specific conditions: cells were exposed for 24 h to 10 µM complexed lycopene, and 
subsequently, cells were irradiated with UV-B radiation (225 mJ/cm2) and left to recover for 
another 24 h period. After exposure and irradiation experiments, the following parameters 
were analyzed: a) Genotoxicity/Clastogenicity by assessing the cell cycle distribution by Flow 
Cytometry (FCM) and analyzing Gene Expression of Apoptosis Biomarkers by RT-PCR; b) 
Apoptosis by performing the Annexin assay by FCM; c) Oxidative Stress Damage by reactive 
oxygen substances (ROS) quantification by FCM. 
Results: Complexed lycopene (10 M) does not affect the profile of apoptotic, necrotic 
and viable cells, nor shows cytostatic effects despite slightly increasing the ROS content. 
However, cell populations previously treated with lycopene and then exposed to UV-B 
radiation show an increase in both dead and viable subpopulations compared to non 
exposed-UV irradiated cells. This is accompanied by a cell cycle delay at S transition and 
consequent decrease of cells in G0/G1 phase, which is not observed in irradiated/non 
exposed cells. 
Conclusion: According to data obtained from all experimental assays, complexed lycopene 
seems to play a corrective or cytotoxic role in irradiated cells depending on the level of 
photodamage.  Thus, our findings may have implications for the management of skin cancer 
and/or other proliferative skin disorders. 
Keywords: UV-B irradiation; Lycopene; HaCaT Cells; Cytotoxicity; Genotoxicity; Oxidative Stress 







Human skin is constantly exposed to the UV irradiation that may induce a number of 
pathobiological cellular changes. Through lipid peroxidation, protein crosslinking and 
DNA damage, UV-A and UV-B radiation can cause photoaging and photocarcinogenesis 
(1-3). Skin is endowed with a variety of enzymatic as well as small molecular 
antioxidants that can inhibit oxidative damage. However, the antioxidant ability of the 
skin is often overwhelmed by excessive ROS production (4). In this regard, emphasis in 
developing novel preventive and therapeutic strategies based on phytocompounds 
capable of ameliorating the adverse effects of ROS has become an important area of 
research. Moreover, primary prevention approaches of skin cancer proved to be 
inadequate in lowering the incidence of this type of cancer, emphasizing the need to 
develop novel skin cancer chemopreventive agents. Among the vast number of 
photochemoprotective agents, botanical antioxidants have given promising results (4). 
Two types of chemopreventive agents could be useful for the management of skin 
cancer. Primarily, the agents that could inhibit the damages caused by UV may prevent 
the formation of initiated cells (cells with cancerous potential). Secondly, the agents 
that could eliminate the initiated cells may reduce the risk of skin cancer (5). 
Lycopene is a powerful antioxidant both in vitro and in vivo against the oxidation of 
proteins, lipids and DNA, and it has been identified as one of the most potent 
scavengers of singlet species of oxygen free radicals – the highest among the 
carotenoids (6, 7). At low oxygen tension, it can also scavenge peroxyl radicals, 
inhibiting the process of lipid peroxidation (8). Lycopene was reported as the most 
quickly depleted antioxidant in skin upon exposure to solar radiation (9) and might play 
a role of protection against UV radiation. Recent research has been developed to assess 
if lycopene has potential for prevention of skin cancer. In fact, lycopene has been shown 
to inhibit proliferation of several types of cancer cells through different mechanisms in 
in vitro systems (10, 11). Chemopreventive antioxidants are mostly studied for their role 
as radical scavengers, but this preventive role can be complemented by a corrective 
activity as selective inducers of apoptosis in transformed cells (12). Moreover, Ribaya-






Marcado et al. (9) suggested a role of lycopene in mitigating photooxidative damage in 
tissues. 
HaCaT cells, a transformed nontumorogenic human cell line from keratinocytes 
epithelial cells were used in this research work (13). Keratinocytes are the predominant 
cell type in the epidermis, the outermost layer of the skin, constituting 95% of the cells 
found there (14). Considering that the principal site of action of UV-B is the epidermis 
layer (15), keratinocytes might be more susceptible to UV-B-induced apoptosis than 
fibroblasts which are located in dermis layer (16). However, keratinocytes may be more 
UV-B resistant in terms of their proliferative ability as measured by colony survival 
assays and have greater ability for UV-DNA repair (16).  
To date, most of the studies on the therapeutical potential of lycopene have been 
performed in vivo (17, 18). These studies may be obscured by the complexity of 
biological system models. In vitro conditions may circumvent some of these 
contingencies, and complement in vivo data within the 3Rs perspective (Refine, Replace, 
Reduce). Despite the lower complexity of in vitro systems, the study of cellular 
photoprotection by antioxidants could be challenging because of the high chemical 
instability (specially to air and light) and strong lipophilicity of many antioxidant 
molecules such as lycopene. According to Zefferino et al. (11) in vitro experiments may 
occasionally produce inconsistent results due to lycopene’s poor solubility in cell culture 
media (19). In fact, lycopene is very hydrophobic (log P ≈ 15) and is usually solubilized in 
organic solvents such as tetrahydrofuran (THF). However, an uncontrolled precipitation 
process may occur upon addition to aqueous media, besides the high toxicity associated 
to these solvents. The solubility and uptake of these large crystals in the cells is quite 
limited and there is almost no protection against chemical degradation (20). Alternative 
ways of delivering lipid-soluble compounds include micelles, microemulsions, 
nanoparticles, water-dispersible beadlets, artificial liposomes, enriched bovine serum, 
or specialized formulations, each of which has an influence on the uptake and stability 
of hydrophobic compounds (19, 21-24). According to Palozza et al., niosomes provide a 
convenient, nontoxic and inexpensive vehicle for β-carotene in cell culture (25). Lipid-





based delivery systems also show UV-blocking effects dependent on lipid composition 
and the particle size (the smaller the particle size, the higher the sunscreen activity). 
Lipid matrices can act as sunscreen carriers and increase the sun protection factor 
obtained after topical application of UV absorbers (BaSO4, SrCO3, TiO2) incorporated 
within these carriers because they provide a fixation medium for these pigments (26, 
27). However, it is difficult to use these hydrophobic systems for cell culture studies.  
The main limitations of different vehicles used for lycopene cell delivery are 
summarized on Table 1. Each vehicle provides specific advantages but also offers some 
limitations such as cytotoxicity, poor solubility and crystallization in the cell medium 
(28). 
Table 1-  Limitations of different vehicles used for lycopene cell delivery (adapted from Lin et al. (28)).  
Vehicle Limitations References 
Tetrahydrofuran 
(THF) 
Rapid oxidation in media, leading to lycopene instability and 
cytotoxicity 





Reduced solvent capacity for carotenoids (< 0.01 mg/mL for 
lycopene). 
(21, 34-36) 
Tween® Possible oxidation of carotenoids, after solvent drying and 
filtration 
(31) 
Micelles Low carotenoid stabilization and increased cytotoxicity (21, 28, 37) 
Water-dispersible 
Beadlets 
Low toxicity, but also low cellular uptake; depends on chemicals 
that interfere in assays (e.g. hexane, chloroform) 
(29, 38, 39) 
 
In addition, the half-life of free lycopene in solution at 37 C is less than few hours. 
Thus, until an efficient method of solubilizing lycopene in aqueous buffers and cell 
culture media is developed, in vitro studies on the effects of lycopene on living cells will 
continue to show considerable variation between laboratories and cell lines, and should 
be interpreted with caution (40).  
Pfitzner et al. (19) have demonstrated that methyl-β-CD (M-β-CD) was an improved 
vehicle for the investigation of carotenoids and other lipophilic compounds in in vitro 
test systems, compared to organic solvents. Carotenoids-M-β-CD complex was superior 
concerning biological availability, missing cytotoxicity and presenting excellent stability 






when compared to other application forms such as organic solvents, mixed micelles, 
liposomes or beadlets. At least, the solubilization with M-β-CD was easily and 
reproducibly achievable under routine laboratory conditions.  
According to these literature references (19, 28) and pre-formulations studies, we 
decided to use another similar CD derivative, dimethyl-β-CD (DM-β-CD), to solubilize 
and stabilize lycopene for cell exposure experiments. We propose that lycopene 
delivered in DM-β-CD complex may be used as a photochemopreventive agent against 
UV-B irradiation (17). To test this hypothesis, we studied the main effects of UV-B 
irradiation on human keratinocytes (HaCaT cells line) after complexed lycopene (Lyc-
DM-β-CD, or more abbreviated, Lyc-CD) exposure under in vitro conditions. For this, 


















Materials and Methods 
Preparation of Lycopene Complex Solution 
In order to avoid the use of organic solvents, lycopene (Extrasynthese, Genay, France 
with a purity ≥ 98%, UV assay) was solubilized by complexation with dimethyl-beta-
cyclodextrin (CD, degree of substitution: 1.8) which was a generous gift from Wacker 
(Stuttgart, Germany). Aqueous solutions of lycopene complexed with CD (1:4 molar 
ratio) were prepared under aseptic conditions within concentrations of  0, 5, 10, 15 and 
20 μM from a concentrated lycopene solution previously stirred with CD during 
approximately 48 h, and sonicated 30 min (before use) always protected from light and 
air. Lycopene  solutions  were always freshly prepared under light and air 
protection and stored at -20 °C (except the pure lycopene standard, stored at -70 °C). 
The osmolarity of the sample containing the highest lycopene concentration was 
determined using an automatic osmometer (Knauer®, Berlin, Germany).  
When non specified, all higher grade reagents were from Sigma-Aldrich (St. Louis, MO, 
USA).  All solutions were prepared using ultrapure water obtained in a MILLI-Q System 
from Millipore® (Billerica, MA, USA).  
 
Human Immortalized Keratinocytes (HaCaT) Cell Line  
The HaCaT cell line was obtained from Cell Lines Services® - CLS (Eppelheim, Germany). 
Handling and culture of these cells were adapted to meet CLS protocol procedures. Cells 
were aseptically grown in Dulbecco's modified Eagle's medium (DMEM, no HEPES, no 
Pyruvate), high glucose, supplemented with 10 % fetal bovine serum (FBS), 2 mM L-
glutamine, 1 % penicillin–streptomycin (10,000 U/mL) and 1 % fungizone (250 U/mL) 
(Gibco®, Life Technologies, Grand Island, NY, USA) at 37 °C in a humidified atmosphere 
with 5 % CO2. 
 
 






HaCaT Cell Growth and Confluence under normal culture conditions 
The standard cell growth conditions were established after the analysis of HaCaT growth 
curves. HaCaT cells were seeded in a 6-well cluster plate (300,000 cells/ well). Cell 
confluence and morphology was daily observed under microscope. After 3 days, cells 
were harvested by trypsinization according to CLS procedure. Briefly, the culture was 
rinsed twice with phosphate-buffered saline solution (PBS Gibco®, without Ca2+ neither 
Mg2+) and PBS containing 0.05 % EDTA to remove desmosomes and incubated at 37 °C 
about 5-10 min. After this time, the EDTA solution was replaced by a 1:1 mixture of 
EDTA/trypsin-solution (final concentrations of 0.025 % and 0.05 %, respectively). The 
trypsinization was achieved after incubating at 37 °C for 15-20 min. At this time, a 
double volume of complete culture medium (with FBS) was added to stop the detaching 
process and cells were suspended with stronger shaking, followed by the use of a 
syringe (21G) because of its mechanical resistance. All cell manipulation and growth and 
subsequent exposure conditions were performed under strict aseptic procedures. 
Cell density was calculated by counting with a hemocytometer (Neubauer® Improved) 
under a phase contrast microscope Nikon Eclipse 80i® (Coyoacán, Mexico). 
 
Selection of Exposure Conditions:  
Selection of UV-irradiation Dose: Ten UV-B lamps (Sankyo Denki G8T5E, Kanagawa, 
Japan) with a peak emission at 312 nm were used as the UV-B source. The UV-B 
irradiation was measured with a VLX 312 radiometer equipped with a UV-B sensor 
(Vilber Lourmat, Marne-la-Vallée Cedex, France).  Around 7,000 cells/well were cultured 
in a 96-well cluster plate with complete medium. Twenty four hours after, the cells were 
exposed to five different UV-B irradiation doses [based on related literature (41-43)] of 
~ 75, 150, 200, 225 and 325 mJ/cm2. In order to prevent UV quenching, prior to 
irradiation, the cell culture medium was replaced by the same volume of PBS after two 
washing steps with PBS. After UV-B irradiation, cells were fed with fresh growth 
medium and incubated for 24h. Cell metabolic activity was assessed as described below 





by the MTT assay (often used as viability method) in order to choose just one UV-B 
dose. Non irradiated samples were used as negative control.  
Selection of Lycopene Complex Dose: Cells were seeded and grown in DMEM, the 
modified Eagle's medium (-MEM, without nucleosides, Gibco®, Life Technologies) for 
24 h, then DMEM medium was replaced with alpha-MEM (also supplemented with 10 % 
FBS, 1 % penicillin–streptomycin and 1 % fungizone) containing complexed lycopene 
solutions (0, 5, 10, 15 and 20 μM). Cells were exposed for 24 h and, after UV-B 
irradiation, HaCaT irradiated cells were grown under standard culture conditions for a 
final 24 h period. The metabolic activity of cell culture was analyzed by MTT assay in 
order to choose just one lycopene dose.  
From cell viability results, the exposure and irradiation conditions were determined 
according to Fig.1. Briefly, for further experiments, HaCaT cells were seeded in a 6-well 
cluster plate (150,000-300,000 cells/2 mL well) and incubated 24 h under the same 
culture conditions, as mentioned above. After this period, the cells were exposed to 
complexed lycopene (10 µM) for 24 h in order to achieve its cellular internalization and 
a higher cell confluence, and after UV-B irradiation (225 mJ/cm2), cells were allowed to 
grow under standard culture conditions for another 24 h period in order to give cells 
time to possibly activate some repair mechanisms.      
 
             Fig.1- Scheme of culture conditions regarding complexed lycopene exposure and UV-B irradiation. 







Cell metabolic activity was assessed by the Thiazolyl Blue Tetrazolium Bromide (Sigma-
Aldrich, St. Louis, MO, USA) assay, which is often used to roughly estimate culture’s 
viability/proliferation characteristic. Cells were seeded at a density of 7,000 cells/ well in 
a 96-well cluster plate. After complexed lycopene exposure and UV-B irradiation, the 
MTT assay was performed according to the following conditions: cells were incubated 
with culture medium containing 50 μL of MTT (1 mg/mL in PBS, pH 7.2) during 4 h at 37 
C, 5 % CO2. After this time, medium was carefully removed and the 150 μL of dimethyl 
sulfoxide was added to each well in order to solubilize the formazan crystals. The plate 
was gently shaken for about 2 h and protected from light. The optical density of reduced 
MTT was measured at 570 nm by spectroscopy on an automatic microtiter plate reader 
(Synergy™ HT Multi-Mode from BioTeK® Instruments Inc., Winooski, VT, USA) equipped 
with specific software (Gen5, Biotek®), and cell metabolic activity (MA 
viability/proliferation characteristics) was calculated according to Eq.1.  
Eq. 1.  Cell MA (%) = (Abs 570 nmsample – Abs 570 nm DMSO)/ (Abs 570nm negative control – Abs 570 nm DMSO) x 100 
 
Besides the negative control (non exposed and non irradiated cells), the assays results 
were also compared to CD aqueous solutions (vehicle control) with the same dilution 
factors used for complexed lycopene samples. 
 
Analysis of Apoptosis by the Annexin Assay  
Apoptosis was measured by flow cytometry using FITC Annexin V Apoptosis Detection 
Kit from BD Pharmingem™ (Franklin Lakes, NJ, USA). After complexed lycopene 
exposure and UV-B irradiation as described before, the cells were gently harvested with 
Accutase® (PAA Laboratories, Pasching, Austria) and washed twice in cold PBS (1 mL). 
Finally, Fluorescein Isothiocyanate (FITC) and Propidium Iodide (PI), 5 µL of each, were 
added to 100 µL of cell suspension (105 cells/mL) in binding buffer. Samples were left in 





the dark for 15 min and 400 μL of “1x Binding Buffer” was added. The samples were 
analyzed by flow cytometry using a Coulter EPICS XL flow cytometer® (Coulter 
Electronics, Hialeah, Florida, USA). Data was acquired using the SYSTEM II™ (v. 2.5) 
software. The cytogram of FITC fluorescence in log scale versus PI fluorescence in log 
scale allows the identification of non-apoptotic cells (Annexin V-FITC negative, PI 
negative), early apoptotic cells (Annexin V-FITC positive, PI negative), late apoptotic cells 
(Annexin V-FITC positive, PI positive) and dead cells (Annexin V-FITC negative, PI 
positive). FCM data was analyzed by FlowJo software® (Tree Star Inc., Ashland, OR). 
 
Analysis of Apoptosis Regulating Genes by RT-PCR  
Total RNA extraction: At least 1x 105 HaCaT cells were rinsed twice with sterile PBS 
after removal of culture medium. After rinsing, cells were lysed in 1 mL TRIzol® reagent 
(Life Technologies, Saint Louis, MO, USA) and after 5-min room temperature incubation, 
200 µL chloroform were added to each sample, shaken on vortex for 10 s, and 
incubated at room temperature for 2 min. Phase separation was achieved by 
centrifugation at 12,000 g for 5 min at 4 °C in Phase-Lock Gel Heavy tubes (5 Prime 3 
Prime, Inc., Boulder, CO, USA). The aqueous phase was mixed with 1 volume 70 % 
ethanol and RNA was further purified using RNeasy Mini Kit columns® (Qiagen, 
 Hilden, Germany)  following the manufacturer’s recommendations.  The total RNA was 
quantified by spectrophotometry at 260-280 and 230-260 nm (Nanodrop 
Spectrophotometer ND-1000®, Thermo Fisher Scientific, Wilmington, DE, USA). 
cDNA synthesis: 1 μg total RNA was reverse-transcribed using the Omniscript RT Kit® 
(Qiagen,  Hilden, Germany) in a reaction mixture containing 1 µM Oligo(dT)18 primer, 5 
mM dNTPs, reaction buffer and RT enzyme according to the manufacturer’s 
instructions. After the enzymatic reaction (incubation at 37 °C for 1 h), cDNA samples 
were prediluted in milliQ water (1:20).  
Quantitative RT-PCR (qPCR): For qPCR, primers were used complementary to the genes 
coding for Bcl-2 and Bax. SDHA (succinate dehydrogenase) was used as the reference 






gene. The target genes and corresponding oligonucleotide primer sequences (5’ to 3’) 
were:  
Bcl-2: GGAGGATTGTGGCCTTCTTT and GCCGGTTCAGGTACTCAGTC;  
Bax: GACGGCCTCCTCTCCTACTT and CAGCCCATCTTCTTCCAGAT;  
SDHA: CTGCAGAACCTGATGCTGTGT and GGATGGGCTTGGAGTAATCG. 
 
Primer design was performed using Primer3 (44) and primer specificity was confirmed 
using the In-Silico PCR UCSC Genome Browser (45). The final individual qPCR reactions 
contained iTaq Universal SYBR Green Supermix (BioRad, Hercules, CA), 1.5 µM each 
primer and 1:4 (v/v) prediluted cDNA (1:20). Two qPCR technical replicates were 
performed per sample in the iQ5 Bio-Rad thermal cycler. The qPCR program included 1 
min denaturation at 95 °C, followed by 60 cycles at 94 °C for 5 s, 58 °C for 15 s, and 72 
°C for 15 s. After qPCR, a melting temperature program was performed. Mean PCR 
efficiencies and cycle thresholds were determined from the fluorescence data using the 
algorithm Real-Time PCR Miner (46). Relative gene expression of cell samples relative to 
SDHA was calculated using the Pfaffl method (47).  
 
 
Cell Cycle Analysis by Flow Cytometry 
After complexed lycopene exposure and UV-B irradiation as described before, the cells 
were harvested with Accutase® and centrifuged at 1157 g for 5 min at 4 C. The 
supernatant was removed and the cells were washed in PBS and suspended in 1 mL 
of 85 % ethanol at 4 °C and kept at -20 °C until analysis. After that, the cells were 
centrifuged twice at 1157 g for 5 min at 4 C and suspended in 800 L PBS and vortexed. 
Samples were then filtered on a nylon mesh (50 μm pore size) to the analysis tubes. PI, 
a DNA intercalating fluorochrome, and RNase were added to the samples (50 L each 
one) and vortexed. The mixture was incubated 20 min at room temperature and then 
analyzed by flow cytometry using a Coulter EPICS XL flow cytometer®. The instrument 
was equipped with an air-cooled argon-ion laser tuned at 15 mW and operating at 488 
nm for excitation. Data was acquired using the SYSTEM II™ (v. 2.5) software. Integral 
fluorescence together with fluorescence pulse height and width emitted from nuclei 





was collected through a 645 dichroic long-pass filter and a 620 band-pass filter and 
converted on 1024 ADC channels. Prior to analysis the amplification was adjusted so 
that the peak corresponding to G0/G1 was positioned at channel 200. This setting was 
kept constant. The results were obtained in the form of three graphics: linear 
fluorescence light intensity (FL), forward angle light scatter (FS) versus side angle light 
scatter (SS) and FL pulse integral versus FL pulse height. This last cytogram was used to 
eliminate partial nuclei and other debris, nuclei with associated cytoplasm and doublets 
(these events have a higher pulse area but the same pulse height as single nuclei). Cell 
cycle analysis was performed using the FlowJo software® and applying the Dean-Jett 
Model. 
 





OH) generation was assayed by Coulter EPICS XL flow cytometer® using 
the fluorescent probe 2,7-dichlorodihydrofluorescein diacetate (H2DCF-DA) which upon 
acetate cleavage is oxidized to fluorescent dichlorofluorescein (DCF) by hydrogen 
peroxide. After complexed lycopene exposure and UV-B irradiation as described before, 
the medium was replaced by serum-free α-MEM containing 10 µM H2DCF-DA for 30 
min, at 37 C in dark. Cells were washed with PBS, trypsinized with Accutase® and 
collected for analysis. ROS formation was estimated by the median fluorescence 
intensity (MFI) parameter using the FlowJo software®.  
 
Statistical Analysis  
The results are reported as mean + SD of at least three replicates/treatment. In 
addition, at least three independent assays were performed for each analysis. The 
results of all these experiments were statistically analyzed by Analysis of Variance 
(ANOVA with All Pairwise/Non Pairwise Multiple Comparison Procedures) using 
SigmaPlot 11.0 software®. The differences were considered statistically significant when 
p < 0.05.  







HaCaT Cell Growth and Confluence under normal culture conditions 
HaCaT cell growth and confluence under normal culture conditions until 120h are 
represented on Fig.2A. As it can be observed, the exponential phase extends until 
approximately 72 h and the full confluence can be maintained more than 1 week. The 
selected confluence for complexed lycopene exposure and UV irradiation in this 
experiment was attained at 24 h and 48 h, respectively. 
 
        
Fig.2- A) HaCaT cells growth and confluence curves under normal culture conditions for 120 hours. 
           B) HaCaT cells observed by phase-contrast microscope (total magnification 10x10x). 
 
Under phase-contrast microscopy, the cells displayed typical intermediate phenotype of 
polygonal cells interspersed with giant often multinucleated cell and single morphology 











Effect of UV-B doses on Cell Metabolic Activity by MTT Assay 
As theoretically expected, increasing UV-B dose resulted in decreased cell metabolic 
activity (Fig.3). UV-B irradiation resulted in distinct morphological changes in HaCaT 
cells, as irradiated cells became round and detached from the surface of the plate.  
MTT Assay
UV-B Irradiation Dose (mJ/ cm
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Fig.3- Effect of different UV-B doses on cell Metabolic activity (MA) determined by MTT Assay. Results are 
expressed as percentage (mean ± SD) of cell MA compared to non irradiated cells (NC). Statistical analysis: 
One Way Anova with All Pairwise Multiple Comparisons by Holm-Sidak method: statistical differences 
between the samples are represented by different letters when p<0.05.                                  
 
According to MTT results, the UV-B condition leading to, approximately 50 % of 
inhibition of cell MA, was 225 mJ/cm2. Therefore, this was the chosen UV-B condition 
for the following studies. 
Complexed lycopene up to 15 M did not affect the enzyme activity (MTT assay) of non-
exposed cells, and only 20 M led to significant decrease in metabolic activity in these 
cells (Fig.4).  Comparing the effect of complexed lycopene exposure between non 
irradiated and irradiated cells (225 mJ/cm2), it is evident that, at doses higher than 10 
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Fig.4- Effect of complexed lycopene exposure on UV-B irradiated (225 mJ/cm
2
) and non irradiated 
HaCaT cells on cell MA measured by MTT assay. Results are expressed as percentage (mean ± SD of 3 
independent experiments with 6 replicates each one). Statistical analysis: One Way Anova with 
Multiple Comparisons versus Control Group (Holm-Sidak method): statistical differences between the 
samples within non irradiated and irradiated groups (in respect to cells not exposed to lycopene) are 
represented by different letters when p < 0.05. 
 
The higher decrease in MA in irradiated cells treated with higher lycopene 
concentrations was further confirmed by a higher number of additional MTT 
experiments. In addition, previous experiments also demonstrated that exposure to the 
vehicle (CD) alone did not significantly alter the MA rates of non irradiated cells (data 
not shown).  
According to these results, we decided to choose an intermediate complexed lycopene 
concentration (10 µM) whose effects have been previously established in with other cell 
lines (48-50). At this lycopene concentration, the cell metabolic activity (and viability) 
was higher than 50 % and was not significantly different from the negative control (non 
a 
a 












exposed cells from irradiated group). Higher lycopene concentrations (e.g. 20 µM) could 
decrease the cell viability due to a prooxidant effect. 
 
Annexin V Assay 
Annexin assay differentiates subpopulations that are necrotic, apoptotic or viable. 
Comparative analysis of these subpopulations in irradiated (225 mJ/cm2) and non 
irradiated HaCaT cells, treated with 10 µM complexed lycopene, was performed using 
the Annexin V assay (Fig.5).  
As shown in Fig.5, within non irradiated cells, complexed lycopene alone did not affect 
(p > 0.05) the percentage of necrotic, apoptotic and viable cells compared to the control 
(non exposed cells). Contrarily, within non exposed cells, irradiation alone increased the 
percentage of both early and late apoptotic cells (p < 0.05), and decreased the 
percentage of viable cells compared to the control. On the other hand, irradiated cells 
previously exposed to complexed lycopene showed a decrease of cells in apoptosis 
compared to irradiated cells alone (p<0.05), while the number of dead cells increased.  
 








NI, Lyc-CD NI 
IR, Lyc-CD IR 
Fig.5- a) Representation of Annexin V-
FITC Dot-Plots Gating (FL1 LOG vs FITC 
LOG) above, and on the right, graphic 
results of UV-B (225 mJ/cm
2
) irradiated 
(IR) and non irradiated (NI) HaCaT cells 
exposed to 10 µM complexed lycopene 
(Lyc-CD); b) apoptotic results are 
expressed as percentage (mean ± SD, n 
= 3) of: non apoptotic or viable cells, 
Q4: Annexin- FTIC (-) and PI (-); early 
apoptotic cells, Q3: Annexin- FTIC (+) 
and PI (-); late apoptotic or dead cells, 
Q2: Annexin- FTIC (+) and PI (+) and 
dead cells, Q1:  Annexin- FTIC (-) and PI 
(+). Statistical analysis: One Way Anova 
with All Pairwise Multiple Comparison 
Procedures (Holm-Sidak method): 
means with different letters are 
significantly different (p < 0.05).  
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Also complementary data showed that irradiated cells previously exposed to the vehicle 
used to solubilize lycopene (CD) presented, once again, results quite similar to those of 
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Fig.6- Representation of Annexin V-FITC Dot-Plots Gating (FL1 LOG vs FITC LOG) of UV-B (225 mJ/cm
2
) 
irradiated (IR) and non irradiated (NI) HaCaT cells exposed to 10 µM complexed lycopene (Lyc-CD) and 















Analysis of Apoptosis Biomarkers and Gene Expression by RT-PCR   
UV-B irradiation has been shown to increase levels of apoptosis biomarkers, specially 
the proapoptotic proteins Bax, thereby inducing apoptosis in the skin cells. The 
pretreatment of complexed lycopene seemed to maintain the modulatory effects of UV-
B towards Bax/Bcl-2 ratio (3.5 ± 1.4) in a way that favored apoptosis (Fig.7). However, it 
should be noted that the number of samples was not enough to detect statistical 
differences between the samples in each group (irradiated and non irradiated cells). 
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Fig.7- - Representation of Bcl-2 and Bax expression. A) and B) expression values normalized to SDHA 
reference gene; C) and D) expression values in HaCaT cells exposed to 10 µM complexed lycopene (Lyc-
CD) normalized to the SDHA reference gene and relative to each CD vehicle control. Cells were irradiated 
with 225 mJ/cm
2 
UV-B (IR) and non irradiated (NI). Results are expressed as mean ± SEM of two technical 
replicates from one independent assay.  





Cell Cycle Analysis  
The Fig.8 shows representative histograms of cell cycle of HaCaT cells after 10 µM 
complexed lycopene exposure and UV-B irradiation (225 mJ/cm2). 
Cell cycle analysis shows that complexed lycopene exposure alone did not significantly 
(p > 0.05) affect the dynamic of cell cycle in comparison to control cells. Comparatively 
to non irradiated and non exposed cells, irradiation induced a decrease in the 
percentage of cells in the G0/G1 phase of cell cycle specially in complexed lycopene and 
CD exposed cells (P = 0.011 and 0.008, respectively) (Fig.8). Although the S and G2 
phases were not significantly affected by any of those treatments, it can be observed a 
higher synthesis (S phase). Furthermore, in irradiated and complexed lycopene exposed 
cells, an increase in the percentage of cells in sub-G0/G1 was detected, often associated 
with apoptotic events. 
 
     
         
Fig.8- Representation of cell cycle histograms and graphic results of UV-B (225 mJ/cm
2
) irradiated (IR) and 













































Fig.9- Representation of cell cycle results of UV-B (225 mJ/cm
2
) irradiated (IR) and non irradiated (NI) 
HaCaT cells exposed to 10 µM complexed lycopene (Lyc-CD) and the respective controls. Results are 
expressed as percentage (mean ± SD). Statistical analysis: One Way Anova with All Pairwise Multiple 
Comparison Procedures: means with different letters are significantly different (p < 0.05). In this case, 
only the statistical differences were marked in order to simplify the results representation. 
 
Reactive Oxygen Species (ROS) Analysis 
Analysis of oxidative stress damage of HaCaT Cells after 10 µM complexed lycopene 
exposure and UV-B irradiation (225 mJ/cm2) was performed by determining reactive 
oxygen species (ROS) by flow cytometry (FCM).  
The results of irradiated and non irradiated cells are represented in Fig. 10. Irradiated 
and non irradiated cells presented a different ROS profile. In fact, two peaks were 
observed in irradiated cells against one in non irradiated cells. The first peak (1) may 
correspond to “non viable” cells which had a higher count number than “viable” cells 
marking DCF-DA (peak 2), as it would be expected considering to the UV-B dose used.  
In this case, the Median Fluorescence Intensity (MFI) corresponded only to the cells 
represented on the 2nd peak and it was much higher than MFI from non irradiated cells, 
as theoretically expected.  





Complexed lycopene appears to attenuate the ROS production in non irradiated cells, as 
theoretically expected. However, the same did not happen in irradiated cells. In 
addition, CD influenced the ROS level of the cells in each group when compared to the 
control (NI/IR).  
          
                         
 
Fig.10- Median Fluorescence Intensity (MFI) histograms, dot-plots gating (SS LOG vs FS LOG) and graphic 
results of HaCaT UV-B irradiated cells, IR (225 mJ/cm
2
) and non irradiated (NI) exposed to 10 µM 
complexed lycopene (Lyc-CD) and to the respective controls marking DCF-DA obtained by FCM. Statistical 
analysis: One Way Anova with Multiple Pairwise Comparisons: medians with different letters are 
significantly different (p < 0.05) within each group (irradiated and non irradiated cells). 













In this work, we used HaCaT cells, a spontaneously transformed human epithelial cell 
line from adult skin which maintains full epidermal differentiation capacity. This cell line 
is immortal (> 140 passages) but remains nontumorigenic, and it is aneuploid 
(hypotetraploid) with unique stable marker chromosomes indicating monoclonal origin 
(13). As performed in this experimental work, further investigation needs to include 
studies dealing with normal cells, their transformation into malignant cells, and the 
association between malignant cells and the surrounding normal cells in order to 
determine the cytotoxicity in both cell populations. 
The level of lycopene normally observed in human plasma is on the order of 0.5 µM 
even with dietary supplementation (21, 48, 49). Therefore, for therapeutic purposes 
(assuming topical application) we used a range above these normal plasma levels (5 up 
to 20 µM). According to MTT results, 20 µM revealed to be toxic in in vitro studies 
(Fig.4). Thus, 10 µM lycopene nominal concentration selected for further studies, 
supporting the selected dose used in other in vitro studies (48-50). 
The option to use cyclodextrins for lycopene solubilization and photoprotection was 
based on data resulting from previous studies (Table 1) on parameters/conditions 
affecting the delivery of lycopene to cells, including the solubilization, stabilization and 
cellular uptake by using other vehicles.  
It is noteworthy that cell culture studies are usually carried out under abnormal 
conditions known as “culture shock”, where cells are exposed to high oxygen tension 
and to free metal ions in the medium (28, 51). Thus, it must always be taken into 
account if the study compound reacts with the cell medium. Different half-life values of 
lycopene under standard cell culture are reported in the literature, e.g., 12-20h (39). 
Our experiments were conducted at 24 h in order to guarantee the lycopene cellular 
uptake. 
The antioxidant action of carotenoids is related to their ability to trap free radicals and 
quench singlet oxygen. However, depending on the redox potential of lycopene and the 





surrounding environment, its antioxidant activity may shift to prooxidant activity (52, 
53). In fact, the HaCaT cells medium (DMEM) contains ferric nitrate (Fe(NO3)3.9 H2O) 
and  Fe(III) can react with excess neutral carotenoids, such as lycopene. Ferric ions have 
been proposed to degrade carotenoids by the following mechanism (54, 55): Fe3+ + 
carotenoid => Fe2+ + carotenoid.+. Although there are many Fe chelators that inhibit the 
reactions of Fe, oxygen, and their metabolites (56), these  chelating agents may also 
mediate toxicity by stimulating Fe-mediated oxygen radical generation). The chelating 
agent used for HaCaT trypsinization was ethylenediaminetetraacetic acid (EDTA) which 
can induce Fenton-chemistry mediated radical damage. In fact, the autoxidation of Fe(II) 
enhanced by EDTA was observed by others (57, 58). Therefore, in order to prevent 
lycopene oxidation by Fe (III), another cell culture medium (-MEM) was used without 
this element during cells exposure to lycopene. A normal cellular growth was observed. 
Furthermore, it should be also noted that the solution with the highest lycopene dose 
had a suitable osmolarity lower than 320 mOsm/ kg.  
During storage, special precautions were taken such as the protection of lycopene from 
temperature, light and air. However, during lycopene exposure, cell culture was 
maintained at 37 °C in a humidified incubator with 5 % CO2 atmosphere. Even 
considering other experimental conditions reported in the literature (59) that comprise 
the addition of lycopene solutions to the cell culture medium under N2 environment, we 
preferred to maintain our protocol to avoid perturbing the cell culture with other 
variable.  
Apoptosis is the best-characterized type of programmed cell death because of its 
importance in development, homeostasis, and pathogenesis of different diseases, such 
as cancer. Cells respond to specific apoptotic signals by initiating intracellular processes 
that result in characteristic physiological changes. Among these changes are 
externalization of phosphatidylserine to the cell surface, depolarization of mitochondrial 
membranes, cleavage and degradation of specific cellular proteins, compaction and 
fragmentation of nuclear chromatin, loss of cell membrane integrity, and cellular 
shrinkage. We studied one of the earliest apoptotic events, i.e., the translocation of 
phosphatidylserine (PS) from the inner to the outer leaflet of the plasma membrane. As 






Annexin V has high affinity to PS, when conjugated with a fluorescent probe as FITC, 
allows the identification of early apoptotic cells. Mitochondrial dysfunction also occurs 
early in apoptosis and is accompanied by a decreased membrane potential and the 
release of mitochondrial proteins such as cytochrome c and Smac/DIABLO. This leads to 
the activation of caspases (early apoptosis) and DNA fragmentation (late apoptosis) (60, 
61).  
Moreover, Bowen et al. (62) have found that HaCaT cell line (which harbors two mutant 
p53 alleles) are more susceptible to apoptosis than normal keratinocytes in vitro, 
possibly because of aberrant signaling pathways resulting from long-term culture (63, 
64). 
In this work, we may have observed a “false negative” Annexin result (Fig.5 and 6) using 
CD as lycopene vehicle (data not shown), as mentioned before and attending to the 
other assays results. In fact, it is well known that CD can complex with lipids, such as 
cholesterol, from the skin cells (65, 66). George et al. (67) demonstrated that 
cholesterol located in the plasma membrane of HaCaT cells is required for lipid raft 
domain formation and activation of UV-B induced apoptosis through Fas-receptor 
activation. Depletion of cholesterol by methyl-β-cyclodextrin reduces Fas aggregation 
which is accompanied with a reduced apoptotic, but increased nonapoptotic death of 
UV-B-irradiated HaCaT cells (67). In addition, free CD molecules (also present in complex 
mixture) might also complex with phosphatidylserine (PS) also present in lipid rafts in 
disrupted membrane cells, decreasing the binding to Annexin V- FITC, thereby causing 
technical interference with this assay. 
Besides cholesterol depletion from cells membranes, free CD molecules might also 
complex with PS in disrupted membrane cells, decreasing the binding to Annexin-FITC 
(Fig.11). In fact, the complex was not filtered, which means that we have all species in 
the complex solution (lycopene insoluble + CD  lycopene- CDsoluble). 






Fig.11- Representation of cell membrane in apoptotic cells and hypothetical interaction with Annexin-FITC 
+ PI and CD  (adapted (60)). 
 
In another parallel work, THF/BHT diluted in FBS was also used to solubilize lycopene. In 
fact, Lin et al. (28) demonstrated that FBS is likely responsible for the improved stability 
and cellular uptake of lycopene (28). As with complexed lycopene, cells exposed to 
lycopene vehiculated in THF-BHT-FBS and irradiated also showed a decreased viability 
compared to non exposed irradiated cells (results not shown). 
Regarding the apoptosis biomarkers, Bcl-2 family proteins can modulate mitochondrial 
permeability through oxidative phosphorylation during apoptosis. Changes in the 
Bax/Bcl-2 ratio suggest a corresponding change in mitochondrial permeability to release 
apoptogenic molecules from the mitochondria to the cytosol (5). In fact, exposed 
irradiated cells presented a higher Bax/ Bcl-2 ratio (Fig.7). 
 
Cell Cycle can be divided into two distinct stages and controlled by a series of cell cycle 
regulators, including cyclins, cyclin-dependent kinases (CDKs), and CDK inhibitors. The 
first stage is the interphase (G1, S, and G2 phases) in which cells are active, growing, and 
DNA is being replicated. The second is the “mitotic phase” (M phase) in which cell 











UV-B irradiation activates diverse cellular responses in human cells, such as cell cycle 
arrest, DNA repair and apoptosis through signal transduction pathways (16). Previous 
studies have shown that UV radiation can cause cell cycle arrest both at G1 (68) and G2 
phases (69) of cell cycle. However, in our study, irradiation did not affect significantly 
the percentage of cells on S and G2 phases (Fig.8 and 9). On the contrary, the 
percentage of cells in G1 phase decreased in irradiated cells, specially those previously 
exposed to complexed lycopene or the respective vehicle alone (cyclodextrins). Cyclin D 
regulates the transition from G0 to early G1 phase, while cyclin E regulates the 
transition of the cell from late G1 phase to S phase; p21 and p27 CDK inhibitors bind and 
inhibit the activity of cyclin E/CDK2 complex, blocking cell cycle progression in G1 phase. 
In fact, after UV irradiation, the half-life of the tumor suppressor (p53) appears to be 
extended which will induce the p21 CDK inhibitor leading to G1 phase arrest or cell 
death by apoptosis. G2-phase checkpoint control does not appear to be affected (70).  It 
has been reported that the growth inhibition of lycopene on MCF-7 breast cancer cells 
was also associated with decreased G1-S cell cycle progression, decreased cyclin D1 
expression, and stabilization of p27 in the cyclin E-CDK complex (7, 71). Cell cycle arrest 
increases the time available for DNA repair before DNA replication and mutation 
fixation (5). Regarding the cell cycle results obtained with CD, it has been reported that 
methyl β-CD inhibits cell growth and induces cell cycle arrest via a prostaglandin E2 
independent pathway in Raw264.7 macrophage cells (72). Thus, a control assay with CD 
alone is mandatory in these studies.  
UV radiation results in an increased generation of ROS that interact with proteins, lipids 
and DNA, overwhelming the antioxidant defense mechanisms of the cells.  
The epidermis is composed mainly of keratinocytes, which are rich in ROS detoxifying 
enzymes such as superoxide dismutase, catalase, glutathione peroxidase, and in low-
molecular-mass antioxidant molecules (73). Although skin spontaneously responds to 
increased ROS levels, this response may not be sufficient to prevent the progression of 
skin cancer (4). Despite the extensive evidence implicating ROS in oxidative DNA 
damage, little is known about its involvement in DNA damage of keratinocytes, which 





are the most relevant cell type in non-melanoma skin cancer. The non-radical singlet 
oxygen and the hydroxyl radical are the major damaging oxidative species that can be 
generated inside cells during normal aerobic metabolism and by processes such as 
photosensitization (74). The major DNA oxidation products include 8-oxo-7-hydro-
deoxy-guanosine (8-oxodG) and 2,6-diamino-4-hydroxy-5-for-mamidopyrimidine (75). 
According to the ROS determination (Fig. 10), the UV-B irradiation significantly altered 
the cells population. This fact could be observed by the appearance of two peaks in the 
histograms of DCF-DA of irradiated cells. The first peak might correspond to dead cells, 
which had a very weak signal of DCF (compatible with autofluorescence). In this case, 
the DCF might not be activated and metabolized within the cell (no fluorescence), and / 
or the cells might not retain the DCF because of the loss of membrane integrity. 
Complexed lycopene increased the ROS level in irradiated cells. Shaw et al. (5) have also 
obtained a significantly decrease of SOD activity (MnSOD) after treatment with 
sanguinarine, enhancing UV-B-mediated oxidative stress in HaCaT cells. However, 
according to Onoue et al. (76), ROS data might not always provide a reliable indication 
for the capacity of a chemical to participant in a photogenotoxic cascade. This fact could 
be more realistic when irradiation is used in experiments. In fact, the photodegradation 
of lycopene may contribute to cytotoxicity, including oxidative damage.  For example, 
apo-6´-lycopene, 2-methyl-hepte-6-one, as well as further reaction products, are 
formed during irradiation of lycopene (33, 77). Nagao (78) found that oxidized 
metabolites of lycopene but not lycopene itself can inhibit cell growth and stimulate 
apoptosis in a different cell line (HL-60). In another study, lycopene in human prostate 
cancer cells inhibited cell growth, but the oxidized mixtures displayed markedly more 
potent growth inhibition (78, 79). On the contrary, some recent studies suggested that 
lycopene or lycopene metabolites may, as β-carotene and its metabolites do, enhance 
carcinogenesis.  
In general, similar results were obtained by Shaw et al. (5) who suggested that 
sanguinarine (also a botanical antioxidant) may protect skin cells (also HaCaT cell line) 
from UV-B- mediated damages via apoptotic elimination of damaged cells that escaped 
from the programmed cell death. These are clearly important observations since 






apoptosis is a mechanism of defense and acts by opposing the creation of damaged and 
preoneoplastic cells, and expansion to a clone. Once mutations arise, apoptosis also 
removes preoneoplastic cells that are aberrantly proliferating due to genetic defects.  
However, further investigation into the dose effect of lycopene, as well as a further 






















According to data obtained from all experimental assays (Scheme 1, in annex to this 
chapter), we demonstrate here that complexed lycopene up to 10 M does not show 
metabolic toxicity (MTT assay) under standard cell culture conditions. On one hand, at 
non toxic dose (10 M) complexed lycopene does not affect the profile of apoptotic, 
necrotic and viable cells, nor shows cytostatic effects despite slightly increasing the ROS 
content. However, cells previously exposed to complexed lycopene when irradiated 
with metabolically damaging UV-B dose, show a distinguishing switch in the dead : 
apoptotic : viable subpopulations compared to non exposed-irradiated cells. On the 
other hand, exposed irradiated cells showed a decrease in G0/G1 phase. In fact, the 
increased sub-G0/G1 phase, and a trend for S-phase delay (even not statistically 
different) could contribute to this cell cycle change. 
Therefore, complexed lycopene might play a corrective role or cytotoxic effect in 
photodamaged and preneoplastic keratinocytes, while allowing other keratynocytes to 
accelerate repairing mechanisms becoming viable. However, future studies will be 
performed regarding the analysis of apoptosis regulating genes by RT-PCR to further 
confirm these results (with statistical significance). In addition, the same studies will be 
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Scheme 1 - Proposal model of the effects of UV irradiation on skin cells and analytical assays used to study those effects. 
Conclusions and Future Perspectives 
 
In summary, tretinoin was  incorporated  in free and  in complexed form (with dimethyl‐
β‐cyclodextrins)  in  ultradeformable  vesicles  (transfersomes)  formulations.  Lycopene 
was  incorporated  in transfersomes and ethosomes, attending to the results previously 
obtained  with  tretinoin.  Tretinoin  and  lycopene  share  similar  physicochemical 
properties, mainly high hydrophobicity and chemical  instability to air and  light.  In fact, 
lycopene  was  incorporated  in  the  most  stable  formulation  tested  for  tretinoin, 
transfersomes with 20 % lipid concentration.  
Carrier‐mediated  tretinoin  and  lycopene  have  improved  the  dermal  drug  delivery. 
Tretinoin  chemical  stability  was  only  achieved  by  incorporating  this  drug  into 
transfersomes  made  of  a  high  phospholipidic  concentration.  In  addition,  this  last 
formulation appears to be a promising delivery system to promote cutaneous delivery 
of tretinoin because it exhibited predominant dermal delivery and showed no toxicity. 
Regarding  the  lycopene  extraction  process,  a  rapid,  simple  and  economically 
advantageous process was  achieved, providing  a  lycopene‐rich  extract.  This  lycopene 
source  may  be,  thus,  taken  as  a  good  alternative  to  the  expensive  commercially 
available  lycopene  to  integrate  topical  formulations.  Extracted  lycopene  loaded‐
deformable  lipidic  carriers  (transfersomes  and  ethosomes)  were  able  to  inhibit  ear 
swelling mediated by ROS  generated within  the  skin by  anthralin  application.  Finally, 









Future  experiments  regarding  optimization  of  lycopene  extraction  process,  stability 
studies  of  lycopene‐loaded  vesicular  nanocarrier  formulations,  and  the  effect  of 
surfactant on physical properties and stability of  those  formulations are also planned. 
Additional  in  vitro  experiments  could  be  performed  in  order  to  further  confirm  the 
chemopreventive role of  lycopene  in photodamaged skin cells with different exposure 
conditions  (e.g., HaCaT  irradiation  to a UV‐B  single dose of 25 mJ/cm2 before and/or 
after  6  h  of  cells  exposure  to  5  µM  extracted  lycopene,  vehiculated  in  0.05 %  THF‐
0.0005 % BHT‐ 1 % FBS system). Other alternative assays could also be used, such as the 
clonogenic  assay,  detection  of  chromosomal  breakage  by  cytokinesis‐blocked 
micronucleus cytome, and SOD and total antioxidant capacity assays, in order to achieve 
the  cell  viability,  apoptosis  and  oxidative  stress  of  exposed  cells,  respectively.  In 
addition, the analysis of more upstream/downstream damage biomarkers will be useful 
to  better  understand  the  cellular mechanisms  behind  the  photodamage  process.  At 
least, the role of lycopene in in vivo conditions regarding the irradiation protocol could 
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